Original Article
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
N Engl J Med 2007; 357:2001-2015November 15, 2007
- Abstract
Background
Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention.
Methods
To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months. The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding.
Results
The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P<0.001). We also found significant reductions in the prasugrel group in the rates of myocardial infarction (9.7% for clopidogrel vs. 7.4% for prasugrel; P<0.001), urgent target-vessel revascularization (3.7% vs. 2.5%; P<0.001), and stent thrombosis (2.4% vs. 1.1%; P<0.001). Major bleeding was observed in 2.4% of patients receiving prasugrel and in 1.8% of patients receiving clopidogrel (hazard ratio, 1.32; 95% CI, 1.03 to 1.68; P=0.03). Also greater in the prasugrel group was the rate of life-threatening bleeding (1.4% vs. 0.9%; P=0.01), including nonfatal bleeding (1.1% vs. 0.9%; hazard ratio, 1.25; P=0.23) and fatal bleeding (0.4% vs. 0.1%; P=0.002).
Conclusions
In patients with acute coronary syndromes with scheduled percutaneous coronary intervention, prasugrel therapy was associated with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding, including fatal bleeding. Overall mortality did not differ significantly between treatment groups. (ClinicalTrials.gov number, NCT00097591.)
Media in This Article
Figure 1
Cumulative Kaplan–Meier Estimates of the Rates of Key Study End Points during the Follow-up Period.Figure 2
Hazard Ratios and Rates of the Primary End Point, According to Selected Subgroups of Study Patients.Article Activity
- Article
The short-term and long-term benefits of dual-antiplatelet therapy with aspirin and clopidogrel have been established for patients with acute coronary syndromes1-3 and those undergoing percutaneous coronary intervention (PCI).4,5 Despite these benefits, many patients continue to have recurrent atherothrombotic events while receiving standard dual antiplatelet therapy.1 In addition, important limitations of clopidogrel remain, such as only a modest antiplatelet effect, with substantial interpatient variability6,7 and a delayed onset of action.5 Small clinical studies have suggested that patients with a reduced pharmacologic response to clopidogrel may be at increased risk for adverse clinical events, including myocardial infarction and coronary-stent thrombosis.8-11
Prasugrel — a novel thienopyridine — is a prodrug that, like clopidogrel, requires conversion to an active metabolite before binding to the platelet P2Y12 receptor to confer antiplatelet activity.12 At the currently studied doses, prasugrel inhibits adenosine diphosphate–induced platelet aggregation more rapidly, more consistently, and to a greater extent than do standard and higher doses of clopidogrel in healthy volunteers13 and in patients with coronary artery disease,14,15 including those undergoing PCI.16 Phase 2 testing of prasugrel, as compared with clopidogrel, in patients undergoing elective or urgent PCI showed a trend toward fewer ischemic events, with an acceptable safety profile.17 Thus, we designed the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction (TRITON–TIMI) 38, a phase 3 trial involving patients with acute coronary syndromes with scheduled PCI, comparing a regimen of prasugrel with the standard-dose regimen of clopidogrel approved by the Food and Drug Administration.18 Although our trial was designed to compare regimens of prasugrel and clopidogrel, it also tests the hypothesis that the use of an agent producing a higher level of inhibition of adenosine diphosphate–induced platelet aggregation and a less-variable response than standard-dose clopidogrel reduces ischemic events.
Methods
TRITON–TIMI 38 was designed as a collaboration between the TIMI Study Group, the sponsors — Daiichi Sankyo and Eli Lilly — and a steering committee of investigators (see the Appendix). Quintiles Corporation provided data- and site-management services. All key prespecified and exploratory analyses were performed by the TIMI Study Group, using an independent copy of the complete database. The academic authors wrote all drafts of the manuscript and vouch for the veracity and completeness of its content. The database was locked on September 22, 2007; the analyses reported herein were completed on October 26, 2007.
Study Population
We enrolled 13,608 patients with acute coronary syndromes (representative of the entire spectrum of those syndromes) with scheduled PCI. Patients were randomly assigned to the clopidogrel group or the prasugrel group in two strata: 10,074 patients with moderate-to-high-risk unstable angina or non–ST-elevation myocardial infarction and 3534 patients with ST-elevation myocardial infarction. The inclusion criteria for patients with unstable angina or non–ST-elevation myocardial infarction were ischemic symptoms lasting 10 minutes or more and occurring within 72 hours before randomization, a TIMI risk score19 of 3 or more, and either ST-segment deviation of 1 mm or more or elevated levels of a cardiac biomarker of necrosis. Patients with ST-elevation myocardial infarction could be enrolled within 12 hours after the onset of symptoms if primary PCI was planned or within 14 days after receiving medical treatment for ST-elevation myocardial infarction.18
Full exclusion criteria have been published previously.18 Key exclusion criteria included an increased risk of bleeding, anemia, thrombocytopenia, a history of pathologic intracranial findings, or the use of any thienopyridine within 5 days before enrollment.18 The protocol was approved by the institutional review boards associated with all participating centers, and written informed consent was provided by all patients.
Study Protocol
A loading dose of study medication (60 mg of prasugrel or 300 mg of clopidogrel) was administered, in a double-blind manner, anytime between randomization and 1 hour after leaving the cardiac catheterization laboratory. Since the protocol was designed as a trial of patients with acute coronary syndromes who were undergoing PCI, the coronary anatomy had to be known to be suitable for PCI before randomization in all patients with unstable angina or non–ST-elevation myocardial infarction, or in those enrolled after medical treatment for ST-elevation myocardial infarction. If the coronary anatomy was previously known or primary PCI for ST-elevation myocardial infarction was planned, pretreatment with the study drug was permitted for up to 24 hours before PCI. Randomization was to occur before PCI was performed, and the study drug was to be administered as soon as possible after randomization.
The choice of vessels treated, devices used, and adjunctive medication administered to support PCI was left to the discretion of the treating physician. After PCI, patients received maintenance doses of either prasugrel (10 mg) or clopidogrel (75 mg) daily. Use of aspirin was required, and a daily dose of 75 to 162 mg was recommended. Study visits were conducted at hospital discharge, at 30 days, at 90 days, and at 3-month intervals thereafter, for a total of 6 to 15 months.18
End Points
The primary efficacy end point was a composite of the rate of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke during the follow-up period. Key secondary end points at 30 and 90 days were the primary composite end point and a composite of death from cardiovascular causes, nonfatal myocardial infarction, or urgent target-vessel revascularization. Key secondary end points for the entire follow-up period were stent thrombosis and a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or rehospitalization due to a cardiac ischemic event. Additional prespecified analyses included an analysis of the rates of the primary end point from randomization to day 3 and a landmark analysis of those data from day 3 to the end of the study. Key safety end points were TIMI major bleeding not related to coronary-artery bypass grafting (CABG), non–CABG-related TIMI life-threatening bleeding, and TIMI major or minor bleeding, as previously defined.18 Stent thrombosis was defined as definite or probable stent thrombosis according to the Academic Research Consortium.20 All components of the primary, secondary, and key safety end points were adjudicated by members of an independent clinical events committee that was unaware of the group assignments.
Statistical Analysis
Efficacy comparisons were performed on the basis of the time to the first event, according to the intention-to-treat principle. Safety analyses were carried out on data from patients who received at least one dose of the study drug. The Gehan–Wilcoxon test was used to compare the treatment groups with regard to the primary efficacy end point18; the log-rank test was used in a prespecified sensitivity analysis for the primary end point and in all analyses of key secondary and safety end points. Because of the substantial overlap between the cohort of patients with unstable angina or non–ST-elevation myocardial infarction and the overall population of patients with acute coronary syndromes, and to preserve the statistical power to detect a difference between the two treatment groups, we used a closed testing procedure. The primary efficacy end point was analyzed in the cohort with unstable angina or non–ST-elevation myocardial infarction first, and only if there was a statistically significant difference between the treatment groups was this end point analyzed in the overall cohort.18 Rates of the end points are expressed as Kaplan–Meier estimates at 15 months and were compared with the use of hazard ratios and two-sided 95% confidence intervals. An independent data monitoring committee monitored the safety and efficacy of the study drugs. P values of less than 0.05 were considered to indicate statistical significance.
We calculated that a total of 875 primary end points would be required for the study to have a 90% power to detect a 20% reduction in the relative risk of the primary end point among patients with unstable angina or non–ST-elevation myocardial infarction receiving prasugrel, as compared with clopidogrel. It was estimated that 9500 patients with unstable angina or non–ST-elevation myocardial infarction would need to be enrolled to achieve this number of end points.18 A prespecified assessment conducted when 650 patients had had a primary end point found a slightly lower-than-expected aggregate rate of the end point, which led us to increase the number of patients in the cohort with unstable angina or non–ST-elevation myocardial infarction to approximately 10,100.18
Results
We randomly assigned 13,608 patients (10,074 with unstable angina or non–ST-elevation myocardial infarction and 3534 with ST-elevation myocardial infarction), from 707 sites in 30 countries, to a treatment group between November 2004 and January 2007. The baseline characteristics were similar to those in contemporary studies of patients with acute coronary syndromes who were undergoing PCI and were well matched between the treatment groups (Table 1Table 1
Baseline Characteristics of the Patients.). The median duration of therapy was 14.5 months. A total of 14 patients (0.1%) were lost to follow-up.Nearly all patients (99%) had PCI at the time of randomization, 94% received at least one intracoronary stent, and 47% received at least one drug-eluting stent. The study drug was administered before the first coronary guidewire was placed in 25% of patients, after the first coronary guidewire was placed and during the PCI or within 1 hour after PCI in 74%, and more than 1 hour after PCI in 1%.
Efficacy End Points
The rate of the primary efficacy end point was significantly reduced in favor of prasugrel among the patients with unstable angina or non–ST-elevation myocardial infarction (hazard ratio, 0.82; 95% confidence interval [CI], 0.73 to 0.93; P=0.002); therefore, as prespecified, the analysis was also performed in the overall cohort of patients with acute coronary syndromes. A significant benefit of prasugrel was also observed in the ST-elevation myocardial infarction cohort alone (hazard ratio, 0.79; 95% CI, 0.65 to 0.97; P=0.02), and there was no significant interaction between treatment group and enrollment stratum (unstable angina or non–ST-elevation myocardial infarction vs. ST-elevation myocardial infarction).
In the overall cohort, a total of 781 patients (12.1%) in the clopidogrel group had the primary end point, as compared with 643 patients (9.9%) in the prasugrel group (hazard ratio, 0.81; 95% CI, 0.73 to 0.90; P<0.001) (Table 2Table 2
Major Efficacy End Points in the Overall Cohort at 15 Months. and Figure 1AFigure 1Cumulative Kaplan–Meier Estimates of the Rates of Key Study End Points during the Follow-up Period.), supporting the primary hypothesis of superior efficacy. A significant reduction in the primary end point was seen in the prasugrel group by the first prespecified time point, 3 days (5.6% in the clopidogrel group vs. 4.7% in the prasugrel group; hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01) (Figure 1B), and persisted throughout the follow-up period. From 3 days to the end of the study, the primary end point had occurred in 6.9% of patients receiving clopidogrel and in 5.6% of patients receiving prasugrel (hazard ratio, 0.80; 95% CI, 0.70 to 0.93; P=0.003) (Figure 1C). The difference between the treatment groups with regard to the rate of the primary end point was largely related to a significant reduction in myocardial infarction in the prasugrel group (9.7% in the clopidogrel group vs. 7.4% in the prasugrel group; hazard ratio, 0.76; 95% CI, 0.67 to 0.85; P<0.001). The rate of myocardial infarction with subsequent death from cardiovascular causes (including arrhythmia, congestive heart failure, shock, and sudden or unwitnessed death) was also reduced in the prasugrel group (0.7% in the clopidogrel group vs. 0.4% in the prasugrel group; hazard ratio, 0.58; 95% CI, 0.36 to 0.93; P=0.02). There was no significant difference between the two treatment groups in the rate of stroke or of death from cardiovascular causes not preceded by recurrent myocardial infarction.Prasugrel showed superior efficacy in major prespecified subgroups (Figure 2Figure 2
Hazard Ratios and Rates of the Primary End Point, According to Selected Subgroups of Study Patients.), without significant interactions between the characteristics of the patients and the treatment group. A benefit with prasugrel with regard to the primary end point was found both with the use of glycoprotein IIb/IIIa–receptor antagonists during the index hospitalization (hazard ratio for prasugrel vs. clopidogrel, 0.79; 95% CI, 0.69 to 0.91; P<0.001) or without such use (hazard ratio, 0.84; 95% CI, 0.72 to 0.99; P=0.03). The benefit tended to be greater among the 3146 patients with diabetes (17.0% of whom had the primary end point in the clopidogrel group, vs. 12.2% in the prasugrel group; hazard ratio, 0.70; 95% CI, 0.58 to 0.85; P<0.001) than among the 10,462 patients without diabetes (10.6% of whom had the primary end point in the clopidogrel group, vs. 9.2% in the prasugrel group; hazard ratio, 0.86; 95% CI, 0.76 to 0.98; P=0.02). There was no significant interaction between treatment effect and diabetes status (P=0.09) or the timing of the study-drug administration (P=0.40).Similar significant reductions were seen for prasugrel in the overall cohort with regard to the prespecified secondary end point of death from cardiovascular causes, nonfatal myocardial infarction, or urgent target-vessel revascularization at 30 days (hazard ratio, 0.78; 95% CI, 0.69 to 0.89; P<0.001) and at 90 days (hazard ratio, 0.79; 95% CI, 0.70 to 0.90; P<0.001). A significant reduction in the rate of urgent target-vessel revascularization alone was also found in the prasugrel group by the end of the follow-up period (hazard ratio, 0.66; 95% CI, 0.54 to 0.81; P<0.001) (Table 2). A reduction in favor of prasugrel was also seen by the end of the follow-up period for the end point of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or rehospitalization for ischemia (hazard ratio, 0.84; 95% CI, 0.76 to 0.92; P<0.001) (Table 2). The rate of definite or probable stent thrombosis, as defined by the Academic Research Consortium, was significantly reduced in the prasugrel group as compared with the clopidogrel group, with 68 patients (1.1%) and 142 patients (2.4%), respectively, having at least one occurrence (hazard ratio, 0.48; 95% CI, 0.36 to 0.64; P<0.001). The significant reduction in the rate of stent thrombosis was also found among patients receiving prasugrel in combination with bare-metal stents alone (hazard ratio, 0.52; 95% CI, 0.35 to 0.77; P<0.001) and among those receiving prasugrel in combination with at least one drug-eluting stent (hazard ratio, 0.43; 95% CI, 0.28 to 0.66; P<0.001).
Safety End Points
Among patients treated with prasugrel, 146 (2.4%) had at least one TIMI major hemorrhage that was not related to CABG, as compared with 111 patients (1.8%) treated with clopidogrel (hazard ratio, 1.32; 95% CI, 1.03 to 1.68; P=0.03) (Table 3Table 3
Thrombolysis in Myocardial Infarction (TIMI) Bleeding End Points in the Overall Cohort at 15 Months.). This excess of TIMI major bleeding included a higher rate of life-threatening bleeding in the prasugrel group (1.4%, vs. 0.9% in the clopidogrel group; hazard ratio, 1.52; 95% CI, 1.08 to 2.13; P=0.01) at the end of the study, as well as from the time of randomization to day 3 (0.4% vs. 0.3%; hazard ratio, 1.38; 95% CI, 0.79 to 2.41; P=0.26) and from day 3 to the end of the study (1.0% vs. 0.6%; hazard ratio, 1.60; 95% CI, 1.05 to 2.44; P=0.03). Fatal TIMI major bleeding occurred in significantly more patients treated with prasugrel (0.4%) than those treated with clopidogrel (0.1%) (P=0.002) (Table 3), and more patients in the prasugrel group had nonfatal life-threatening bleeding (1.1%, vs. 0.9% in the clopidogrel group; hazard ratio, 1.25; 95% CI, 0.87 to 1.81; P=0.23). A higher rate of TIMI major bleeding related to instrumentation and a significantly higher rate of spontaneous TIMI major bleeding were seen in the prasugrel group than in the clopidogrel group (Table 3). Intracranial hemorrhage was reported in 19 patients (0.3%) receiving prasugrel and 17 patients (0.3%) receiving clopidogrel (P=0.74). The combination of non–CABG-related TIMI major or minor hemorrhage was more frequent among patients receiving prasugrel than among those receiving clopidogrel (hazard ratio, 1.31; 95% CI, 1.11 to 1.56; P=0.002) (Table 3).Few patients underwent CABG; among them, the rate of TIMI major bleeding was also greater with prasugrel than with clopidogrel (Table 3). More patients treated with prasugrel (2.5%, vs. 1.4% of patients treated with clopidogrel; P<0.001) discontinued the study drug owing to adverse events related to hemorrhage.
When the rates of certain efficacy and bleeding end points — death from any cause, nonfatal myocardial infarction, nonfatal stroke, and TIMI major hemorrhage — were included in a prespecified analysis of net clinical benefit, the findings favored prasugrel (13.9% of patients in the clopidogrel group vs. 12.2% in the prasugrel group; hazard ratio, 0.87; 95% CI, 0.79 to 0.95; P=0.004). Death from cardiovascular causes (including death related to intracranial hemorrhage or to bleeding related to a cardiovascular procedure) or fatal hemorrhage occurred in 151 patients (2.4%) receiving clopidogrel and in 142 patients (2.2%) receiving prasugrel (hazard ratio, 0.94; 95% CI, 0.75 to 1.18; P=0.59).
As a result of the discordance between the efficacy results (lower rates of ischemic end points in the prasugrel group than in the clopidogrel group) and the safety results (higher rates of bleeding end points with prasugrel than with clopidogrel) during the entire follow-up period, we performed a series of post hoc exploratory analyses to identify the subgroups of patients who did not have a favorable net clinical benefit (defined as the rate of death from any cause, nonfatal myocardial infarction, nonfatal stroke, or non–CABG-related nonfatal TIMI major bleeding) from the use of prasugrel or who had net harm. There were three specific groups of interest; patients who had a previous stroke or transient ischemic attack had net harm from prasugrel (hazard ratio, 1.54; 95% CI, 1.02 to 2.32; P=0.04), patients 75 years of age or older had no net benefit from prasugrel (hazard ratio, 0.99; 95% CI, 0.81 to 1.21; P=0.92), and patients weighing less than 60 kg had no net benefit from prasugrel (hazard ratio, 1.03; 95% CI, 0.69 to 1.53; P=0.89). In both treatment groups, patients with at least one of these three risk factors had higher rates of bleeding than those without them (Table 4Table 4
The Balance of Efficacy and Safety in Selected Subgroups.). Patients with a history of cerebrovascular events had no evidence of a clinical benefit from prasugrel (as compared with clopidogrel), as evaluated by the primary efficacy end point, and had a strong trend toward a greater rate of TIMI major bleeding (P=0.06), including intracranial hemorrhage in six patients (2.3%) in the prasugrel group, as compared with none in the clopidogrel group (P=0.02). As a result, there was a significant interaction between a history of cerebrovascular events and the degree of net clinical benefit of prasugrel as compared with clopidogrel (Table 4), indicating a significant harm from prasugrel among patients with a history of cerebrovascular events (518 patients), as compared with a significant benefit from prasugrel among patients without such a history (13,090 patients). There was also a significant interaction between the presence or absence of any of these three risk factors and the degree of net clinical benefit for prasugrel as compared with clopidogrel (P=0.006), though no significant harm was evident. Among patients without any of these three risk factors, there was greater efficacy with prasugrel (hazard ratio, 0.74; 95% CI, 0.66 to 0.84; P<0.001), no significant difference in the rate of major bleeding in the prasugrel group and the clopidogrel group (hazard ratio, 1.24; 95% CI, 0.91 to 1.69; P=0.17), and a substantially favorable net clinical benefit for the use of prasugrel (Table 4).The rate of serious adverse events not related to hemorrhage was similar in the prasugrel group and the clopidogrel group (occurring in 22.5% and 22.8% of patients, respectively; P=0.52). The study drug was discontinued owing to adverse events not related to hemorrhage in 4.7% of patients treated with prasugrel and in 5.0% of patients treated with clopidogrel (P=0.37). The adverse events reported included severe thrombocytopenia in 17 patients in the prasugrel group (0.3%) and 18 patients in the clopidogrel group (0.3%) (P=0.86); neutropenia in 2 patients (<0.1%) and 10 patients (0.2%) (P=0.02), respectively; and colonic neoplasms in 13 patients (0.2%) and 4 patients (0.1%) (P=0.03). Known gastrointestinal bleeding preceded the diagnosis of colonic neoplasms in nine patients (seven in the prasugrel group and two in the clopidogrel group).
Discussion
The risk of myocardial ischemic events in patients with acute coronary syndromes has been shown to be reduced by means of platelet inhibition with the use of aspirin21 and, even more effectively as compared with the use of aspirin alone, dual-antiplatelet therapy with aspirin and ticlopidine or clopidogrel, two inhibitors of the P2Y12 adenosine-diphosphate receptor.1-3,5 Our results show that the treatment of patients with acute coronary syndromes, across the full spectrum of such syndromes, with prasugrel (a 60-mg loading dose, followed by a 10-mg maintenance dose), as compared with clopidogrel at the standard, approved dose, resulted in a significant 2.2% absolute reduction and a 19% relative reduction in the rate of the primary efficacy end point (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). The rates of ischemic events were also reduced in the prasugrel group, with a 2.3% absolute reduction and a 24% relative reduction for myocardial infarction, a 1.2% absolute reduction and a 34% relative reduction for urgent target-vessel revascularization, and a 1.3% absolute reduction and a 52% relative reduction for stent thrombosis, a rare but potentially devastating clinical event. Our study was not powered to detect a reduction in the rate of death from cardiovascular causes, and no significant benefit was seen for prasugrel over clopidogrel. However, a 0.3% absolute reduction and a 42% relative reduction were found for recurrent myocardial infarction followed by death from cardiovascular causes.
The reduction in the rate of ischemic events by means of antiplatelet agents, including both oral agents (aspirin and clopidogrel)1,21 and intravenous agents (glycoprotein IIb/IIIa–receptor antagonists),22-24 has uniformly been accompanied by an increase in bleeding. The Antithrombotic Trialists' Collaboration reported a proportional increase in the odds of major bleeding of 60% with the use of antiplatelet agents (largely aspirin), as compared with placebo.21 In the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial, therapy with clopidogrel plus aspirin, as compared with aspirin alone, was associated with a 38% increase in the odds of major bleeding.1 The reduction in ischemic events we observed with prasugrel as compared with standard-dose clopidogrel was, as expected, associated with a significant increase in the rate of bleeding. The relative rate of TIMI major hemorrhage was increased by 32% with prasugrel (Table 3). There was an increase in the rate of life-threatening bleeding with prasugrel, including a significant increase in fatal major hemorrhage. Bleeding episodes, including major or life-threatening hemorrhage, were more frequent in the prasugrel group than in the clopidogrel group, both near the time of PCI and after PCI. Though few patients underwent CABG, major bleeding occurred at a higher rate among those receiving prasugrel than among those receiving clopidogrel. This finding suggests that, with a strategy of more potent platelet inhibition, greater attention to the discontinuation of therapy before surgery may be needed.25
Although the results of post hoc subgroup analyses should be considered exploratory, we identified three subgroups of interest that had less clinical efficacy and greater absolute levels of bleeding than the overall cohort, resulting in less net clinical benefit or in clinical harm. These included patients with a history of stroke or transient ischemic attack before enrollment, the elderly (age ≥75 years), and those with a body weight of less than 60 kg, risk factors that have been previously identified as being associated with an increased risk of adverse outcomes from the use of antiplatelet or antithrombotic agents.26,27 Patients who had had a cerebrovascular event before enrollment in our trial had numerically worse clinical outcomes, as measured in terms of the primary end point, and more frequent bleeding (including intracranial bleeding) than did those without such a history. In previous studies of patients with stroke,28 dual-antiplatelet therapy has been associated with an increased risk of adverse outcomes, particularly intracranial bleeding, as compared with single-antiplatelet therapy. We therefore believe that our findings regarding prasugrel among patients with a history of cerebrovascular events add to the concerns about the risk of intensive inhibition of platelet aggregation in this population. Among the elderly and among patients with a body weight of less than 60 kg in whom neither net benefit nor net harm was observed, it would be expected that increased levels of the active metabolite of prasugrel may have led to an increased risk of bleeding, owing to altered disposition of the drug or smaller body size. In contrast, a large majority of patients without any of these risk factors had a significant net clinical benefit with the prasugrel regimen studied, as compared with the clopidogrel regimen (hazard ratio, 0.80; 95% CI, 0.71 to 0.89; P<0.001). Additional work to define populations with an increased risk of bleeding, in association with oral regimens yielding high degrees of inhibition of platelet aggregation, is likely to be helpful in guiding therapy.
In addition to the results of our key prespecified safety analyses, we noted a higher rate of adverse events related to colonic cancer in the prasugrel group than in the clopidogrel group. Though we cannot fully rule out either a possible causative effect or the play of chance, this imbalance may have resulted from the more potent antiplatelet effect of prasugrel bringing more events to medical attention, a phenomenon seen with other anticoagulant agents, including warfarin.29,30
Treatment with prasugrel at the dosage used in our trial has been shown to generate higher and more consistent levels of active metabolite than treatment with approved doses of clopidogrel.13 This results in higher levels of mean inhibition of platelet aggregation, lower interpatient variability in such inhibition, and fewer patients considered to have poor responsiveness or hyporesponsiveness when platelet function is assessed in the laboratory.13 Considerable research has focused on the presence and clinical meaning of hyporesponsiveness to clopidogrel in patients with coronary artery disease who have undergone PCI.6-11 The data from our trial, which was adequately powered to evaluate clinical events, show that, as compared with standard-dose clopidogrel therapy, a regimen that improves the inhibition of platelet aggregation is associated with fewer ischemic events. This improvement in the rate of ischemic events as a result of greater platelet inhibition was not assured, given the absence of increased efficacy with higher doses of aspirin31 and the higher rates of ischemic events seen with the addition of oral glycoprotein IIb/IIIa–receptor antagonists (potent inhibitors of platelet aggregation) to aspirin.32
As a result of the intention to have all patients undergo PCI, our trial was largely a comparison of prasugrel therapy and clopidogrel therapy among patients treated with a thienopyridine at the time of the identification of coronary anatomy appropriate for PCI, rather than a comparison of routine pretreatment with either agent before diagnostic cardiac catheterization. A strategy of clopidogrel loading when coronary anatomy is known is now used by many cardiologists because of concern about surgical bleeding if a patient receives clopidogrel and then (because of a finding on coronary angiography) goes on to undergo CABG.25 Pharmacodynamic data have shown that the degree of inhibition of platelet aggregation achieved with prasugrel within 30 minutes after treatment is similar to the peak effect of clopidogrel 6 hours after administration, suggesting that prolonged pretreatment may not be necessary for prasugrel to achieve its therapeutic effect.13 The more rapid onset of an antiplatelet effect with prasugrel than with clopidogrel may have played an important role in the efficacy benefit, an assertion supported by the reduction in the rate of early myocardial infarction (before day 3) (Figure 1B), despite the lack of pretreatment. However, when considering only end points occurring after day 3 (Figure 1C), the time at which the use of each drug should have resulted in the steady-state inhibition of platelet aggregation, the significant reduction in the rate of ischemic end points persisted, suggesting a continued benefit of greater inhibition of platelet aggregation during maintenance therapy.
Partly because of data reporting an improved inhibition of platelet aggregation,33,34 many clinicians have adopted the use of a higher-than-standard loading dose of clopidogrel in patients with PCI, a practice endorsed by guideline committees.35,36 The clinical-efficacy data supporting the use of such higher-dose clopidogrel have been from small studies and have been inconsistent.37,38 The use of prasugrel (60 mg) has been shown to result in a greater inhibition of platelet aggregation than the use of clopidogrel (600 mg) in patients with chronic coronary artery disease.15 The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation (PRINCIPLE)–TIMI 44 trial16 showed a markedly superior inhibition of platelet aggregation, with regard to multiple measures of platelet function, in patients who had undergone elective PCI and who had received the regimen of prasugrel used in our study as compared with a higher-than-standard dose regimen of clopidogrel (a 600-mg loading dose and a 150-mg maintenance dose) — though the PRINCIPLE–TIMI 44 trial was not powered to study clinical end points.
In our study of a selected population with moderate-to-high-risk acute coronary syndromes, on average, for every 1000 patients treated with prasugrel as compared with clopidogrel at the doses studied, 23 myocardial infarctions were prevented, with an excess of six non–CABG-related TIMI major hemorrhages. The estimated number of patients needed to be treated with prasugrel at the dosage studied, as compared with standard-dose clopidogrel, to prevent one primary efficacy end point during a 15-month period was 46. The number of patients who would have to be treated to result in an excess non–CABG-related TIMI major hemorrhage was 167.
Our data support the hypothesis that the greater inhibition of adenosine diphosphate–induced platelet aggregation by means of the tested regimen of prasugrel, a potent oral P2Y12 inhibitor, is more effective at preventing ischemic events than is the inhibition conferred by a standard regimen of clopidogrel. However, this beneficial effect is accompanied by an increase in the rate of major bleeding. When considering the choice of antiplatelet regimens for the treatment of patients with acute coronary syndromes who are undergoing PCI, clinicians need to weigh the benefits and risks of intensive inhibition of platelet aggregation.
Supported by research grants from Daiichi Sankyo and Eli Lilly.
Drs. Wiviott and Braunwald, Ms. McCabe, Ms. Murphy, and Drs. Gibson and Antman report receiving research grants from Eli Lilly, Daiichi Sankyo, and Sanofi-Aventis. In addition, Dr. Wiviott reports receiving consulting fees or paid advisory board fees from Sanofi-Aventis and lecture fees from Eli Lilly and Daiichi Sankyo; Dr. Braunwald, consulting fees or paid advisory board fees from Daiichi Sankyo and Sanofi-Aventis and lecture fees from Eli Lilly and Sanofi-Aventis; Dr. Montalescot, consulting fees or paid advisory board fees, lecture fees, and research grants from Bristol-Myers Squibb, Eli Lilly, and Sanofi-Aventis; and Dr. Ruzyllo, lecture fees from Eli Lilly. Dr. Ardissino reports receiving consulting fees or paid advisory board fees from AstraZeneca, Daiichi Sankyo, Merck Sharp & Dohme, and Sanofi-Aventis; lecture fees from Merck Sharp & Dohme and Sanofi-Aventis; and research grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme, Sanofi-Aventis, and Schering-Plough; and Dr. De Servi, consulting fees or paid advisory board fees from Eli Lilly, lecture fees from Eli Lilly and Sanofi-Aventis, and research grants from Sanofi-Aventis. Drs. Riesmeyer and Weerakkody report being employees of Eli Lilly and holding equity ownership or stock options therein. Dr. Gibson reports receiving lecture fees from Daiichi Sankyo, Eli Lilly, and Sanofi-Aventis; and Dr. Antman, consulting fees or paid advisory board fees from Sanofi-Aventis and lecture fees from Eli Lilly and Sanofi-Aventis. No other potential conflict of interest relevant to this article was reported.
This article (10.1056/NEJMoa0706482) was published at www.nejm.org on November 4, 2007.
Source Information
From Brigham and Women's Hospital and Harvard Medical School, Boston (S.D.W., E.B., C.H.M., S.A.M., C.M.G., E.M.A.); Institut de Cardiologie and INSERM Unit 856, Pitié–Salpêtrière University Hospital, Paris (G.M.); Instytut Kardiologii, Warsaw, Poland (W.R.); Bikur Cholim Hospital, Jerusalem, Israel (S.G.); Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany (F.-J.N.); Azienda Ospedaliero–Universitaria di Parma, Parma, Italy (D.A.); Azienda Ospedaliera Civile di Legano, Legano, Italy (S.D.S.); and Eli Lilly Research Laboratories, Indianapolis (J.R., G.W.).
Address reprint requests to Dr. Antman at the Cardiovascular Division, Brigham and Women's Hospital, TIMI Study Group, 350 Longwood Ave., 1st Fl., Boston, MA 02115, or at eantman@rics.bwh.harvard.edu.
The members of the Steering and Operations Committees of the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction (TRITON–TIMI) 38 are listed in the Appendix. The TRITON–TIMI 38 Investigators are listed in the Supplementary Appendix, available with the full text of this article at www.nejm.org.
Appendix
The members of the Operations and Steering Committees of the TRITON–TIMI 38 were as follows (with principal investigators at participating centers listed separately, in the Supplementary Appendix): TIMI Study Group, Brigham and Women's Hospital, Boston: E. Braunwald (study chair), E.M. Antman (principal investigator), S.D. Wiviott (investigator), C.M. Gibson (investigator), C.H. McCabe (director), S.A. Murphy (lead biostatistician), J. Buros (biostatistician), S. McHale (project manager); Sponsors: Eli Lilly — J. Riesmeyer, J.A. Ware, G. Weerakkody, W. Macias, E. Moscarelli, J. Croaning; Daiichi Sankyo — J. Warmke, F. Plat, T. Bocanegra, J. Hanyok, C. Hsu; Data Coordinating Center (Quintiles): K. Long, D. White, S. Boyle; Steering Committee: all members of the TIMI Study Group and sponsor staff listed above; France — G. Montalescot (coprincipal investigator), P.G. Steg; Norway — L. Aaberge; Denmark — H.R. Anderson; Italy — D. Ardissino, S. De Servi; Australia — P. Aylward; Chile — R. Corbalan; South Africa — A. Dalby; Slovak Republic — V. Fridrich; United States — M. Furman, D. Kereiakes, N. Kleiman, J. Popma; Canada — S. Goodman; Israel — S. Gottlieb; Argentina — E. Gurfinkel; Austria — K. Huber; Hungary — M. Keltai; Spain — J. Lopez-Sendon; Switzerland — T. Luscher; Germany — F.-J. Neumann, A. Schomig; Brazil — J. Nicolau; Poland — W. Ruzyllo; Sweden — F. Schersten; Portugal — R. Seabra-Gomes; Iceland — A. Sigurdsson; Finland — M. Syvanne; Belgium — F. Van de Werf; the Netherlands — F. Verheugt; New Zealand — H. White; Czech Republic — P. Widimsky; United Kingdom — R. Wilcox; Data Monitoring Committee: D.O. Williams (chair); D. DeMets (statistician); C. Bode, S. King, U. Sigwart; Clinical Events Committee: B. Scirica (administrative chair), E. Awtry, C. Berger, S. Bernard, A. Desai, E. Gelfand, C. Ho, F. Jaffer, S. Kathiresan, D. Leeman, M. Link, W. Maisel, F. Ruberg, U. Tedrow, J. Vita, P. Zimetbaum.
- References
References
1
The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
Full Text | Web of Science | Medline2
Chen ZM ,Jiang LX ,Chen YP , et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-1621
CrossRef | Web of Science | Medline3
Sabatine MS ,Cannon CP ,Gibson CM , et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-1189
Full Text | Web of Science | Medline4
Mehta SR ,Yusuf S . Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. J Am Coll Cardiol 2003;41:Suppl S:79S-88S
CrossRef | Web of Science | Medline5
Steinhubl SR ,Berger PB ,Mann JT III , et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-2420[Erratum, JAMA 2003;289:987.]
CrossRef | Web of Science | Medline6
Gurbel PA ,Bliden KP . Durability of platelet inhibition by clopidogrel. Am J Cardiol 2003;91:1123-1125
CrossRef | Web of Science | Medline7
Serebruany VL ,Steinhubl SR ,Berger PB ,Malinin AI ,Bhatt DL ,Topol EJ . Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-251
CrossRef | Web of Science | Medline8
Buonamici P ,Marcucci R ,Migliorini A , et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49:2312-2317
CrossRef | Web of Science | Medline9
Gurbel PA ,Bliden KP ,Samara W , et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005;46:1827-1832
CrossRef | Web of Science | Medline10
Hochholzer W ,Trenk D ,Bestehorn HP , et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48:1742-1750
CrossRef | Web of Science | Medline11
Matetzky S ,Shenkman B ,Guetta V , et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175
CrossRef | Web of Science | Medline12
Niitsu Y ,Jakubowski JA ,Sugidachi A ,Asai F . Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost 2005;31:184-194
CrossRef | Web of Science | Medline13
Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153:66.e9-66.e16.
14
Jernberg T ,Payne CD ,Winters KJ , et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166-1173
CrossRef | Web of Science | Medline15
Varenhorst C ,Braun O ,James S , et al. Greater inhibition of platelet aggregation with prasugrel 60 mg loading dose compared with a clopidogrel 600 mg loading dose in aspirin-treated patients. Eur Heart J 2007;28:Suppl:189-18916
Wiviott SD, Trenk D, Frelinger AL III, et al. Prasugrel compared to high loading and maintenance dose clopidogrel in patients with planned percutaneous coronary intervention: the PRINCIPLE-TIMI 44 trial. Circulation (in press).
17
Wiviott SD ,Antman EM ,Winters KJ , et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005;111:3366-3373
CrossRef | Web of Science | Medline18
Wiviott SD ,Antman EM ,Gibson CM , et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006;152:627-635
CrossRef | Web of Science | Medline19
Antman EM ,Cohen M ,Bernink PJ , et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000;284:835-842
CrossRef | Web of Science | Medline20
Mauri L ,Hsieh W ,Massaro JM ,Ho KKL ,D'Agostino R ,Cutlip DE . Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-1029
Full Text | Web of Science | Medline21
Antithrombotic Trialists' Collaboration
CrossRef | Web of Science22
Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-1435[Erratum, Lancet 1997;350:744.]
CrossRef | Web of Science | Medline23
The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators
Full Text | Web of Science | Medline24
The PURSUIT Trial Investigators
Full Text | Web of Science | Medline25
Fox KA ,Mehta SR ,Peters R , et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004;110:1202-1208
CrossRef | Web of Science | Medline26
Alexander KP ,Chen AY ,Roe MT , et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005;294:3108-3116
CrossRef | Web of Science | Medline27
Mahaffey KW ,Harrington RA ,Simoons ML , et al. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Circulation 1999;99:2371-2377
Web of Science | Medline28
Diener HC ,Bogousslavsky J ,Brass LM , et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-337
CrossRef | Web of Science | Medline29
Carey RJ . Warfarin-induced rectal bleeding as clue to colon cancer. Lancet 1984;1:505-506
CrossRef | Web of Science | Medline30
Jaffin BW ,Bliss CM ,LaMont JT . Significance of occult gastrointestinal bleeding during anticoagulation therapy. Am J Med 1987;83:269-272
CrossRef | Web of Science | Medline31
Campbell CL ,Smyth S ,Montalescot G ,Steinhubl SR . Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007;297:2018-2024
CrossRef | Web of Science | Medline32
Cannon CP . Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials. Clin Cardiol 2000;23:Suppl 6:VI-14
CrossRef | Medline33
Montalescot G ,Sideris G ,Meuleman C , et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006;48:931-938
CrossRef | Web of Science | Medline34
von Beckerath N ,Taubert D ,Pogatsa-Murray G ,Schomig E ,Kastrati A ,Schomig A . Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005;112:2946-2950
Web of Science | Medline35
Silber S ,Albertsson P ,Aviles FF , et al. Guidelines for percutaneous coronary interventions. Eur Heart J 2005;26:804-847
CrossRef | Web of Science | Medline36
Smith SC Jr ,Feldman TE ,Hirshfeld JW Jr , et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:e166-e286
CrossRef | Medline37
Patti G ,Colonna G ,Pasceri V ,Pepe LL ,Montinaro A ,Di Sciascio G . Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) study. Circulation 2005;111:2099-2106
CrossRef | Web of Science | Medline38
Wolfram RM ,Torguson RL ,Hassani SE , et al. Clopidogrel loading dose (300 versus 600 mg) strategies for patients with stable angina pectoris subjected to percutaneous coronary intervention. Am J Cardiol 2006;97:984-989
CrossRef | Web of Science | Medline
- Citing Articles (855)
Citing Articles
1
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting, Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2012) 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary. Catheterization and Cardiovascular Interventions 79:3, 453-495
CrossRef2
Teddy Kosoglou, Walter K. Kraft, Bharath Kumar, Paul Statkevich, Fengjuan Xuan, Lei Ma, Lisa K. Jennings, James E. Schiller, Ronald B. Langdon, David L. Cutler. (2012) Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease. European Journal of Clinical Pharmacology
CrossRef3
Alexander Altenburg, Patrick Haage. (2012) Antiplatelet and Anticoagulant Drugs in Interventional Radiology. CardioVascular and Interventional Radiology 35:1, 30-42
CrossRef4
Ulrica Alström, Fredrik Granath, Örjan Friberg, Anders Ekbom, Elisabeth Ståhle. (2012) Risk factors for re-exploration due to bleeding after coronary artery bypass grafting. Scandinavian Cardiovascular Journal 46:1, 39-44
CrossRef5
Luke Kim, Konstantinos Charitakis, Rajesh V. Swaminathan, Dmitriy N. Feldman. (2012) Novel Antiplatelet Therapies. Current Atherosclerosis Reports 14:1, 78-84
CrossRef6
Jean-Philippe Collet, Stephen O’Connor. (2012) Clinical effects and outcomes with new P2Y12 inhibitors in ACS. Fundamental & Clinical Pharmacology 26:1, 16-18
CrossRef7
Josephine A. Mauskopf, Jonathan B. Graham, Jay P. Bae, Krishnan Ramaswamy, Anthony J. Zagar, Elizabeth A. Magnuson, David J. Cohen, Eric S. Meadows. (2012) Cost-effectiveness of prasugrel in a US managed care population. Journal of Medical Economics 15:1, 166-174
CrossRef8
Davide Capodanno, Valeria Calvi, Corrado Tamburino. (2012) Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Journal of Cardiovascular Medicine 13:2, 162-163
CrossRef9
Davide Capodanno, Dominick J. Angiolillo. (2012) Antithrombotic Pharmacotherapy in the Elderly: General Issues and Clinical Conundrums. Current Treatment Options in Cardiovascular Medicine 14:1, 57-68
CrossRef10
Mathieu Pankert, Jacques Quilici, Thomas Cuisset. (2012) Role of Antiplatelet Therapy in Secondary Prevention of Acute Coronary Syndrome. Journal of Cardiovascular Translational Research 5:1, 41-51
CrossRef11
Robert W. Harrison, Kenneth W. Mahaffey. (2012) Clopidogrel and PPI Interaction: Clinically Relevant or Not?. Current Cardiology Reports 14:1, 49-58
CrossRef12
Thomas Höchtl, Iannis Tentzeris, Karsten Schrör, Kurt Huber. (2012) Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents. Fundamental & Clinical Pharmacology 26:1, 2-10
CrossRef13
Brigitte E. Ickx, David Faraoni. (2012) Management of the clotting system. Current Opinion in Anaesthesiology 25:1, 80-85
CrossRef14
Christian W. Hamm, Jean-Pierre Bassand, Stefan Agewall, Jeroen Bax, Eric Boersma, Hector Bueno, Pio Caso, Dariusz Dudek, Stephan Gielen, Kurt Huber, Magnus Ohman, Mark C. Petrie, Frank Sonntag, Miguel Sousa Uva, Robert F. Storey, William Wijns, Doron Zahger. (2012) Guía de práctica clínica de la ESC para el manejo del síndrome coronario agudo en pacientes sin elevación persistente del segmento ST. Revista Española de Cardiología 65:2, 173.e1-173.e55
CrossRef15
Karsten Schrör, Jolanta M. Siller-Matula, Kurt Huber. (2012) Pharmacokinetic basis of the antiplatelet action of prasugrel. Fundamental & Clinical Pharmacology 26:1, 39-46
CrossRef16
Julio F. Marchini, Andre Manica, Kevin Croce. (2012) Stent Thrombosis: Understanding and Managing a Critical Problem. Current Treatment Options in Cardiovascular Medicine 14:1, 91-107
CrossRef17
Sergio Leonardi, Pierluigi Tricoci, Kenneth W. Mahaffey. (2012) Promises of PAR-1 Inhibition in Acute Coronary Syndrome. Current Cardiology Reports 14:1, 32-39
CrossRef18
Sandra L. Close. (2012) Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant?. Fundamental & Clinical Pharmacology 26:1, 19-26
CrossRef19
Pravin Pratap, Sameer Gupta, Michael Berlowtiz. (2012) Routine Invasive Versus Conservative Management Strategies in Acute Coronary Syndrome: Time for a “Hybrid” Approach. Journal of Cardiovascular Translational Research 5:1, 30-40
CrossRef20
Mark R. Thomas, Robert F. Storey. (2012) Optimal Management of Antiplatelet Therapy and Proton Pump Inhibition Following Percutaneous Coronary Intervention. Current Treatment Options in Cardiovascular Medicine 14:1, 24-38
CrossRef21
Erin Y Oh, Teena Abraham, Nasser Saad, Jonathan H Rapp, Fabienne L Vastey, Eric Balmir. (2012) A comprehensive comparative review of adenosine diphosphate receptor antagonists. Expert Opinion on Pharmacotherapy 13:2, 175-191
CrossRef22
Harvey D. White, Derek P. Chew, Harold L. Dauerman, Kenneth W. Mahaffey, C. Michael Gibson, Gregg W. Stone, Luis Gruberg, Robert A. Harrington, Deepak L. Bhatt. (2012) Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. American Heart Journal 163:2, 182-190.e4
CrossRef23
Kirk N. Garratt, David P. Lee, Eileen M. Rose, Kellie J. Windle, Hsini Liao, Chuke E. Nwachuku, Kenneth J. Winters, Thomas S. Bowman, Keith D. Dawkins. (2012) Rationale and design of the TAXUS Libertē Post-Approval Study: Examination of patients receiving the TAXUS Liberté stent with concomitant prasugrel therapy in routine interventional cardiology practice. American Heart Journal 163:2, 142-148.e6
CrossRef24
Tomohisa Tada, Robert A. Byrne, Adnan Kastrati. (2012) A case where the principle of “one question, one answer” may work better. American Heart Journal 163:2, 133-135
CrossRef25
Raban Jeger, Matthias Pfisterer, Hannes Alber, Franz Eberli, Søren Galatius, Christoph Naber, Giovanni Pedrazzini, Hans Rickli, Jan Skov Jensen, André Vuilliomenet, Nicole Gilgen, Christoph Kaiser. (2012) Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: The BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design. American Heart Journal 163:2, 136-141.e1
CrossRef26
Jolanta M. Siller-Matula, Georg Delle-Karth, Günter Christ, Thomas Neunteufl, Gerald Maurer, Kurt Huber, Alexander Tolios, Christa Drucker, Bernd Jilma. (2012) Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. International Journal of Cardiology
CrossRef27
Estelle Vautrin, Gilles Barone-Rochette, Benoit Berthoud, Stéphanie Marlière, Hélène Bouvaist, Bernard Bertrand, Olivier Ormezzano, Jacques Machecourt, Gérald Vanzetto. (2012) Very late stent thrombosis after drug eluting stent: Management therapy guided by intravascular ultrasound imaging. International Journal of Cardiology 154:3, 349-351
CrossRef28
Udaya S. Tantry, Eliano P. Navarese, Paul A. Gurbel. (2012) Does Gender have an Influence on Platelet Function and the Efficacy of Oral Antiplatelet Therapy?. Interventional Cardiology Clinics
CrossRef29
P. W. Armstrong, R. A. Harrington. (2012) Road mapping ATLAS ACS 2: are we there yet?. European Heart Journal
CrossRef30
Joanne Shannon, Antonio Colombo. (2012) Revascularization in multivessel CAD: a functional approach. Nature Reviews Cardiology
CrossRef31
Chris Dockendorff, Omozuanvbo Aisiku, Lynn VerPlank, James R. Dilks, Daniel A. Smith, Susanna F. Gunnink, Louisa Dowal, Joseph Negri, Michelle Palmer, Lawrence MacPherson, Stuart L. Schreiber, Robert Flaumenhaft. (2012) Discovery of 1,3-Diaminobenzenes as Selective Inhibitors of Platelet Activation at the PAR1 Receptor. ACS Medicinal Chemistry Letters120130112355004
CrossRef32
P. A. Gurbel, E. M. Ohman, Y.-H. Jeong, U. S. Tantry. (2012) Toward a therapeutic window for antiplatelet therapy in the elderly. European Heart Journal
CrossRef33
Dobri Hazarbasanov, Vasil Velchev, Bozhidar Finkov, Arman Postadjian, Emil Kostov, Nizar Rifai, Dániel Aradi. (2012) Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis
CrossRef34
Sampath Aalla, Goverdhan Gilla, Dattatray Shamrao Metil, Anumula Raghupathi Reddy, Prabhakar Reddy Vummenthala, Padi Pratap Reddy. (2012) Process improvements of prasugrel hydrochloride–An adenosine diphosphate receptor antagonist. Organic Process Research & Development120106083643009
CrossRef35
Robert Janknegt, Lex Ruiters, Hugo ten Cate. (2012) InforMatrix: ADP antagonists in acute coronary syndromes. Expert Opinion on Pharmacotherapy1-29
CrossRef36
Mega, Jessica L., Braunwald, Eugene, Wiviott, Stephen D., Bassand, Jean-Pierre, Bhatt, Deepak L., Bode, Christoph, Burton, Paul, Cohen, Marc, Cook-Bruns, Nancy, Fox, Keith A.A., Goto, Shinya, Murphy, Sabina A., Plotnikov, Alexei N., Schneider, David, Sun, Xiang, Verheugt, Freek W.A., Gibson, C. Michael, . (2012) Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. New England Journal of Medicine 366:1, 9-19
Full Text37
Roe, Matthew T., Ohman, E. Magnus, . (2012) A New Era in Secondary Prevention after Acute Coronary Syndrome. New England Journal of Medicine 366:1, 85-87
Full Text38
Tricoci, Pierluigi, Huang, Zhen, Held, Claes, Moliterno, David J., Armstrong, Paul W., Van de Werf, Frans, White, Harvey D., Aylward, Philip E., Wallentin, Lars, Chen, Edmond, Lokhnygina, Yuliya, Pei, Jinglan, Leonardi, Sergio, Rorick, Tyrus L., Kilian, Ann M., Jennings, Lisa H.K., Ambrosio, Giuseppe, Bode, Christoph, Cequier, Angel, Cornel, Jan H., Diaz, Rafael, Erkan, Aycan, Huber, Kurt, Hudson, Michael P., Jiang, Lixin, Jukema, J. Wouter, Lewis, Basil S., Lincoff, A. Michael, Montalescot, Gilles, Nicolau, José Carlos, Ogawa, Hisao, Pfisterer, Matthias, Prieto, Juan Carlos, Ruzyllo, Witold, Sinnaeve, Peter R., Storey, Robert F., Valgimigli, Marco, Whellan, David J., Widimsky, Petr, Strony, John, Harrington, Robert A., Mahaffey, Kenneth W., . (2012) Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. New England Journal of Medicine 366:1, 20-33
Full Text39
Guliz Erdem, Marcus Flather. (2012) Evaluación del riesgo de hemorragia en los síndromes coronarios agudos. Revista Española de Cardiología 65:1, 4-6
CrossRef40
L. M. Rademakers, W. Dewilde, D. Kerkhof. (2012) Early double stent thrombosis associated with clopidogrel hyporesponsivenesss. Netherlands Heart Journal 20:1, 38-41
CrossRef41
William B. White, Deborah Grady, Linda C. Giudice, Scott M. Berry, Joanne Zborowski, Michael C. Snabes. (2012) A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder. American Heart Journal 163:1, 27-32
CrossRef42
Omar Ait-Mokhtar, Laurent Bonello, Saida Benamara, Franck Paganelli. (2012) High on Treatment Platelet Reactivity. Heart, Lung and Circulation 21:1, 12-21
CrossRef43
Sukhjinder S. Nijjer, Justin E. Davies, Darrel P. Francis. (2012) Quantitative comparison of clopidogrel 600mg, prasugrel and ticagrelor, against clopidogrel 300mg on major adverse cardiovascular events and bleeding in coronary stenting: Synthesis of CURRENT-OASIS-7, TRITON-TIMI-38 and PLATO. International Journal of Cardiology
CrossRef44
Eric L. Eisenstein, David F. Kong, Patricia A. Cowper, Jay P. Bae, Krishnan Ramaswamy, Kevin J. Anstrom. (2012) Nonfatal myocardial infarction and long-term outcomes in coronary artery disease. American Heart Journal 163:1, 95-103
CrossRef45
Nanette K. Wenger. (2012) 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): Highlights for the Clinician. Clinical Cardiology 35:1, 3-8
CrossRef46
Guido Parodi, Benedetta Bellandi, Francesco Venditti, Nazario Carrabba, Renato Valenti, Angela Migliorini, Silvia Grassellini, Erica Ramazzotti, David Antoniucci. (2012) Residual Platelet Reactivity, Bleedings, and Adherence to Treatment in Patients Having Coronary Stent Implantation Treated With Prasugrel. The American Journal of Cardiology 109:2, 214-218
CrossRef47
Ehrin J. Armstrong, Khung Keong Yeo, Usman Javed, Ehtisham Mahmud, Mitul Patel, Kendrick A. Shunk, John S. MacGregor, Reginald I. Low, Jason H. Rogers. (2012) Angiographic Stent Thrombosis at Coronary Bifurcations. JACC: Cardiovascular Interventions 5:1, 57-63
CrossRef48
Guliz Erdem, Marcus Flather. (2012) Assessing Bleeding Risk in Acute Coronary Syndromes. Revista Española de Cardiología (English Edition) 65:1, 4-6
CrossRef49
Giuseppe Musumeci, Roberta Rossini, Corrado Lettieri, Davide Capodanno, Michele Romano, Renato Rosiello, Giulio Guagliumi, Orazio Valsecchi, Antonello Gavazzi, Dominick J. Angiolillo. (2012) Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef50
Alberto Menozzi, Daniela Lina, Giulio Conte, Francesco Mantovani, Diego Ardissino. (2012) Antiplatelet therapy in acute coronary syndromes. Expert Opinion on Pharmacotherapy 13:1, 27-42
CrossRef51
Tullio Palmerini, Laura Alessi, Nicole Rizzo, George Dangas. (2012) Percutaneous revascularization of left main. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef52
Karthik Balasubramaniam, Girish N. Viswanathan, Sally M. Marshall, Azfar G. Zaman. (2012) Increased Atherothrombotic Burden in Patients with Diabetes Mellitus and Acute Coronary Syndrome: A Review of Antiplatelet Therapy. Cardiology Research and Practice 2012, 1-18
CrossRef53
Ronan P. Kelly, Sandra L. Close, Nagy A. Farid, Kenneth J. Winters, Lei Shen, Fanni Natanegara, Joseph A. Jakubowski, Mary Ho, Joseph R. Walker, David S. Small. (2012) Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. British Journal of Clinical Pharmacology 73:1, 93-105
CrossRef54
Kyung Woo Park, Hyo-Soo Kim. (2012) Options to Overcome Clopidogrel Response Variability. Circulation Journal 76:2, 287-292
CrossRef55
Grzegorz Grzesk, Marek Kozinski, Eliano Pio Navarese, Marek Krzyzanowski, Elzbieta Grzesk, Aldona Kubica, Jolanta Maria Siller-Matula, Fausto Castriota, Jacek Kubica. (2012) Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: A placebo-controlled study in rats. Thrombosis Research
CrossRef56
Laurent Bonello, Laurence Camoin-Jau, Julien Mancini, Jacques Bessereau, Charlotte Grosdidier, Marie-Christine Alessi, Michel Ostorero, Françoise Dignat-George, Franck Paganelli. (2012) Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade. Thrombosis Research
CrossRef57
Thomas O. Bergmeijer, Jurriën M. ten Berg. (2012) Valor de la determinación del genotipo de CYP2C19 *2 y *17 en la práctica clínica. Prometedor, aunque todavía no está listo. Revista Española de Cardiología
CrossRef58
Thomas O. Bergmeijer, Jurriën M. ten Berg. (2012) Value of CYP2C19 *2 and *17 Genotyping in Clinical Practice. Promising but Not Ready Yet. Revista Española de Cardiología (English Edition)
CrossRef59
S. D. Kristensen, M. Würtz, E. L. Grove, R. De Caterina, K. Huber, D. J. Moliterno, F.-J. Neumann. (2012) Contemporary use of glycoprotein IIb/IIIa inhibitors. Thrombosis and Haemostasis 107:2,
CrossRef60
Peter Damman, Pier Woudstra, Wichert J. Kuijt, Robbert J. Winter, Stefan K. James. (2011) P2Y12 platelet inhibition in clinical practice. Journal of Thrombosis and Thrombolysis
CrossRef61
D C Sylvester, A P Coatesworth. (2011) Antiplatelet therapy in ENT surgery: a review. The Journal of Laryngology & Otology1-6
CrossRef62
J. Wouter Jukema, Jean-Philippe Collet, Leonardo De Luca. (2011) Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel. Current Medical Research and Opinion1-9
CrossRef63
Karin Mauer, Jorge F. Saucedo. 2011. Cardiology-In-Depth Look: Advances in Antiplatelet Therapy. .
CrossRef64
Paul A. Gurbel, Udaya S. Tantry. 2011. Resistance to Antiplatelet Therapy. .
CrossRef65
(2011) How much of the world do you need for meaningful clinical trials? * Christmas Greetings 2011 * Book review: 'Cardiovascular catheterization and intervention' * A Textbook of Coronary, Peripheral, and Structural Heart Disease * The Brazilian Archives of Cardiology is the only cardiology journal in Latino America and the Southern hemisphere with an impact factor * The Mediterranean Diet, Part II * The TIMI story. European Heart Journal 32:24, 3057-3063
CrossRef66
G. Lemesle, C. Delhaye. (2011) La thrombose de stent, de plus en plus rare !. Annales de Cardiologie et d'Angéiologie 60:6, 338-346
CrossRef67
Laurent Bonello, Florence Sabatier, Laurence Camoin-Jau, Franck Paganelli, Françoise Dignat-George. (2011) Platelets and endothelium: Two key players in percutaneous coronary intervention. Archives of Cardiovascular Diseases 104:12, 601-603
CrossRef68
D. ALEXOPOULOS, A. PANAGIOTOU, I. XANTHOPOULOU, D. KOMNINAKIS, G. KASSIMIS, P. DAVLOUROS, C. FOURTOUNAS, D. GOUMENOS. (2011) Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. Journal of Thrombosis and Haemostasis 9:12, 2379-2385
CrossRef69
S. S. Nijjer, G. Watson, T. Athanasiou, I. S. Malik. (2011) Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. European Heart Journal 32:23, 2970-2988
CrossRef70
S. Koul, J. G. Smith, F. Schersten, S. James, B. Lagerqvist, D. Erlinge. (2011) Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. European Heart Journal 32:23, 2989-2997
CrossRef71
Shinichiro Uchiyama. (2011) Clopidogrel Resistance: Identifying and Overcoming a Barrier to Effective Antiplatelet Treatment. Cardiovascular Therapeutics 29:6, e100-e111
CrossRef72
Eugenia Nikolsky, Roxana Mehran, George D. Dangas, Jennifer Yu, Helen Parise, Ke Xu, Stuart J. Pocock, Gregg W. Stone. (2011) Outcomes of Patients Treated With Triple Antithrombotic Therapy After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] Trial). The American Journal of Cardiology
CrossRef73
Yannick Sudrat, Jennifer Even, Capucine Le Goubey, Jean-Philippe Molle, Laurent Devoize. (2011) Nouvelles stratégies anticoagulantes et antiagrégantes : état des lieux et proposition de prise en charge en chirurgie orale. Actualités Odonto-Stomatologiques:256, 277-288
CrossRef74
Marco Valgimigli. (2011) Clinical dilemmas on managing antiplatelet therapies after percutaneous coronary intervention. Current Opinion in Cardiology 26, S1-S3
CrossRef75
Michael J. Zellweger, Matthias E. Pfisterer. (2011) Therapeutic Strategies in Patients with Chronic Stable Coronary Artery Disease. Cardiovascular Therapeutics 29:6, e23-e30
CrossRef76
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. Journal of the American College of Cardiology 58:24, 2550-2583
CrossRef77
E. Franco, I.J. Núñez-Gil, D. Vivas, B. Ruiz Mateos, B. Ibañez, N. Gonzalo, C. Macaya, A. Fernández Ortiz. (2011) Heart failure and non-ST-segment elevation myocardial infarction: A review for a widespread situation. European Journal of Internal Medicine 22:6, 533-540
CrossRef78
Leonardo Bolognese, Dominick J. Angiolillo. (2011) Unravelling the benefit against the risk of long-term dual antiplatelet therapy. Current Opinion in Cardiology 26, S22-S30
CrossRef79
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Journal of the American College of Cardiology 58:24, e44-e122
CrossRef80
, B. Scheller, B. Levenson, M. Joner, R. Zahn, V. Klauss, C. Naber, V. Schächinger, A. Elsässer. (2011) Medikamente freisetzende Koronarstents und mit Medikamenten beschichtete Ballonkatheter. Der Kardiologe 5:6, 411-435
CrossRef81
Joseph A. Jakubowski, Chunmei Zhou, Blaine Egan, Maggie Wells, Maya Kotob-Yahfoufi, Atsuhiro Sugidachi, Jeffrey R. Dahlen. (2011) Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y 12 antagonism. Platelets 22:8, 619-625
CrossRef82
Takamichi Ono, Koichi Kaikita, Seiji Hokimoto, Satomi Iwashita, Koichiro Yamamoto, Yuji Miyazaki, Eiji Horio, Koji Sato, Kenichi Tsujita, Tomohide Abe, Mariko Deguchi, Shinji Tayama, Hitoshi Sumida, Seigo Sugiyama, Hiroshige Yamabe, Sunao Nakamura, Kazuko Nakagawa, Hisao Ogawa. (2011) Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention. Thrombosis Research 128:6, e130-e136
CrossRef83
Anupama Shivaraju, Vikas Patel, Gregg C. Fonarow, Hui Xie, Adhir R. Shroff, Mladen I. Vidovich. (2011) Temporal trends in gastrointestinal bleeding associated with percutaneous coronary intervention: Analysis of the 1998-2006 Nationwide Inpatient Sample (NIS) database. American Heart Journal 162:6, 1062-1068.e5
CrossRef84
L. David Hillis, Peter K. Smith, Jeffrey L. Anderson, John A. Bittl, Charles R. Bridges, John G. Byrne, Joaquin E. Cigarroa, Verdi J. DiSesa, Loren F. Hiratzka, Adolph M. Hutter, Michael E. Jessen, Ellen C. Keeley, Stephen J. Lahey, Richard A. Lange, Martin J. London, Michael J. Mack, Manesh R. Patel, John D. Puskas, Joseph F. Sabik, Ola Selnes, David M. Shahian, Jeffrey C. Trost, Michael D. Winniford. (2011) 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: Executive Summary. Journal of the American College of Cardiology 58:24, 2584-2614
CrossRef85
Giuseppe Musumeci, Emilio Di Lorenzo, Marco Valgimigli. (2011) Dual antiplatelet therapy duration. Current Opinion in Cardiology 26, S4-S14
CrossRef86
AMEET BAKHAI, JEAN FERRIERES, ANDRES IÑIGUEZ, MAGALI SARTRAL, MARK BELGER, CLAUDE SCHMITT, UWE ZEYMER. (2011) Clinical Outcomes, Resource Use, and Costs at 1 Year in Patients with Acute Coronary Syndrome Undergoing PCI:. Journal of Interventional Cardiologyno-no
CrossRef87
Sebastien Armero, Laurent Bonello, Julie Berbis, Laurence Camoin-Jau, Gilles Lemesle, Laurent Jacquin, Caroline Bonello-Burignat, Michel Pansieri, Frederic Collet, Michel Ostorero, Françoise Dignat-George, Franck Paganelli. (2011) Rate of Nuisance Bleedings and Impact on Compliance to Prasugrel in Acute Coronary Syndromes. The American Journal of Cardiology 108:12, 1710-1713
CrossRef88
Hiroyoshi Yokoi, Takeshi Kimura, Takaaki Isshiki, Hisao Ogawa, Yasuo Ikeda. (2011) Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention. Thrombosis Research
CrossRef89
J. A. de Lemos, E. S. Brilakis. (2011) No free lunches: balancing bleeding and efficacy with ticagrelor. European Heart Journal 32:23, 2919-2921
CrossRef90
Timm Bauer, Uwe Zeymer, Matthias Hochadel, Helge Möllmann, Franz Weidinger, Ralf Zahn, Holger M. Nef, Christian W. Hamm, Jean Marco, Anselm K. Gitt. (2011) Prima-vista multi-vessel percutaneous coronary intervention in haemodynamically stable patients with acute coronary syndromes: Analysis of over 4.400 patients in the EHS-PCI registry. International Journal of Cardiology
CrossRef91
C. Patrono, F. Andreotti, H. Arnesen, L. Badimon, C. Baigent, J.-P. Collet, R. De Caterina, D. Gulba, K. Huber, S. Husted, S. D. Kristensen, J. Morais, F.-J. Neumann, L. H. Rasmussen, A. Siegbahn, P.-G. Steg, R. F. Storey, F. Van de Werf, F. Verheugt. (2011) Antiplatelet agents for the treatment and prevention of atherothrombosis. European Heart Journal 32:23, 2922-2932
CrossRef92
R. C. Becker, J. P. Bassand, A. Budaj, D. M. Wojdyla, S. K. James, J. H. Cornel, J. French, C. Held, J. Horrow, S. Husted, J. Lopez-Sendon, R. Lassila, K. W. Mahaffey, R. F. Storey, R. A. Harrington, L. Wallentin. (2011) Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal 32:23, 2933-2944
CrossRef93
L. David Hillis, Peter K. Smith, Jeffrey L. Anderson, John A. Bittl, Charles R. Bridges, John G. Byrne, Joaquin E. Cigarroa, Verdi J. DiSesa, Loren F. Hiratzka, Adolph M. Hutter, Michael E. Jessen, Ellen C. Keeley, Stephen J. Lahey, Richard A. Lange, Martin J. London, Michael J. Mack, Manesh R. Patel, John D. Puskas, Joseph F. Sabik, Ola Selnes, David M. Shahian, Jeffrey C. Trost, Michael D. Winniford. (2011) 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. Journal of the American College of Cardiology 58:24, e123-e210
CrossRef94
, C. W. Hamm, J.-P. Bassand, S. Agewall, J. Bax, E. Boersma, H. Bueno, P. Caso, D. Dudek, S. Gielen, K. Huber, M. Ohman, M. C. Petrie, F. Sonntag, M. S. Uva, R. F. Storey, W. Wijns, D. Zahger, , J. J. Bax, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, C. Funck-Brentano, D. Hasdai, A. Hoes, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, A. Torbicki, A. Vahanian, S. Windecker, , S. Windecker, S. Achenbach, L. Badimon, M. Bertrand, H. E. Botker, J.-P. Collet, F. Crea, N. Danchin, E. Falk, J. Goudevenos, D. Gulba, R. Hambrecht, J. Herrmann, A. Kastrati, K. Kjeldsen, S. D. Kristensen, P. Lancellotti, J. Mehilli, B. Merkely, G. Montalescot, F.-J. Neumann, L. Neyses, J. Perk, M. Roffi, F. Romeo, M. Ruda, E. Swahn, M. Valgimigli, C. J. Vrints, P. Widimsky. (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal 32:23, 2999-3054
CrossRef95
Paul St. Laurent. (2011) Acute Coronary Syndrome: New and Evolving Therapies. Critical Care Nursing Clinics of North America 23:4, 559-571
CrossRef96
Dimitrios Alexopoulos. (2011) P2Y12 inhibitors adjunctive to primary PCI therapy in STEMI: Fighting against the activated platelets. International Journal of Cardiology
CrossRef97
Alberto Cordero, Pedro Morillas, Vicente Bertomeu-González, Juan Quiles, Federico Soria, Josep Guindo, Pilar Mazón, Manuel Anguita, Luís Rodríguez-Padial, José Ramón González-Juanatey, Vicente Bertomeu-Martínez, . (2011) Pathological ankle-brachial index is equivalent of advanced age in acute coronary syndromes. European Journal of Clinical Investigation 41:12, 1268-1274
CrossRef98
Thomas Cuisset, Mathieu Pankert, Jacques Quilici. (2011) Synergy between pharmacological and mechanical reperfusion in ST-segment elevation myocardial infarction patients. Journal of Cardiovascular Medicine 12:12, 860-867
CrossRef99
G. DE LUCA, F. BELLANDI, K. HUBER, M. NOC, A. S. PETRONIO, H. -R. ARNTZ, M. MAIOLI, H. M. GABRIEL, S. ZORMAN, M. DE CARLO, T. RAKOWSKI, M. GYONGYOSI, D. DUDEK. (2011) Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient’s data meta-analysis. Journal of Thrombosis and Haemostasis 9:12, 2361-2370
CrossRef100
Thomas Gremmel, Christoph W. Kopp, Deddo Moertl, Daniela Seidinger, Renate Koppensteiner, Simon Panzer, Christine Mannhalter, Sabine Steiner. (2011) Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests. Thrombosis Research
CrossRef101
M. Elbaz. (2011) Le rapport bénéfice-risque des nouveaux agents antiagrégants plaquettaires. Archives des Maladies du Coeur et des Vaisseaux - Pratique 2011:203, 27-31
CrossRef102
B. A. Konkle. (2011) Acquired Disorders of Platelet Function. Hematology 2011:1, 391-396
CrossRef103
A. D. Michelson. (2011) Advances in Antiplatelet Therapy. Hematology 2011:1, 62-69
CrossRef104
Jack Leon-Max Mutnick. (2011) Desensitization to prasugrel: cardiology's increased need for allergy consultation. Annals of Allergy, Asthma & Immunology
CrossRef105
J. Silvain, G. Cayla, J.-S. Hulot, J. Finzi, M. Kerneis, S. A. O'Connor, A. Bellemain-Appaix, O. Barthelemy, F. Beygui, J.-P. Collet, G. Montalescot. (2011) High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. European Heart Journal
CrossRef106
J. Oldgren, A. Budaj, C. B. Granger, Y. Khder, J. Roberts, A. Siegbahn, J. G. P. Tijssen, F. Van de Werf, L. Wallentin, . (2011) Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. European Heart Journal 32:22, 2781-2789
CrossRef107
M. Roffi, D. J. Angiolillo, A. P. Kappetein. (2011) Current concepts on coronary revascularization in diabetic patients. European Heart Journal 32:22, 2748-2757
CrossRef108
Thomas Cuisset, Jacques Quilici, Charlotte Grosdidier, Laurent Fourcade, Bénédicte Gaborit, Mathieu Pankert, Laurent Molines, Pierre-Emmanuel Morange, Jean Louis Bonnet, Marie-Christine Alessi. (2011) Comparison of Platelet Reactivity and Clopidogrel Response in Patients ≤75 Years Versus >75 Years Undergoing Percutaneous Coronary Intervention for Non–ST-Segment Elevation Acute Coronary Syndrome. The American Journal of Cardiology 108:10, 1411-1416
CrossRef109
Aldona Kubica, Marek Kozinski, Grzegorz Grzesk, Tomasz Fabiszak, Eliano Pio Navarese, Aleksander Goch. (2011) Genetic determinants of platelet response to clopidogrel. Journal of Thrombosis and Thrombolysis 32:4, 459-466
CrossRef110
Stephen D. Wiviott, Willibald Hochholzer. (2011) On-Clopidogrel Platelet Reactivity. Journal of the American College of Cardiology 58:19, 1955-1957
CrossRef111
Sanjiv Khangura, Wendy L. Gordon. (2011) Prasugrel as an Alternative for Clopidogrel-Associated Neutropenia. Canadian Journal of Cardiology 27:6, 869.e9-869.e11
CrossRef112
Zenon Huczek, Krzysztof J. Filipiak, Janusz Kochman, Marcin Michalak, Marek Roik, Marcin Grabowski, Grzegorz Opolski. (2011) Medium on-treatment platelet reactivity to ADP is favorable in patients with acute coronary syndromes undergoing coronary stenting. Platelets 22:7, 521-529
CrossRef113
Timothy V. Nguyen, Tin H. Lac, Marina Iskhakova, Alexandra Srbljak. (2011) A Prescriber's Guides to Oral Antiplatelet Therapy. The Journal for Nurse Practitioners 7:10, 847-852
CrossRef114
Johanne Silvain, Guillaume Cayla, Stephen A O’Connor, Jean-Philippe Collet, Gilles Montalescot. (2011) Antiplatelet options for secondary prevention in acute coronary syndromes. Expert Review of Cardiovascular Therapy 9:11, 1403-1415
CrossRef115
Chee Tang Chin, Tracy Y. Wang, Kevin J. Anstrom, Baojin Zhu, Jen-Fue Maa, John C. Messenger, Kelley A. Ryan, Linda Davidson-Ray, Marjorie Zettler, Mark B. Effron, Daniel B. Mark, Eric D. Peterson. (2011) Treatment with Adenosine Diphosphate Receptor Inhibitors—Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study design: Expanding the paradigm of longitudinal observational research. American Heart Journal 162:5, 844-851
CrossRef116
Sukhdeep S. Basra, Peter Tsai, Nasser M. Lakkis. (2011) Safety and Efficacy of Antiplatelet and Antithrombotic Therapy in Acute Coronary Syndrome Patients With Chronic Kidney Disease. Journal of the American College of Cardiology 58:22, 2263-2269
CrossRef117
Charles V. Pollack, Gerard X. Brogan, Marc Cohen, Deborah Diercks, Cindy Grines, Timothy D. Henry, Neal S. Kleiman, Robert P. Giugliano. (2011) ED to catheterization laboratory: a roundtable integrating trials with practice. The American Journal of Emergency Medicine 29:9, 1203-1216
CrossRef118
Sidney C. Smith, Emelia J. Benjamin, Robert O. Bonow, Lynne T. Braun, Mark A. Creager, Barry A. Franklin, Raymond J. Gibbons, Scott M. Grundy, Loren F. Hiratzka, Daniel W. Jones, Donald M. Lloyd-Jones, Margo Minissian, Lori Mosca, Eric D. Peterson, Ralph L. Sacco, John Spertus, James H. Stein, Kathryn A. Taubert. (2011) AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. Journal of the American College of Cardiology 58:23, 2432-2446
CrossRef119
Marie-Ange Paget, Christy ChuangStein, Christine Fletcher, Carol Reid. (2011) Subgroup analyses of clinical effectiveness to support health technology assessments. Pharmaceutical Statistics 10:6, 532-538
CrossRef120
Shantu S. Bundhoo, Richard A. Anderson, Ewelina Sagan, Jessica Dada, Rebeca Harris, Julian P. Halcox, Derek Lang, Philip E. James. (2011) Direct Vasoactive Properties of Thienopyridine-Derived Nitrosothiols. Journal of Cardiovascular Pharmacology 58:5, 550-558
CrossRef121
Jean-Pierre Bassand. (2011) Current antithrombotic agents for acute coronary syndromes: Focus on bleeding risk. International Journal of Cardiology
CrossRef122
Sotirios Tsiodras, Christos S. Mantzoros. (2011) Drug-drug interactions in HIV medicine: a not so simple and straightforward road to the future. Metabolism 60:11, 1497-1499
CrossRef123
S. SAVONITTO, M. CARACCIOLO, M. CATTANEO, S. DE SERVI. (2011) Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery. Journal of Thrombosis and Haemostasis 9:11, 2133-2142
CrossRef124
D. Divchev, C. Nienaber, H. Ince. (2011) Therapiestrategien beim akuten Koronarsyndrom und nach koronaren Interventionen. Der Internist 52:11, 1292-1300
CrossRef125
Shantu S. Bundhoo, Richard A. Anderson, Ewelina Sagan, Nurudeen Hassan, Andrew G. Pinder, Stephen C. Rogers, Keith Morris, Philip E. James. (2011) Direct formation of thienopyridine-derived nitrosothiols — Just add nitrite!. European Journal of Pharmacology 670:2-3, 534-540
CrossRef126
Stefano De Servi, Eliano Pio Navarese, Maurizio D’Urbano, Stefano Savonitto. (2011) Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor. Current Medical Research and Opinion 27:11, 2117-2122
CrossRef127
Somjot S. Brar, Jurrien ten Berg, Rossella Marcucci, Matthew J. Price, Marco Valgimigli, Hyo-Soo Kim, Giuseppe Patti, Nicoline J. Breet, Germano DiSciascio, Thomas Cuisset, George Dangas. (2011) Impact of Platelet Reactivity on Clinical Outcomes After Percutaneous Coronary Intervention. Journal of the American College of Cardiology 58:19, 1945-1954
CrossRef128
Youssef Daali, Virginie Ancrenaz, Marija Bosilkovska, Pierre Dayer, Jules Desmeules. (2011) Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug–drug interaction in HIV patients. Metabolism 60:11, 1584-1589
CrossRef129
Pamela Moceri, Denis Doyen, Pierre Cerboni, Emile Ferrari. (2011) Doubling the dose of Clopidogrel restores the loss of antiplatelet effect induced by esomeprazole. Thrombosis Research 128:5, 458-462
CrossRef130
Matteo Nicola Dario Di Minno, Anna Guida, Marina Camera, Susanna Colli, Giovanni Di Minno, Elena Tremoli. (2011) Overcoming limitations of current antiplatelet drugs: A concerted effort for more profitable strategies of intervention. Annals of Medicine 43:7, 531-544
CrossRef131
David H. Fitchett, Pierre Theroux, James M. Brophy, Warren J. Cantor, Jafna L. Cox, Milan Gupta, Heather Kertland, Shamir R. Mehta, Robert C. Welsh, Shaun G. Goodman. (2011) Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 1: Non-ST–Segment Elevation ACS. Canadian Journal of Cardiology 27:6, S387-S401
CrossRef132
Satyendra Giri. (2011) Optimal treatment of ACS patients: Issues and considerations for upstream antiplatelet therapy. International Journal of Cardiology
CrossRef133
Erasmia Broussalis, Monika Killer, Mark McCoy, Andrea Harrer, Eugen Trinka, Jörg Kraus. (2011) Current therapies in ischemic stroke. Part A. Recent developments in acute stroke treatment and in stroke prevention. Drug Discovery Today
CrossRef134
Renier Myburgh, Warren E. Hochfeld, Tyren M. Dodgen, James Ker, Michael S. Pepper. (2011) Cardiovascular pharmacogenetics. Pharmacology & Therapeutics
CrossRef135
N. Assez, E. Wiel, C. Lemanski-Brulin, C. Adriansen, P. Goldstein. (2011) Syndromes coronariens aigus : prise en charge thérapeutique en urgence. Annales françaises de médecine d'urgence
CrossRef136
L. Jacquin, J. -P. Auffray, J. Bessereau, A. Champenois, M. Ostorero, L. Bonello. (2011) Le ticagrelor dans les syndromes coronaires aigus : résultats de l’étude PLATO. Annales françaises de médecine d'urgence
CrossRef137
Teddy Kosoglou, Larisa Reyderman, Claudia Kasserra, Lisa K. Jennings, Sophia Young, Fengjuan Xuan, Jinglan Pei, Stephen E. Maxwell, James Schiller, Alan G. Meehan, David L. Cutler. (2011) No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects. European Journal of Clinical Pharmacology
CrossRef138
P. G. Steg, S. R. Mehta, J. W. Jukema, G. Y. H. Lip, C. M. Gibson, F. Kovar, P. Kala, A. Garcia-Hernandez, R. W. Renfurm, C. B. Granger, . (2011) RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. European Heart Journal 32:20, 2541-2554
CrossRef139
Yanushi Dullewe Wijeyeratne, Stan Heptinstall. (2011) Anti-platelet therapy: ADP receptor antagonists. British Journal of Clinical Pharmacology 72:4, 647-657
CrossRef140
Timothy D. Warner, Sven Nylander, Carl Whatling. (2011) Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. British Journal of Clinical Pharmacology 72:4, 619-633
CrossRef141
Gabriella Passacquale, Albert Ferro. (2011) Current concepts of platelet activation: possibilities for therapeutic modulation of heterotypic vs. homotypic aggregation. British Journal of Clinical Pharmacology 72:4, 604-618
CrossRef142
José Antonio Páramo. (2011) Nueva era en la terapia antiplaquetar basada en los resultados de ensayos clínicos recientes. Medicina Clínica 137:11, 504-508
CrossRef143
Stephen D. Wiviott, Nihar Desai, Sabina A. Murphy, Guiseppe Musumeci, Michael Ragosta, Elliott M. Antman, Eugene Braunwald. (2011) Efficacy and Safety of Intensive Antiplatelet Therapy With Prasugrel from TRITON-TIMI 38 in a Core Clinical Cohort Defined by Worldwide Regulatory Agencies. The American Journal of Cardiology 108:7, 905-911
CrossRef144
Jeffrey C. Trost, Richard A. Lange. (2011) Treatment of acute coronary syndrome: Part 1: Non-ST-segment acute coronary syndrome. Critical Care Medicine 39:10, 2346-2353
CrossRef145
P. D. M. LEADBEATER, N. S. KIRKBY, S. THOMAS, A.-R. DHANJI, A. T. TUCKER, G. L. MILNE, J. A. MITCHELL, T. D. WARNER. (2011) Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel. Journal of Thrombosis and Haemostasis 9:10, 2050-2056
CrossRef146
Giuseppe De Luca. (2011) Glycoprotein IIb-IIIa Inhibitors. Cardiovascular Therapeuticsno-no
CrossRef147
Paul A Gurbel, Young-Hoon Jeong, Udaya S Tantry. (2011) Vorapaxar: a novel protease-activated receptor-1 inhibitor. Expert Opinion on Investigational Drugs 20:10, 1445-1453
CrossRef148
David E. Kandzari, Colin S. Barker, Martin B. Leon, Laura Mauri, William Wijns, Jean Fajadet, Roxana Mehran. (2011) Dual Antiplatelet Therapy Duration and Clinical Outcomes Following Treatment With Zotarolimus-Eluting Stents. JACC: Cardiovascular Interventions 4:10, 1119-1128
CrossRef149
Neena S. Abraham. (2011) Prescribing proton pump inhibitor and clopidogrel together. Current Opinion in Gastroenterology 27:6, 558-564
CrossRef150
Arthur W. Bracey, Meredith A. Reyes, Alice J. Chen, Maryam Bayat, Paul M. Allison. (2011) How do we manage patients treated with antithrombotic therapy in the perioperative interval. Transfusion 51:10, 2066-2077
CrossRef151
A.A. Rivellese, P.M. Piatti. (2011) Consensus on: Screening and therapy of coronary heart disease in diabetic patients. Nutrition, Metabolism and Cardiovascular Diseases 21:10, 757-764
CrossRef152
Norela V. Ocampo, Javad Tafreshi, Christopher L. Hauschild, Ramdas G. Pai. (2011) Cardiovascular Medications and Risk of Cancer. The American Journal of Cardiology 108:7, 1045-1051
CrossRef153
M.J. Fernández Herranz, M.A. Espinosa Castro, H. Bueno Zamora, A.I. Castuera Gil. (2011) Tratamiento extrahospitalario y en Urgencias del síndrome coronario agudo sin elevación del segmento ST. Medicine - Programa de Formación Médica Continuada Acreditado 10:87, 5903-5906
CrossRef154
Antonio Tello-Montoliu, Salvatore D. Tomasello, Masafumi Ueno, Dominick J. Angiolillo. (2011) Antiplatelet therapy: thrombin receptor antagonists. British Journal of Clinical Pharmacology 72:4, 658-671
CrossRef155
Axel Labriolle, Jean Philippe Doazan, Gilles Lemesle, Laurent Bonello. (2011) Genotypic and Phenotypic Assessment of Platelet Function and Response to P2Y12 Antagonists. Current Cardiology Reports 13:5, 439-450
CrossRef156
Nalyaka Sambu, Nick Curzen. (2011) Monitoring the effectiveness of antiplatelet therapy: opportunities and limitations. British Journal of Clinical Pharmacology 72:4, 683-696
CrossRef157
Giuseppe Patti, György Bárczi, Dejan Orlic, Fabio Mangiacapra, Giuseppe Colonna, Vincenzo Pasceri, Emanuele Barbato, Béla Merkely, István Édes, Miodrag Ostojic, William Wijns, Germano Di Sciascio. (2011) Outcome Comparison of 600- and 300-mg Loading Doses of Clopidogrel in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology 58:15, 1592-1599
CrossRef158
Dimitrios Alexopoulos, Ioanna Xanthopoulou, Panagiota Mylona, Angelos Perperis, Aggeliki Panagiotou, Gerasimos Dimitropoulos, Grigorios Tsigkas, George Hahalis, Periklis Davlouros. (2011) Prevalence of contraindications and conditions for precaution for prasugrel administration in a real world acute coronary syndrome population. Journal of Thrombosis and Thrombolysis 32:3, 328-333
CrossRef159
Helmi Lutsep. (2011) Update on selecting and adjusting antiplatelet therapy for prevention of noncardiogenic, recurrent ischemic stroke. Expert Review of Cardiovascular Therapy 9:10, 1295-1303
CrossRef160
Terry K. W. Ma, Yat-Yin Lam, Victoria P. Tan, Bryan P. Yan. (2011) Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?. British Journal of Clinical Pharmacology 72:4, 697-706
CrossRef161
Adnan Kastrati, Robert A. Byrne, Stefanie Schulz. (2011) Will We Ever Know the Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation?. JACC: Cardiovascular Interventions 4:10, 1129-1132
CrossRef162
M. A. Gaglia, R. Waksman. (2011) Systematic review of thienopyridine discontinuation and its impact upon clinical outcomes. European Heart Journal 32:19, 2358-2364
CrossRef163
Inder M. Singh, David R. Holmes. (2011) Myocardial Revascularization by Percutaneous Coronary Intervention: Past, Present, and the Future. Current Problems in Cardiology 36:10, 375-401
CrossRef164
Anna Estefanell-Tejero, Carmen López-Cabezas, Gisela Riu-Viladoms, Carlos Falces-Salvador. (2011) Eficacia y tolerabilidad de un protocolo de desensibilización a clopidogrel. Medicina Clínica
CrossRef165
S. Agewall, L. Badimon, L. Drouet, T. Eschenhagen, S. Husted, T. Simon, G. Steg. (2011) Oral antiplatelet agents in ACS: from pharmacology to clinical differences. Fundamental & Clinical Pharmacology 25:5, 564-571
CrossRef166
Teddy Kosoglou, Larisa Reyderman, Renger G. Tiessen, André A. Vliet, Robert R. Fales, Robert Keller, Bo Yang, David L. Cutler. (2011) Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. European Journal of Clinical Pharmacology
CrossRef167
Arun Kalyanasundaram, A. Michael Lincoff. (2011) Managing adverse effects and drug–drug interactions of antiplatelet agents. Nature Reviews Cardiology 8:10, 592-600
CrossRef168
D. J. Quinlan, J. W. Eikelboom, S. G. Goodman, R. C. Welsh, D. H. Fitchett, P. Theroux, S. R. Mehta. (2011) Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. European Heart Journal 32:18, 2256-2265
CrossRef169
Dániel Aradi, Orsolya Rideg, András Vorobcsuk, Tamás Magyarlaki, Balázs Magyari, Attila Kónyi, Tünde Pintér, Iván G. Horváth, András Komócsi. (2011) Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity. European Journal of Clinical Investigationno-no
CrossRef170
B. Fuentes, J. Gállego, A. Gil-Nuñez, A. Morales, F. Purroy, J. Roquer, T. Segura, J. Tejada, A. Lago, E. Díez-Tejedor, M. Alonso de Leciñana, J. Álvarez-Sabin, J. Arenillas, S. Calleja, I. Casado, M. Castellanos, J. Castillo, A. Dávalos, F. Díaz-Otero, J.A. Egido, J.C. López-Fernández, M. Freijo, A. García Pastor, F. Gilo, P. Irimia, J. Maestre, J. Masjuan, J. Martí-Fábregas, P. Martínez-Sánchez, E. Martínez-Vila, C. Molina, F. Nombela, M. Ribó, M. Rodríguez-Yañez, F. Rubio, J. Serena, P. Simal, J. Vivancos. (2011) Guía para el tratamiento preventivo del ictus isquémico y AIT (II). Recomendaciones según subtipo etiológico. Neurología
CrossRef171
Gianluca Campo, Matteo Miccoli, Matteo Tebaldi, Jlenia Marchesini, Luca Fileti, Monia Monti, Marco Valgimigli, Roberto Ferrari. (2011) Genetic determinants of on-clopidogrel high platelet reactivity. Platelets 22:6, 399-407
CrossRef172
Thomas Cuisset, Jacques Quilici, William Cohen, Laurent Fourcade, Noémie Saut, Mathieu Pankert, Bénédicte Gaborit, Patrizia Carrieri, Pierre-Emmanuel Morange, Jean Louis Bonnet, Marie-Christine Alessi. (2011) Usefulness of High Clopidogrel Maintenance Dose According to CYP2C19 Genotypes in Clopidogrel Low Responders Undergoing Coronary Stenting for Non ST Elevation Acute Coronary Syndrome. The American Journal of Cardiology 108:6, 760-765
CrossRef173
M. LEVI, E. EERENBERG, P. W. KAMPHUISEN. (2011) Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. Journal of Thrombosis and Haemostasis 9:9, 1705-1712
CrossRef174
Béatrice Hechler, Christian Gachet. (2011) P2 receptors and platelet function. Purinergic Signalling 7:3, 293-303
CrossRef175
Marco Valgimigli, Monica Minarelli. (2011) Triple Antiplatelet Therapy in Acute Coronary Syndromes. Drugs 71:13, 1703-1719
CrossRef176
Stephen O’Connor, Gilles Montalescot, Jean-Philippe Collet. (2011) The P2Y12 receptor as a target of antithrombotic drugs. Purinergic Signalling 7:3, 325-332
CrossRef177
Willibald Hochholzer, Dietmar Trenk, Jessica L. Mega, Tanja Morath, Christian Stratz, Christian M. Valina, Michelle L. O'Donoghue, Isabell Bernlochner, Charles F. Contant, Jianping Guo, Marc S. Sabatine, Albert Schömig, Franz-Josef Neumann, Adnan Kastrati, Stephen D. Wiviott, Dirk Sibbing. (2011) Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy. American Heart Journal 162:3, 518-526.e5
CrossRef178
Corinne R. Fantz, Anne M. Winkler. (2011) Does Platelet Function Testing Predict Bleeding?-Pro. Point of Care: The Journal of Near-Patient Testing & Technology 10:3, 133-135
CrossRef179
Asim N. Cheema, Atif Mohammad, Tony Hong, Henry R. Jakubovic, Gurpreet S. Parmar, Waseem Sharieff, M. Bernadette Garvey, Michael J.B. Kutryk, Neil P. Fam, John J. Graham, Robert J. Chisholm. (2011) Characterization of Clopidogrel Hypersensitivity Reactions and Management With Oral Steroids Without Clopidogrel Discontinuation. Journal of the American College of Cardiology 58:14, 1445-1454
CrossRef180
Etienne Puymirat, Nadia Aïssaoui, Pierre Coste, Gilles Dentan, Vincent Bataille, Elodie Drouet, Geneviève Mulak, Dider Carrié, Didier Blanchard, Tabassome Simon, Nicolas Danchin. (2011) Comparison of Efficacy and Safety of a Standard Versus a Loading Dose of Clopidogrel for Acute Myocardial Infarction in Patients ≥75 Years of Age (from the FAST-MI Registry). The American Journal of Cardiology 108:6, 755-759
CrossRef181
Atsuhiro Sugidachi, Shinji Yamaguchi, Joseph A Jakubowski, Kosaku Ohno, Atsuyuki Tomizawa, Masami Hashimoto, Yoichi Niitsu. (2011) Selective Blockade of P2Y12 Receptors by Prasugrel Inhibits Myocardial Infarction Induced by Thrombotic Coronary Artery Occlusion in Rats. Journal of Cardiovascular Pharmacology 58:3, 329-334
CrossRef182
John J. Ricotta, Ali AbuRahma, Enrico Ascher, Mark Eskandari, Peter Faries, Brajesh K. Lal. (2011) Updated Society for Vascular Surgery guidelines for management of extracranial carotid disease. Journal of Vascular Surgery 54:3, e1-e31
CrossRef183
Michael Kornfeld, Joseph R. Munsayac. 2011. Antiplatelet Medications. , 47-65.
CrossRef184
David Lao, Andrew Boyle. 2011. Antithrombotic Therapy for Non-ST-Elevation Acute Coronary Syndrome. , 223-240.
CrossRef185
Alexander, John H., Lopes, Renato D., James, Stefan, Kilaru, Rakhi, He, Yaohua, Mohan, Puneet, Bhatt, Deepak L., Goodman, Shaun, Verheugt, Freek W., Flather, Marcus, Huber, Kurt, Liaw, Danny, Husted, Steen E., Lopez-Sendon, Jose, De Caterina, Raffaele, Jansky, Petr, Darius, Harald, Vinereanu, Dragos, Cornel, Jan H., Cools, Frank, Atar, Dan, Leiva-Pons, Jose Luis, Keltai, Matyas, Ogawa, Hisao, Pais, Prem, Parkhomenko, Alexander, Ruzyllo, Witold, Diaz, Rafael, White, Harvey, Ruda, Mikhail, Geraldes, Margarida, Lawrence, Jack, Harrington, Robert A., Wallentin, Lars, . (2011) Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. New England Journal of Medicine 365:8, 699-708
Full Text186
Abbie Edwards, Joseph A. Jakubowski, Andreas R. Rechner, Atsuhiro Sugidachi, Paul Harrison. (2011) Evaluation of the INNOVANCE PFA P2Y test cartridge: Sensitivity to P2Y 12 blockade and influence of anticoagulant. Platelets1-10
CrossRef187
Liam E. Kavanagh, Gregory S. Jack, Nathan Lawrentschuk. (2011) Prevention and management of TURP-related hemorrhage. Nature Reviews Urology 8:9, 504-514
CrossRef188
Suzanne V. Arnold, David J. Cohen, Elizabeth A. Magnuson. (2011) Cost-effectiveness of oral antiplatelet agents—current and future perspectives. Nature Reviews Cardiology 8:10, 580-591
CrossRef189
Tariq Ahmad, Deepak Voora, Richard C. Becker. (2011) The pharmacogenetics of antiplatelet agents: towards personalized therapy?. Nature Reviews Cardiology 8:10, 560-571
CrossRef190
Charles F. Jackson, Nanette K. Wenger. (2011) Enfermedad cardiovascular en el anciano. Revista Española de Cardiología 64:8, 697-712
CrossRef191
Hannes F. Alber, Kurt Huber, Otmar Pachinger, Matthias Frick. (2011) Prasugrel vs. Ticagrelor in acute coronary syndromes: Which one to choose?. Wiener klinische Wochenschrift 123:15-16, 468-476
CrossRef192
Jung-Won Suh, Ki-Bae Seung, Chung-Hwan Kwak, Kwon-Sam Kim, Soon-Jun Hong, Tae-Ho Park, Sang-Hyun Kim, Young-Jin Choi, Seung-Jea Joo, Seung-Jea Tahk, Hyo-Soo Kim. (2011) Comparison of Antiplatelet Effect and Tolerability of Clopidogrel Resinate With Clopidogrel Bisulfate in Patients With Coronary Heart Disease (CHD) or CHD-Equivalent Risks: A Phase IV, Prospective, Double-Dummy, Parallel-Group, 4-Week Noninferiority Trial. Clinical Therapeutics 33:8, 1057-1068
CrossRef193
S A Scott, K Sangkuhl, E E Gardner, C M Stein, J-S Hulot, J A Johnson, D M Roden, T E Klein, A R Shuldiner. (2011) Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy. Clinical Pharmacology & Therapeutics 90:2, 328-332
CrossRef194
Beau M Hawkins, Jorge F Saucedo, Sunil V Rao. (2011) The rationale and evidence for triple antiplatelet therapy in acute coronary syndromes. Clinical Investigation 1:8, 1155-1165
CrossRef195
Philip Joseph, Koon Teo. (2011) Optimal Medical Therapy, Lifestyle Intervention, and Secondary Prevention Strategies for Cardiovascular Event Reduction in Ischemic Heart Disease. Current Cardiology Reports 13:4, 287-295
CrossRef196
Masafumi Ueno, José L. Ferreiro, Salvatore D. Tomasello, Antonio Tello-Montoliu, Davide Capodanno, Naveen Seecheran, Murali Kodali, Kodlipet Dharmashankar, Bhaloo Desai, Ronald K. Charlton, Theodore A. Bass, Dominick J. Angiolillo. (2011) Impact of Pentoxifylline on Platelet Function Profiles in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel. JACC: Cardiovascular Interventions 4:8, 905-912
CrossRef197
J. Donald Easton. (2011) Antithrombotic Management for Transient Ischemic Attack and Ischemic Stroke (Other than Atrial Fibrillation). Current Atherosclerosis Reports 13:4, 314-320
CrossRef198
Isabell Bernlochner, Robert A Byrne, Adnan Kastrati, Dirk Sibbing. (2011) The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. Expert Review of Cardiovascular Therapy 9:8, 999-1014
CrossRef199
Giuseppe Biondi-Zoccai, Marzia Lotrionte, Pierfrancesco Agostoni, Antonio Abbate, Enrico Romagnoli, Giuseppe Sangiorgi, Dominick J. Angiolillo, Marco Valgimigli, Luca Testa, Fiorenzo Gaita, Imad Sheiban. (2011) Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. International Journal of Cardiology 150:3, 325-331
CrossRef200
Christoph Varenhorst, Sasha Koul, David Erlinge, Bo Lagerqvist, Agneta Siegbahn, Lars Wallentin, Stefan James. (2011) Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention—A case-control study. American Heart Journal 162:2, 363-371
CrossRef201
Marco Ranucci, Solomon Aronson, Wulf Dietrich, Cornelius M. Dyke, Axel Hofmann, Keyvan Karkouti, Marcel Levi, Gavin J. Murphy, Frank W. Sellke, Linda Shore-Lesserson, Christian von Heymann. (2011) Patient blood management during cardiac surgery: Do we have enough evidence for clinical practice?. The Journal of Thoracic and Cardiovascular Surgery 142:2, 249.e1-249.e32
CrossRef202
Renato D. Lopes, Richard C. Becker, John H. Alexander, Paul W. Armstrong, Robert M. Califf, Mark Y. Chan, Mark Crowther, Christopher B. Granger, Robert A. Harrington, Elaine M. Hylek, Stefan K. James, E. Marc Jolicoeur, Kenneth W. Mahaffey, L. Kristin Newby, Eric D. Peterson, Karen S. Pieper, Frans Werf, Lars Wallentin, Harvey D. White, Antonio C. Carvalho, Roberto R. Giraldez, Helio P. Guimaraes, Helena B. Nader, Renato A. K. Kalil, Joyce M. A. Bizzachi, Antonio C. Lopes, David A. Garcia. (2011) Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14–16, 2010, São Paulo, Brazil. Journal of Thrombosis and Thrombolysis 32:2, 242-266
CrossRef203
Charles F. Jackson, Nanette K. Wenger. (2011) Cardiovascular Disease in the Elderly. Revista Española de Cardiología (English Edition) 64:8, 697-712
CrossRef204
Lawrence Rajan, David J. Moliterno. (2011) Beyond Aspirin and Clopidogrel: Is There a Need for Additional Antiplatelet Therapy in ACS?. Current Cardiology Reports 13:4, 303-311
CrossRef205
Rubén Casado-Arroyo, María Muñoz-Villalenguas, Ángel Lanas Arbeloa. (2011) Antiagregantes plaquetarios e inhibidores de la bomba de protones. ¿Cómo optimizar el riesgo-beneficio en los pacientes con riesgo cardiovascular y riesgo de hemorragia gastrointestinal?. Gastroenterología y Hepatología 34:7, 478-491
CrossRef206
Christopher W. Good, Peter B. Berger. (2011) P2Y12 Antagonists in Acute Coronary Syndrome: In Whom Should They Be Started, and When?. Current Cardiology Reports 13:4, 320-326
CrossRef207
Elise Camilleri, Laurent Jacquin, Franck Paganelli, Laurent Bonello. (2011) Personalized Antiplatelet Therapy: Review of the Latest Clinical Evidence. Current Cardiology Reports 13:4, 296-302
CrossRef208
SUSAN BEZENEK, JAMES HERMILLER, ALEXANDRA LANSKY, MANEJEH YAQUB, KYOKO HATTORI, SHERRY CAO, POORNIMA SOOD, KRISHNAKUTTY SUDHIR. (2011) Low Stent Thrombosis Risk with the XIENCE V® Everolimus-Eluting Coronary Stent: Evidence from Randomized and Single-Arm Clinical Trials. Journal of Interventional Cardiology 24:4, 326-341
CrossRef209
Dimitrios Alexopoulos. (2011) Prasugrel resistance: Fact or fiction. Platelets1-8
CrossRef210
Udaya S. Tantry, Paul A. Gurbel. (2011) Assessment of oral antithrombotic therapy by platelet function testing. Nature Reviews Cardiology 8:10, 572-579
CrossRef211
Omair Yousuf, Deepak L. Bhatt. (2011) The evolution of antiplatelet therapy in cardiovascular disease. Nature Reviews Cardiology 8:10, 547-559
CrossRef212
C Y Lu, J Karnon, M J Sorich. (2011) The Importance of High-Quality Evidence of the Long-Term Impact of Nonfatal Events Used in Randomized Controlled Trials: A Case Study of Prasugrel. Clinical Pharmacology & Therapeutics 90:1, 27-29
CrossRef213
Cheol Ung Choi, Seung-Woon Rha, Dong Joo Oh, Kanhaiya L. Poddar, Jin Oh Na, Jin Won Kim, Hong Euy Lim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Taek Jong Hong, Jong-Seon Park, Young Jo Kim, Seung Ho Hur, In Whan Seong, Jei Keon Chae, Myeong Chan Cho, Jang Ho Bae, Dong Hoon Choi, Yang Soo Jang, In Ho Chae, Hyo Soo Kim, Chong Jin Kim, Jung Han Yoon, Tae Hoon Ahn, Seung-Jea Tahk, Wook Sung Chung, Ki Bae Seung, Shung Chall Chae, Seung Jung Park, Young Keun Ahn, Myung Ho Jeong. (2011) Response to the letter regarding the article “Do East Asians have different hypercoagulable states compared with Western population?”. American Heart Journal 162:1, e21-e22
CrossRef214
Zeshan Qureshi, Alex R. Hobson. (2011) Clopidogrel “Resistance”: Where are We Now?. Cardiovascular Therapeuticsno-no
CrossRef215
Hisao Ogawa, Seiji Hokimoto, Koichi Kaikita, Koichiro Yamamoto, Tadasuke Chitose, Takamichi Ono, Kenichi Tsujita. (2011) Current status and prospects of antiplatelet therapy in percutaneous coronary intervention in Japan: Focus on adenosine diphosphate receptor inhibitors. Journal of Cardiology 58:1, 6-17
CrossRef216
D. Sibbing, W. Koch, S. Massberg, R. A. Byrne, J. Mehilli, S. Schulz, K. Mayer, I. Bernlochner, A. Schomig, A. Kastrati. (2011) No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. European Heart Journal 32:13, 1605-1613
CrossRef217
Michalis Hamilos, Olivier Muller, Argyrios Ntalianis, Catalina Trana, Jozef Bartunek, Giovanna Sarno, Fabio Mangiacapra, Karen Dierickx, Peter Meeus, Thomas Cuisset, Bernard Bruyne, William Wijns, Emanuele Barbato. (2011) Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. Journal of Thrombosis and Thrombolysis 32:1, 64-71
CrossRef218
Brendan Bell, Jamie Layland, Karl Poon, Christian Spaulding, Darren Walters. (2011) Focused Clinical Review: Periprocedural Management of Antiplatelet Therapy in Patients with Coronary Stents. Heart, Lung and Circulation 20:7, 438-445
CrossRef219
PH. G. STEG, S. H. DORMAN, P. AMARENCO. (2011) Atherothrombosis and the role of antiplatelet therapy. Journal of Thrombosis and Haemostasis 9, 325-332
CrossRef220
E. P. Navarese, M. Verdoia, A. Schaffer, P. Suriano, M. Kozinski, F. Castriota, S. De Servi, J. Kubica, G. De luca. (2011) Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. QJM 104:7, 561-569
CrossRef221
Guang-Ming Tan, Yat-Yin Lam, Bryan P. Yan. (2011) Novel Platelet ADP P2Y12 Inhibitors in the Treatment of Acute Coronary Syndrome. Cardiovascular Therapeuticsno-no
CrossRef222
Harvey D White. (2011) Editorial: do we need another bleeding definition? What does the Bleeding Academic Research Consortium definition have to offer?. Current Opinion in Cardiology 26:4, 275-278
CrossRef223
Laurent Bonello, Michel Pansieri, Julien Mancini, Roland Bonello, Luc Maillard, Pierre Barnay, Philippe Rossi, Omar Ait-Mokhtar, Bernard Jouve, Frederic Collet, Jean Pascal Peyre, Olivier Wittenberg, Axel de Labriolle, Elise Camilleri, Edouard Cheneau, Elma Cabassome, Françoise Dignat-George, Laurence Camoin-Jau, Franck Paganelli. (2011) High On-Treatment Platelet Reactivity After Prasugrel Loading Dose and Cardiovascular Events After Percutaneous Coronary Intervention in Acute Coronary Syndromes. Journal of the American College of Cardiology 58:5, 467-473
CrossRef224
Mitchell D. Weinberg, Joe F. Lau, Kenneth Rosenfield, Jeffrey W. Olin. (2011) Peripheral artery disease. Part 2: medical and endovascular treatment. Nature Reviews Cardiology 8:8, 429-441
CrossRef225
Joshua Lehrer, David P. Lee. 2011. Unstable Angina and Non-ST Elevation Myocardial Infarction. , 43-52.
CrossRef226
Tarek AN Ahmed, Ioannis Karalis, J Wouter Jukema. (2011) Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises. Expert Opinion on Emerging Drugs 16:2, 203-233
CrossRef227
Andrew Cunningham, C. Michael Stein, Cecilia P. Chung, James R. Daugherty, Walter E. Smalley, Wayne A. Ray. (2011) An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiology and Drug Safety 20:6, 560-566
CrossRef228
Stefano De Servi, Stefano Savonitto. (2011) How to explain the reduced cardiovascular mortality in the ticagrelor arm of the PLATO trial?. International Journal of Cardiology 149:2, 265-267
CrossRef229
Dominick J Angiolillo, Marco Roffi, Antonio Fernandez-Ortiz. (2011) Tackling the thrombotic burden in patients with acute coronary syndrome and diabetes mellitus. Expert Review of Cardiovascular Therapy 9:6, 697-710
CrossRef230
Sergey Preisman, Ehud Raanani. (2011) Reply to Cattano and Pivalizza. European Journal of Cardio-Thoracic Surgery 39:6, 1085-1086
CrossRef231
Deepu Alexander, Allen Jeremias. (2011) Rivaroxaban in the contemporary treatment of acute coronary syndromes. Expert Opinion on Investigational Drugs 20:6, 849-857
CrossRef232
Mariano A Giorgi, Hernán Cohen Arazi, Claudio D Gonzalez, Guillermo Di Girolamo. (2011) Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. Expert Opinion on Pharmacotherapy 12:8, 1285-1295
CrossRef233
Pierre Fontana, Pierre Albaladejo, Charles-Marc Samama. (2011) Gestion périopératoire des nouveaux antiplaquettaires. Le Praticien en Anesthésie Réanimation 15:3, 188-193
CrossRef234
M. J. Chapman, H. N. Ginsberg, P. Amarenco, F. Andreotti, J. Boren, A. L. Catapano, O. S. Descamps, E. Fisher, P. T. Kovanen, J. A. Kuivenhoven, P. Lesnik, L. Masana, B. G. Nordestgaard, K. K. Ray, Z. Reiner, M.-R. Taskinen, L. Tokgozoglu, A. Tybjaerg-Hansen, G. F. Watts, . (2011) Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal 32:11, 1345-1361
CrossRef235
N. J. Breet, H. E. Donkersgoed, J. W. Werkum, H. J. Bouman, J. C. Kelder, F. Zijlstra, C. M. Hackeng, J. M. Berg. (2011) Is platelet inhibition due to thienopyridines increased in elderly patients, in patients with previous stroke and patients with low body weight as a possible explanation of an increased bleeding risk?. Netherlands Heart Journal 19:6, 279-284
CrossRef236
RADHAKRISHNAN RAMARAJ, MOHAMMAD REZA MOVAHED, MEHRNOOSH HASHEMZADEH. (2011) Novel Antiplatelet Agent Ticagrelor in the Management of Acute Coronary Syndrome. Journal of Interventional Cardiology 24:3, 199-207
CrossRef237
J. Douglas Kirk, Michael Kontos, Deborah B. Diercks. (2011) Upstream treatment of acute coronary syndrome in the ED. The American Journal of Emergency Medicine 29:4, 446-456
CrossRef238
Farhad Abtahian, Benjamin Olenchock, Fang-Shu Ou, Michael C. Kontos, Jorge F. Saucedo, Benjamin M. Scirica, Nihar Desai, Eric Peterson, Matthew Roe, Christopher P. Cannon, Stephen D. Wiviott. (2011) Effect of Prior Stroke on the Use of Evidence-Based Therapies and In-Hospital Outcomes in Patients With Myocardial Infarction (from the NCDR ACTION GWTG Registry). The American Journal of Cardiology 107:10, 1441-1446
CrossRef239
Xiao-dong Wang, Dai-fu Zhang, Shao-wei Zhuang, Yan Lai. (2011) Modifying Clopidogrel Maintenance Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Improves Clinical Outcome in Patients With Clopidogrel Resistance. Clinical Cardiology 34:5, 332-338
CrossRef240
Mark D. Huffman, Deepak Bhatnagar. (2011) Novel Treatments for Cardiovascular Disease Prevention. Cardiovascular Therapeuticsno-no
CrossRef241
R. Scott Wright, Jeffrey L. Anderson, Cynthia D. Adams, Charles R. Bridges, Donald E. Casey, Steven M. Ettinger, Francis M. Fesmire, Theodore G. Ganiats, Hani Jneid, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre Theroux, Nanette K. Wenger, James Patrick Zidar. (2011) 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline). Journal of the American College of Cardiology 57:19, 1920-1959
CrossRef242
Daniel E. Forman, Michael W. Rich, Karen P. Alexander, Susan Zieman, Mathew S. Maurer, Samer S. Najjar, Joseph C. Cleveland, Harlan M. Krumholz, Nanette K. Wenger. (2011) Cardiac Care for Older Adults. Journal of the American College of Cardiology 57:18, 1801-1810
CrossRef243
Mao Chen, Jia-Fu Wei, Yuan-Ning Xu, Xiao-Jing Liu, De-Jia Huang. (2011) A Meta-Analysis of Impact of Proton Pump Inhibitors on Antiplatelet Effect of Clopidogrel. Cardiovascular Therapeuticsno-no
CrossRef244
Stefan Lischke, David J Schneider. (2011) Recent developments in the use of antiplatelet agents to prevent cardiovascular events. Future Cardiology 7:3, 403-413
CrossRef245
Jeremy S. Paikin, Doug S. Wright, John W. Eikelboom. (2011) Effectiveness and safety of combined antiplatelet and anticoagulant therapy: A critical review of the evidence from randomized controlled trials. Blood Reviews 25:3, 123-129
CrossRef246
W. Motz, W. Kerner. (2011) Kardiale Endorganschäden bei Diabetes. Der Internist 52:5, 505-517
CrossRef247
Davide Capodanno, Corrado Tamburino, George Dangas. (2011) The optimal pharmacological formula for percutaneous coronary intervention. Expert Opinion on Pharmacotherapy 12:7, 1075-1086
CrossRef248
Antonio Tello-Montoliu, Masafumi Ueno, Dominick J Angiolillo. (2011) Antiplatelet drug therapy: role of pharmacodynamic and genetic testing. Future Cardiology 7:3, 381-402
CrossRef249
Michael A. Burke, Richard Lee, Dan J. Fintel. (2011) Early clopidogrel use in non–ST elevation acute coronary syndrome and subsequent coronary artery bypass grafting. American Heart Journal 161:5, 832-841
CrossRef250
M. Oberhänsli, S. Puricel, M. Togni, S. Cook. (2011) Koronare Stent-Thrombosen. Herz 36:3, 241-253
CrossRef251
Alan D. Bell, André Roussin, Raymond Cartier, Wee Shian Chan, James D. Douketis, Anil Gupta, Maria E. Kraw, Thomas F. Lindsay, Michael P. Love, Neesh Pannu, Rémi Rabasa-Lhoret, Ashfaq Shuaib, Philip Teal, Pierre Théroux, Alexander G.G. Turpie, Robert C. Welsh, Jean-François Tanguay. (2011) The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines. Canadian Journal of Cardiology 27:3, S1-S59
CrossRef252
Thomas Gremmel, Sabine Steiner, Daniela Seidinger, Renate Koppensteiner, Simon Panzer, Christoph W. Kopp. (2011) A high maintenance dose increases the inhibitory response to clopidogrel in patients with high on-treatment residual platelet reactivity. International Journal of Cardiology
CrossRef253
Annunziata Nusca, Germano Di Sciascio. 2011. Oral Antiplatelet Agents in PCI. , 101-109.
CrossRef254
Gilles Montalescot, Leonardo Bolognese, Dariusz Dudek, Patrick Goldstein, Christian Hamm, Jean-Francois Tanguay, Jur ten Berg, Petr Widimsky, Junxiang Luo, Debra L. Miller, Jochen Goedicke. (2011) A Comparison of prasugrel at the time of percutaneous Coronary intervention or as pretreatment at the time of diagnosis in patients with non–ST-segment elevation myocardial infarction: Design and rationale for the ACCOAST study. American Heart Journal 161:4, 650-656.e1
CrossRef255
Michelle T. Martin, Sarah A. Spinler, Edith A. Nutescu. (2011) Emerging Antiplatelet Therapies in Percutaneous Coronary Intervention: A Focus on Prasugrel. Clinical Therapeutics 33:4, 425-442
CrossRef256
Kurt Huber, Bashar Hamad, Peter Kirkpatrick. (2011) Ticagrelor. Nature Reviews Drug Discovery 10:4, 255-256
CrossRef257
Charles Brown, Brijen Joshi, Nauder Faraday, Ashish Shah, David Yuh, Jeffrey J. Rade, Charles W. Hogue. (2011) Emergency Cardiac Surgery in Patients with Acute Coronary Syndromes. Anesthesia & Analgesia 112:4, 777-799
CrossRef258
R. A. Ajjan, Peter J. Grant. (2011) The Role of Antiplatelets in Hypertension and Diabetes Mellitus. The Journal of Clinical Hypertension 13:4, 305-313
CrossRef259
Udaya S. Tantry, Dean J. Kereiakes, Paul A. Gurbel. (2011) Clopidogrel and Proton Pump Inhibitors. JACC: Cardiovascular Interventions 4:4, 365-380
CrossRef260
Giuseppe Patti, Vincenzo Pasceri, Vincenzo Vizzi, Elisabetta Ricottini, Germano Di Sciascio. (2011) Usefulness of Platelet Response to Clopidogrel by Point-of-Care Testing to Predict Bleeding Outcomes in Patients Undergoing Percutaneous Coronary Intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study). The American Journal of Cardiology 107:7, 995-1000
CrossRef261
Dimitrios Alexopoulos, Gerasimos Dimitropoulos, Periklis Davlouros, Ioanna Xanthopoulou, George Kassimis, Eleana F. Stavrou, George Hahalis, Aglaia Athanassiadou. (2011) Prasugrel Overcomes High On-Clopidogrel Platelet Reactivity Post-Stenting More Effectively Than High-Dose (150-mg) Clopidogrel. JACC: Cardiovascular Interventions 4:4, 403-410
CrossRef262
Amelia Carro, Rachel Bastiaenen, Juan Carlos Kaski. (2011) Age Related Issues in Reperfusion of Myocardial Infarction. Cardiovascular Drugs and Therapy 25:2, 139-148
CrossRef263
D. J. Angiolillo, J. J. Badimon, J. F. Saucedo, A. L. Frelinger, A. D. Michelson, J. A. Jakubowski, B. Zhu, C. K. Ojeh, B. A. Baker, M. B. Effron. (2011) A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. European Heart Journal 32:7, 838-846
CrossRef264
Philippe Kolh, William Wijns. (2011) Joint ESC/EACTS guidelines on myocardial revascularization. Journal of Cardiovascular Medicine 12:4, 264-267
CrossRef265
In-Suk Kim, Young-Hoon Jeong, Yongwhi Park, Ki-Soo Park, Seong-Eun Yun, Jeong-Rang Park, Seok-Jae Hwang, Eun-Ha Koh, Choong Hwan Kwak, Jin-Yong Hwang, Sunjoo Kim. (2011) Platelet Inhibition by Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel in Patients With Acute Myocardial Infarction According to Cytochrome P450 2C19 Genotype. JACC: Cardiovascular Interventions 4:4, 381-391
CrossRef266
Monika Killer, Eugen Trinka, Jörg Kraus, Erasmia Broussalis. (2011) Discovery, development and effectiveness of coagulation-inhibiting drugs for stroke therapy. Expert Opinion on Drug Discovery 6:4, 353-369
CrossRef267
Renato D. Lopes. (2011) Antiplatelet agents in cardiovascular disease. Journal of Thrombosis and Thrombolysis 31:3, 306-309
CrossRef268
Maria M. Wanitschek, Otmar Pachinger, Hannes F. Alber. (2011) Akutes Koronarsyndrom. Wiener klinisches Magazin 14:2, 8-14
CrossRef269
Seung-Jung Park, Duk-Woo Park, Jun-Hyok Oh. (2011) Antiplatelet therapy in elderly patients. Aging Health 7:2, 311-320
CrossRef270
ROBERT P. GIUGLIANO, CHARLES V POLLACK Jr., GERARD X BROGAN Jr., MARC COHEN, DEBORAH B DIERCKS, CINDY L GRINES, TIMOTHY D. HENRY, NEAL S KLEIMAN. (2011) Acute Coronary Syndromes: From the Emergency Department to the Catheterization Laboratory-Integrating Evidence from Recent ACS/NSTEMI Trials into Clinical Practice: An Evidence-Based Review of Recent Clinical Trial Results and Report on a Roundtable Discu. Journal of Interventional Cardiology 24:2, 119-136
CrossRef271
Andrea Rubboli. (2011) The antithrombotic management of patients on oral anticoagulation undergoing coronary stent implantation: an update. Internal and Emergency Medicine
CrossRef272
Nikolaus Sarafoff, Lydia Neumann, Tanja Morath, Isabell Bernlochner, Julinda Mehilli, Albert Schömig, Adnan Kastrati, Dirk Sibbing. (2011) Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. American Heart Journal 161:3, 605-610
CrossRef273
Harvey D. White. (2011) Oral antiplatelet therapy for atherothrombotic disease: Current evidence and new directions. American Heart Journal 161:3, 450-461
CrossRef274
Baojin Zhu, Mark B Effron, Pandurang M Kulkarni, Ying G Li, Joseph A Jakubowski, Debra L Miller, Brian A Baker, Junxiang Luo, David S Small, Kenneth J Winters. (2011) The Onset of Inhibition of Platelet Aggregation With Prasugrel Compared With Clopidogrel Loading Doses Using Gatekeeping Analysis of Integrated Clinical Pharmacology Data. Journal of Cardiovascular Pharmacology 57:3, 317-324
CrossRef275
Alan D. Bell, André Roussin, Raymond Cartier, Wee Shian Chan, James D. Douketis, Anil Gupta, Maria E. Kraw, Thomas F. Lindsay, Michael P. Love, Neesh Pannu, Rémi Rabasa-Lhoret, Ashfaq Shuaib, Philip Teal, Pierre Théroux, A. Graham Turpie, Robert C. Welsh, Jean-François Tanguay. (2011) The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines Executive Summary. Canadian Journal of Cardiology 27:2, 208-221
CrossRef276
Philip Urban, Alexandre Abizaid, Adrian Banning, Antonio L. Bartorelli, Ana Cebrian Baux, Vladimír Džavík, Stephen Ellis, Runlin Gao, David Holmes, Myung Ho Jeong, Victor Legrand, Franz-Josef Neumann, Maria Nyakern, Christian Spaulding, Stephen Worthley. (2011) Stent Thrombosis and Bleeding Complications After Implantation of Sirolimus-Eluting Coronary Stents in an Unselected Worldwide Population. Journal of the American College of Cardiology 57:13, 1445-1454
CrossRef277
Udaya S Tantry, Dean J Kereiakes, Paul A Gurbel. (2011) Role of ticagrelor in the treatment of coronary artery disease. Clinical Investigation 1:3, 429-437
CrossRef278
B. Gellen, E. Teiger. (2011) Thrombose de stent. Archives des Maladies du Coeur et des Vaisseaux - Pratique 2011:196, 31-34
CrossRef279
Victor L. Serebruany. (2011) Timing of thienopyridine loading and outcomes in the TRITON trial: the FDA Prasugrel Action Package outlook. Cardiovascular Revascularization Medicine 12:2, 94-98
CrossRef280
Markus Haass. (2011) Highlights of the latest clinical trials from the 2010 Scientific Sessions of the American Heart Association. Future Cardiology 7:2, 163-167
CrossRef281
Benjamin Z. Galper, Jennifer Stant, Mireya Reilly, Sondra Walter, Michael Collins, Osman Sayan, Gerald Neuberg, Leslie Miller, Jeffery W. Moses, Gregg W. Stone, James Giglio, LeRoy E. Rabbani. (2011) Updating the Chest Pain Algorithm. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 10:1, 9-16
CrossRef282
James J. Nawarskas, Sara M. Clark. (2011) Ticagrelor. Cardiology in Review 19:2, 95-100
CrossRef283
Tzu-Hsien Tsai, Sarah Chua, Hisham Hussein, Steve Leu, Chiung-Jen Wu, Chi-Ling Hang, Hsiu-Yu Fang, Sheng-Ying Chung, Morgan Fu, Huang-Chung Chen, Li-Teh Chang, Kuo-Ho Yeh, Hon-Kan Yip. (2011) Outcomes of patients with Killip class III acute myocardial infarction after primary percutaneous coronary intervention*. Critical Care Medicine 39:3, 436-442
CrossRef284
Samir B. Damani, Eric J. Topol. (2011) Emerging clinical applications in cardiovascular pharmacogenomics. Wiley Interdisciplinary Reviews: Systems Biology and Medicine 3:2, 206-215
CrossRef285
Hong-Guang Xie, Jian-Jun Zou, Zuo-Ying Hu, Jun-Jie Zhang, Fei Ye, Shao-Liang Chen. (2011) Individual variability in the disposition of and response to clopidogrel: Pharmacogenomics and beyond. Pharmacology & Therapeutics 129:3, 267-289
CrossRef286
M. Cattaneo. (2011) The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 117:7, 2102-2112
CrossRef287
, Bob Wilffert, Jesse Swen, Hans Mulder, Daan Touw, Anke-Hilse Maitland-Van der Zee, Vera Deneer. (2011) From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. International Journal of Clinical Pharmacy 33:1, 3-9
CrossRef288
Claes Held, Nils Åsenblad, Jean Pierre Bassand, Richard C. Becker, Christopher P. Cannon, Marc J. Claeys, Robert A. Harrington, Jay Horrow, Steen Husted, Stefan K. James, Kenneth W. Mahaffey, José C. Nicolau, Benjamin M. Scirica, Robert F. Storey, Marius Vintila, Joseph Ycas, Lars Wallentin. (2011) Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery. Journal of the American College of Cardiology 57:6, 672-684
CrossRef289
Megan M. Donohue, David L. Tirschwell. (2011) Implications of Pharmacogenetic Testing for Patients Taking Warfarin or Clopidogrel. Current Neurology and Neuroscience Reports 11:1, 52-60
CrossRef290
Matthew J Price, Colin M Barker. (2011) Functional testing methods for the antiplatelet effect of P2Y 12 receptor antagonists. Biomarkers in Medicine 5:1, 43-51
CrossRef291
Ada Stefanescu, Stephen D. Wiviott. (2011) Considerations Regarding Antiplatelet Therapy in the Elderly. Current Cardiovascular Risk Reports 5:1, 86-95
CrossRef292
Serkan Cay, Goksel Cagirci, Sinan Aydogdu, Yucel Balbay, Nihat Sen, Orhan Maden, Ahmet D. Demir, Ali R. Erbay. (2011) Safety of Clopidogrel in Older Patients. Drugs & Aging 28:2, 119-129
CrossRef293
David J. Schneider. (2011) Mechanisms Potentially Contributing to the Reduction in Mortality Associated With Ticagrelor Therapy
Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 57:6, 685-687
CrossRef294
Dimitrios Alexopoulos. (2011) CYP2C19*2 allele: guiding medication choice after percutaneous coronary intervention. Interventional Cardiology 3:1, 1-4
CrossRef295
Ian BA Menown. (2011) Aspirin, P2Y 12 blockers, cilostazol, PAR-1 blockers and emerging antiplatelet therapies: can biomarkers guide clinical development and practice?. Biomarkers in Medicine 5:1, 1-3
CrossRef296
Charles-Marc Samama. (2011) Gestion péri–opératoire des antiplaquettaires et des anticoagulants. Revue Francophone des Laboratoires 2011:429, 17-19
CrossRef297
Marco Cattaneo. (2011) Resistance to anti-platelet agents. Thrombosis Research 127, S61-S63
CrossRef298
Tracy Y. Wang, Antonio Gutierrez, Eric D. Peterson. (2011) Percutaneous coronary intervention in the elderly. Nature Reviews Cardiology 8:2, 79-90
CrossRef299
Soochong Kim, Satya P. Kunapuli. (2011) P2Y12 receptor in platelet activation. Platelets 22:1, 54-58
CrossRef300
Fiona Foo, Keith G Oldroyd. (2011) Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention. Biomarkers in Medicine 5:1, 9-30
CrossRef301
Richard Hall, C. David Mazer. (2011) Antiplatelet Drugs. Anesthesia & Analgesia 112:2, 292-318
CrossRef302
James A Shand, Ian BA Menown, Robert F Storey. (2011) Ticagrelor: from concept to clinical evaluation. Biomarkers in Medicine 5:1, 53-62
CrossRef303
Joseph A. Jakubowski, Jeffrey S. Riesmeyer, Sandra L. Close, Amy G. Leishman, David Erlinge. (2011) TRITON and Beyond: New Insights into the Profile of Prasugrel. Cardiovascular Therapeuticsno-no
CrossRef304
A Maeda, H Ando, T Asai, H Ishiguro, N Umemoto, M Ohta, M Morishima, A Sumida, T Kobayashi, K Hosohata, K Ushijima, A Fujimura. (2011) Differential Impacts of CYP2C19 Gene Polymorphisms on the Antiplatelet Effects of Clopidogrel and Ticlopidine. Clinical Pharmacology & Therapeutics 89:2, 229-233
CrossRef305
Joseph A Jakubowski. (2011) Beyond platelet functional testing: value in the aggregate. Biomarkers in Medicine 5:1, 5-8
CrossRef306
Joshua P Leitner, Jinnette Dawn Abbott. (2011) Drug-eluting stents and glycoprotein IIbIIIa inhibitors in the pharmacoinvasive management of ST elevation MI. Interventional Cardiology 3:1, 17-21
CrossRef307
Byron Cryer, Deepak L Bhatt, Frank L Lanza, Jing-fei Dong, Lenard M Lichtenberger, Upendra K Marathi. (2011) Low-Dose Aspirin-Induced Ulceration Is Attenuated by Aspirin–Phosphatidylcholine: A Randomized Clinical Trial. The American Journal of Gastroenterology 106:2, 272-277
CrossRef308
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting, Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef309
A. L. Frelinger, A. D. Michelson, S. D. Wiviott, D. Trenk, F.-J. Neumann, D. L. Miller, J. A. Jakubowski, T. M. Costigan, C. H. McCabe, E. M. Antman, E. Braunwald. (2011) Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Thrombosis and Haemostasis 106:2, 219-226
CrossRef310
P. Capranzano, C. Tamburino, D. Capodanno, E. Miccichè, L. D'Urso, V. Calvi, D. J. Angiolillo, C. Tamburino. (2011) Platelet function profiles in the elderly: Results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. Thrombosis and Haemostasis 106:6, 1149-1157
CrossRef311
Jerome L. Fleg, Wilbert S. Aronow, William H. Frishman. (2011) Cardiovascular drug therapy in the elderly: benefits and challenges. Nature Reviews Cardiology 8:1, 13-28
CrossRef312
P. A. Gurbel, E. Mahla, U. S. Tantry. (2011) Peri-operative platelet function testing: The potential for reducing ischaemic and bleeding risks. Thrombosis and Haemostasis 106:2, 248-252
CrossRef313
Olivier Morel, Soraya El Ghannudi, Laurence Jesel, Bogdan Radulescu, Nicolas Meyer, Marie-Louise Wiesel, Sophie Caillard, Umberto Campia, Bruno Moulin, Christian Gachet, Patrick Ohlmann. (2011) Cardiovascular Mortality in Chronic Kidney Disease Patients Undergoing Percutaneous Coronary Intervention Is Mainly Related to Impaired P2Y12 Inhibition by Clopidogrel. Journal of the American College of Cardiology 57:4, 399-408
CrossRef314
T. Gremmel, S. Panzer. (2011) Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel. Thrombosis and Haemostasis 106:2, 211-218
CrossRef315
W. Korte, M. Cattaneo, P.-G. Chassot, S. Eichinger, C. von Heymann, N. Hofmann, H. Rickli, M. Spannagl, B. Ziegler, F. Verheugt, K. Huber. (2011) Peri-operative management of antiplatelet therapy in patients with coronary artery disease. Thrombosis and Haemostasis 105:5, 743-749
CrossRef316
S. Ylä-Herttuala, J. F. Bentzon, M. Daemen, E. Falk, H. M. Garcia-Garcia, J. Herrmann, I. Hoefer, J. W. Jukema, R. Krams, B. R. Kwak, N. Marx, M. Naruszewicz, A. Newby, G. Pasterkamp, P. W. J. C. Serruys, J. Waltenberger, C. Weber, L. Tokgözoglu. (2011) Stabilisation of atherosclerotic plaques. Thrombosis and Haemostasis 106:1, 1-19
CrossRef317
Ivan C. Rokos, Michael E. Farkouh, James Reiffel, Ovidiu Dressler, Roxana Mehran, Gregg W. Stone. (2011) Correlation between index electrocardiographic patterns and Pre-intervention angiographic findings: Insights from the HORIZONS-AMI trial. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef318
Ojikumar Lukram, Mukund Zarapkar, Chandan Kumar Jha, Shivaji Parmar, Keshav S. Tomar, Amit Hande. (2011) Electrospray ionization LC-MS/MS validated method for the determination of the active metabolite (R-138727) of prasugrel in human plasma and its application to a bioequivalence study. Drug Testing and Analysisn/a-n/a
CrossRef319
V. L. Serebruany. (2011) Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified. Thrombosis and Haemostasis 105:5, 752-759
CrossRef320
A. Schäfer, U. Flierl, J. Kössler, N. Seydelmann, A. Kobsar, S. Störk, J. Bauersachs. (2011) Early determination of clopidogrel responsiveness by platelet reactivity indexidentifies patients at risk for cardiovascular events after myocardial infarction. Thrombosis and Haemostasis 106:1, 141-148
CrossRef321
David Erlinge. 2011. P2Y Receptors in Health and Disease. , 417-439.
CrossRef322
A. R. Rechner. (2011) Platelet function testing in clinical diagnostics. Hämostaseologie 31:2, 79-87
CrossRef323
B. Ivandic, N. Frey. (2011) New approaches and indications for the analysis of platelet function in cardiology. Hämostaseologie 31:2, 73-76
CrossRef324
Gyoung-Jun Rho, Woo-Ram Shin, Tae-Sik Kong, Min-Sun Kim, Chang-Ju Lee, Byung-Hee Lee. (2011) Significance of Clopidogrel Resistance Related to the Stent-Assisted Angioplasty in Patients with Atherosclerotic Cerebrovascular Disease. Journal of Korean Neurosurgical Society 50:1, 40
CrossRef325
D. Sibbing, R. A. Byrne, I. Bernlochner, A. Kastrati. (2011) High platelet reactivity and clinical outcome – Fact and fiction. Thrombosis and Haemostasis 106:2, 191-202
CrossRef326
M. Cattaneo. (2011) Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate. Thrombosis and Haemostasis 105:Suppl. 1, S67-S74
CrossRef327
I. Tentzeris, J. Siller-Matula, S. Farhan, R. Jarai, J. Wojta, K. Huber. (2011) Platelet function variability and non-genetic causes. Thrombosis and Haemostasis 105:Suppl. 1, S60-S66
CrossRef328
Manuel Piqué, Isabel Hernández, Antonio Miñano, Fernando Worner Diz. (2011) Administración upstream de inhibidores de la glucoproteína IIb/IIIa en el síndrome coronario agudo sin elevación del segmento ST: la estrategia TACTICS. Revista Española de Cardiología Suplementos 11, 27-32
CrossRef329
José Luis Ferreiro, Joan Antoni Gómez-Hospital, Dominick J. Angiolillo, Ángel Cequier. (2011) ¿Los nuevos antagonistas del receptor P2Y12 pueden reemplazar a los inhibidores de la glucoproteína IIb/IIIa?. Revista Española de Cardiología Suplementos 11, 14-19
CrossRef330
Qiang Fu, Nobuaki Suzuki, Kaoru Takada, Hirosada Yamamoto, Shuichi Ishikawa, Naoyuki Yokoyama, Ken Kozuma, Takaaki Isshiki. (2011) Effect of cilostazol on optimized standard antiplatelet therapy in a patient with a cytochrome P450 2C19 *2/*2 genotype. Cardiovascular Intervention and Therapeutics 26:1, 79-82
CrossRef331
Harold P. Adams, Patricia H. Davis. 2011. Antithrombotic Therapy for Treatment of Acute Ischemic Stroke. , 971-991.
CrossRef332
Wei C Lau, Terrence D Welch, Theresa Shields, Melvyn Rubenfire, Udaya S Tantry, Paul A Gurbel. (2011) The Effect of St Johnʼs Wort on the Pharmacodynamic Response of Clopidogrel in Hyporesponsive Volunteers and Patients: Increased Platelet Inhibition by Enhancement of CYP3A4 Metabolic Activity. Journal of Cardiovascular Pharmacology 57:1, 86-93
CrossRef333
D. P. Faxon, J. W. Eikelboom, P. B. Berger, D. R. Holmes, D. L. Bhatt, D. J. Moliterno, R. C. Becker, D. J. Angiolillo. (2011) Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. Thrombosis and Haemostasis 106:4, 572-584
CrossRef334
Susan D. Housholder-Hughes. (2011) Non-ST-Segment Elevation Acute Coronary Syndrome. AACN Advanced Critical Care 22:2, 113-124
CrossRef335
Manolis Vavuranakis, Dimitrios A. Vrachatis, Theodore G. Papaioannou, Stefanos Archontakis, Konstantinos I. Kalogeras, Maria G. Kariori, Anthi Gafou, Carmen Moldovan, Panagiotis Tzamalis, Christodoulos Stefanadis. (2011) Residual Platelet Reactivity After Clopidogrel Loading in Patients With ST-Elevation Myocardial Infarction Undergoing an Unexpectedly Delayed Primary Percutaneous Coronary Intervention. Circulation Journal 75:9, 2105-2112
CrossRef336
T. Ben Morrison, Brian M. Horst, Michael J. Brown, Malcolm R. Bell, Paul R. Daniels. (2011) Bridging with glycoprotein IIb/IIIa inhibitors for periprocedural management of antiplatelet therapy in patients with drug eluting stents. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef337
R. F. Storey. (2011) Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. Thrombosis and Haemostasis 105:Suppl. 1, S75-S81
CrossRef338
Alan HB Wu. (2011) Drug metabolizing enzyme activities versus genetic variances for drug of clinical pharmacogenomic relevance. Clinical Proteomics 8:1, 12
CrossRef339
D. J. Angiolillo, P. Capranzano, J. L. Ferreiro, M. Ueno, D. Capodanno, K. Dharmashankar, A. Darlington, S. Sumner, B. Desai, R. K. Charlton, L. C. Box, M. Zenni, L. A. Guzman, T. A. Bass. (2011) Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. Thrombosis and Haemostasis 106:2, 253-262
CrossRef340
David P. Faxon. (2011) Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef341
P. W. Radke, H. Schunkert. (2010) Diabetics with acute coronary syndrome: advances, challenges, and uncertainties. European Heart Journal 31:24, 2971-2973
CrossRef342
S. James, D. J. Angiolillo, J. H. Cornel, D. Erlinge, S. Husted, F. Kontny, J. Maya, J. C. Nicolau, J. Spinar, R. F. Storey, S. R. Stevens, L. Wallentin, . (2010) Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. European Heart Journal 31:24, 3006-3016
CrossRef343
V. Wenzel, S.G. Russo, H.R. Arntz, J. Bahr, M.A. Baubin, B.W. Böttiger, B. Dirks, U. Kreimeier, M. Fries, C. Eich. (2010) Kommentar zu den Leitlinien 2010 zur kardiopulmonalen Reanimation des European Resuscitation Council. Der Anaesthesist 59:12, 1105-1123
CrossRef344
Syed A Raza, Wanda M Popescu, Ion S Jovin. (2010) Perioperative stent thrombosis. Interventional Cardiology 2:6, 821-828
CrossRef345
Gilles Montalescot, Jean-Sébastien Hulot, Jean-Philippe Collet. (2010) Antiplatelet Therapy and Coronary Artery Bypass Graft Surgery. Journal of the American College of Cardiology 56:24, 2003-2005
CrossRef346
Neena S. Abraham, Mark A. Hlatky, Elliott M. Antman, Deepak L. Bhatt, David J. Bjorkman, Craig B. Clark, Curt D. Furberg, David A. Johnson, Charles J. Kahi, Loren Laine, Kenneth W. Mahaffey, Eamonn M. Quigley, James Scheiman, Laurence S. Sperling, Gordon F. Tomaselli. (2010) ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Journal of the American College of Cardiology 56:24, 2051-2066
CrossRef347
Iñigo Lozano, Vicente Barriales, Juan Rondan, Concepcion Suarez. (2010) Elevation of high-sensitivity cardiac troponin T and composite end points in randomized trials. American Heart Journal 160:6, e47
CrossRef348
Elias B. Hanna, Sunil V. Rao, Steven V. Manoukian, Jorge F. Saucedo. (2010) The Evolving Role of Glycoprotein IIb/IIIa Inhibitors in the Setting of Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions 3:12, 1209-1219
CrossRef349
Ivan C. Rokos, William J. French, Amal Mattu, Graham Nichol, Michael E. Farkouh, James Reiffel, Gregg W. Stone. (2010) Appropriate Cardiac Cath Lab activation: Optimizing electrocardiogram interpretation and clinical decision-making for acute ST-elevation myocardial infarction. American Heart Journal 160:6, 995-1003.e8
CrossRef350
Annemarie M. Armani. (2010) Prasugrel. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 9:4, 199-202
CrossRef351
T. Petrovic, K. Tazarourte, C. Lapandry, F. Adnet, F. Lapostolle. (2010) Syndrome coronaire aigu avec élévation du segment ST : stratégies de prise en charge en préhospitalier. Annales de Cardiologie et d'Angéiologie 59:6, 329-334
CrossRef352
P. Aubry, X. Halna du Fretay. (2010) Traitements antithrombotiques du syndrome coronarien aigu avec sus-décalage ST. Annales de Cardiologie et d'Angéiologie 59:6, 335-343
CrossRef353
Julio Marchini, David Morrow, Frederic Resnic, Andre Manica, James Kirshenbaum, Christopher Cannon, Kevin Croce. (2010) An Algorithm for Use of Prasugrel (Effient) in Patients Undergoing Cardiac Catheterization and Percutaneous Coronary Intervention. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 9:4, 192-198
CrossRef354
Toshiaki Otsuka, Tomoyuki Kawada, Chikao Ibuki, Yoshihiko Seino. (2010) Elevation of high-sensitivity cardiac troponin T and composite end points in randomized trials: Author reply. American Heart Journal 160:6, e49
CrossRef355
Raute Sunder-Plassmann, Christine Mannhalter. (2010) Pharmacogenetics guided anticoagulation. Clinical Chemistry and Laboratory Medicine 48:S1, S119-S127
CrossRef356
Thomas J. Povsic, Bruce A. Sullenger, Steven L. Zelenkofske, Christopher P. Rusconi, Richard C. Becker. (2010) Translating Nucleic Acid Aptamers to Antithrombotic Drugs in Cardiovascular Medicine. Journal of Cardiovascular Translational Research 3:6, 704-716
CrossRef357
Wiebke Gogarten, Erik Vandermeulen, Hugo Van Aken, Sibylle Kozek, Juan V Llau, Charles M Samama. (2010) Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. European Journal of Anaesthesiology 27:12, 999-1015
CrossRef358
I. S. Mackenzie, M. W. H. Coughtrie, T. M. MacDonald, L. Wei. (2010) Antiplatelet drug interactions. Journal of Internal Medicine 268:6, 516-529
CrossRef359
Chin-Leng Poh, Pei Ho, Chi-Hang Lee. (2010) Noncardiac surgery following percutaneous coronary intervention. Interventional Cardiology 2:6, 841-850
CrossRef360
Neena S Abraham, Mark A Hlatky, Elliott M Antman, Deepak L Bhatt, David J Bjorkman, Craig B Clark, Curt D Furberg, David A Johnson, Charles J Kahi, Loren Laine, Kenneth W Mahaffey, Eamonn M Quigley, James Scheiman, Laurence S Sperling, Gordon F Tomaselli. (2010) ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. The American Journal of Gastroenterology 105:12, 2533-2549
CrossRef361
Joakim Alfredsson, Eva Swahn. (2010) Management of acute coronary syndromes from a gender perspective. Fundamental & Clinical Pharmacology 24:6, 719-728
CrossRef362
David S. Small, Nagy A. Farid, Christopher D. Payne, Christopher S. Konkoy, Joseph A. Jakubowski, Kenneth J. Winters, Daniel E. Salazar. (2010) Effect of Intrinsic and Extrinsic Factors on the Clinical Pharmacokinetics and Pharmacodynamics of Prasugrel. Clinical Pharmacokinetics 49:12, 777-798
CrossRef363
Savanna Steele, Craig R Lee. (2010) Research Highlights. Pharmacogenomics 11:12, 1687-1690
CrossRef364
H. Benamer, B. Meftout, B. Chevalier. (2010) Le risque de saignement dans les syndromes coronariens aigus avec sus-décalage du segment ST. Annales de Cardiologie et d'Angéiologie 59:6, 356-361
CrossRef365
L. Lorgis, C. Richard, M. Zeller, A. Gudjoncik, P. Buffet, I. L’Huillier, Y. Cottin. (2010) Les anti-agrégants plaquettaires au cours du syndrome coronarien aigu. Données des grandes études. Annales de Cardiologie et d'Angéiologie 59, S47-S55
CrossRef366
Laura Mauri, Dean J. Kereiakes, Sharon-Lise T. Normand, Stephen D. Wiviott, David J. Cohen, David R. Holmes, Sripal Bangalore, Donald E. Cutlip, Michael Pencina, Joseph M. Massaro. (2010) Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. American Heart Journal 160:6, 1035-1041.e1
CrossRef367
Bhatt, Deepak L., Cryer, Byron L., Contant, Charles F., Cohen, Marc, Lanas, Angel, Schnitzer, Thomas J., Shook, Thomas L., Lapuerta, Pablo, Goldsmith, Mark A., Laine, Loren, Scirica, Benjamin M., Murphy, Sabina A., Cannon, Christopher P., . (2010) Clopidogrel with or without Omeprazole in Coronary Artery Disease. New England Journal of Medicine 363:20, 1909-1917
Full Text368
, Bob Wilffert, Jesse Swen, Hans Mulder, Daan Touw, Anke-Hilse Maitland-Van der Zee, Vera Deneer. (2010) From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. Pharmacy World & Science
CrossRef369
J. Silvain, A. Pena, G. Cayla, D. Brieger, A. Bellemain-Appaix, T. Chastre, J.-B. Vignalou, F. Beygui, O. Barthelemy, J.-P. Collet, G. Montalescot. (2010) Impact of red blood cell transfusion on platelet activation and aggregation in healthy volunteers: results of the TRANSFUSION study. European Heart Journal 31:22, 2816-2821
CrossRef370
Giuseppe Luca, Guido Parodi, David Antoniucci. (2010) Safety and benefits of protamine administration to revert anticoagulation soon after coronary angioplasty. A meta-analysis. Journal of Thrombosis and Thrombolysis 30:4, 452-458
CrossRef371
Thomas Cuisset, Corinne Frere, Pierre Julien Moro, Jacques Quilici, Coline Pons, Bénédicte Gaborit, Laurence Camoin, Pierre-Emmanuel Morange, Jean-Louis Bonnet, Marie-Christine Alessi. (2010) Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome. Thrombosis Research 126:5, e400-e402
CrossRef372
Chadi Dib, Elias B. Hanna, Mazen S. Abu-Fadel. (2010) A New Era for Antiplatelet Therapy in Patients With Acute Coronary Syndrome. The American Journal of the Medical Sciences 340:5, 407-411
CrossRef373
Davide Capodanno, Dominick J. Angiolillo. (2010) Antithrombotic Therapy in the Elderly. Journal of the American College of Cardiology 56:21, 1683-1692
CrossRef374
Sébastien Arméro, Laurence Camoin Jau, Omar Aït Mokhtar, Julien Mancini, Caroline Burignat-Bonello, Iliassou Tahirou, Stéphane Arques, Françoise Dignat-George, Franck Paganelli, Laurent Bonello. (2010) Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy. Platelets 21:7, 503-507
CrossRef375
Stephen D. Wiviott, Jessica L. Mega. (2010) Another Step on the Road to Tailored Antiplatelet Therapy
CrossRef376
H.-R. Arntz, L.L. Bossaert, N. Danchin, N. Nicolau. (2010) Initiales Management des akuten Koronarsyndroms. Notfall + Rettungsmedizin 13:7, 621-634
CrossRef377
Nina S. Huang, Huzefa H. Master, Julie A. Fusco, Zoon H. Park. (2010) Ticagrelor: A Novel Oral Antiplatelet Agent. The Consultant Pharmacist 25:11, 745-755
CrossRef378
Fabio Mangiacapra, Olivier Muller, Argyrios Ntalianis, Catalina Trana, Guy R. Heyndrickx, Jozef Bartunek, Marc Vanderheyden, William Wijns, Bernard De Bruyne, Emanuele Barbato. (2010) Comparison of 600 Versus 300-mg Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Coronary Angioplasty. The American Journal of Cardiology 106:9, 1208-1211
CrossRef379
Erasto Gutierrez, Roberto Jordan, Asit Baran Shil. (2010) OUTCOME AFTER PRIMARY ANGIOPLASTY FOR ACUTE MYOCARDIAL INFARCTION IN OLD AGE. Journal of the American Geriatrics Society 58:11, 2236-2237
CrossRef380
S. Goto, H. Ogawa, M. Takeuchi, M. D. Flather, D. L. Bhatt, . (2010) Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. European Heart Journal 31:21, 2601-2613
CrossRef381
Anne Bellemain-Appaix, David Brieger, Farzin Beygui, Johanne Silvain, Ana Pena, Guillaume Cayla, Olivier Barthélémy, Jean-Philippe Collet, Gilles Montalescot. (2010) New P2Y12 Inhibitors Versus Clopidogrel in Percutaneous Coronary Intervention. Journal of the American College of Cardiology 56:19, 1542-1551
CrossRef382
Jean-Luc Reny, Robert F. Bonvini, John M. Bonvini, Marco Roffi, Pierre Fontana. (2010) Poor Responsiveness to Antiplatelet Drugs in Acute Coronary Syndromes: Clinical Relevance and Management. Cardiovascular Therapeuticsno-no
CrossRef383
I. Cornelissen, D. Palmer, T. David, L. Wilsbacher, C. Concengco, P. Conley, A. Pandey, S. R. Coughlin. (2010) Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis. Proceedings of the National Academy of Sciences 107:43, 18605-18610
CrossRef384
, , W. Wijns, P. Kolh, N. Danchin, C. Di Mario, V. Falk, T. Folliguet, S. Garg, K. Huber, S. James, J. Knuuti, J. Lopez-Sendon, J. Marco, L. Menicanti, M. Ostojic, M. F. Piepoli, C. Pirlet, J. L. Pomar, N. Reifart, F. L. Ribichini, M. J. Schalij, P. Sergeant, P. W. Serruys, S. Silber, M. Sousa Uva, D. Taggart, , A. Vahanian, A. Auricchio, J. Bax, C. Ceconi, V. Dean, G. Filippatos, C. Funck-Brentano, R. Hobbs, P. Kearney, T. McDonagh, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, P. E. Vardas, P. Widimsky, , P. Kolh, O. Alfieri, J. Dunning, S. Elia, P. Kappetein, U. Lockowandt, G. Sarris, P. Vouhe, , P. Kearney, L. von Segesser, S. Agewall, A. Aladashvili, D. Alexopoulos, M. J. Antunes, E. Atalar, A. Brutel de la Riviere, A. Doganov, J. Eha, J. Fajadet, R. Ferreira, J. Garot, J. Halcox, Y. Hasin, S. Janssens, K. Kervinen, G. Laufer, V. Legrand, S. A. M. Nashef, F.-J. Neumann, K. Niemela, P. Nihoyannopoulos, M. Noc, J. J. Piek, J. Pirk, Y. Rozenman, M. Sabate, R. Starc, M. Thielmann, D. J. Wheatley, S. Windecker, M. Zembala. (2010) Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal 31:20, 2501-2555
CrossRef385
Hans-Richard Arntz, Leo L. Bossaert, Nicolas Danchin, Nikolaos I. Nikolaou. (2010) European Resuscitation Council Guidelines for Resuscitation 2010 Section 5. Initial management of acute coronary syndromes. Resuscitation 81:10, 1353-1363
CrossRef386
Pier Mannuccio Mannucci, Massimo Franchini. (2010) New antiplatelet agents in acute coronary syndromes (ACS): An update. European Journal of Internal Medicine 21:5, 465-466
CrossRef387
Łukasz A Małek, Adam Witkowski. (2010) Use of antiplatelet therapies during primary percutaneous coronary intervention for acute myocardial infarction. Interventional Cardiology 2:5, 705-718
CrossRef388
Young-Hoon Jeong, Jung-Hyun Cho, Min-Kyung Kang, Jin-Sin Koh, In-Suk Kim, Yongwhi Park, Seok-Jae Hwang, Choong Hwan Kwak, Jin-Yong Hwang. (2010) Smoking at least 10 cigarettes per day increases platelet inhibition by clopidogrel in patients with ST-segment-elevation myocardial infarction. Thrombosis Research 126:4, e334-e338
CrossRef389
W. Fischbach, H. Darius, M. Gross, H. Koop, I. Kruck, K.U. Petersen. (2010) Gleichzeitige Anwendung von Thrombozytenaggregationshemmern und Protonenpumpeninhibitoren (PPIs). Der Kardiologe 4:5, 353-364
CrossRef390
Rossella Marcucci, Gian Franco Gensini. (2010) High on-clopidogrel platelet reactivity and risk of MACE after PCI with stent implantation. Interventional Cardiology 2:5, 619-621
CrossRef391
Gianluca Campo, Luca Fileti, Marco Valgimigli, Matteo Tebaldi, Elisa Cangiano, Caterina Cavazza, Jlenia Marchesini, Roberto Ferrari. (2010) Poor response to clopidogrel: current and future options for its management. Journal of Thrombosis and Thrombolysis 30:3, 319-331
CrossRef392
Marco Cattaneo, Gian Marco Podda. (2010) State of the art of new P2Y12 antagonists. Internal and Emergency Medicine 5:5, 385-391
CrossRef393
Betti Giusti, Rosanna Abbate. (2010) Response to antiplatelet treatment: from genes to outcome. The Lancet 376:9749, 1278-1281
CrossRef394
David R. Holmes, Dean J. Kereiakes, Scot Garg, Patrick W. Serruys, Gregory J. Dehmer, Stephen G. Ellis, David O. Williams, Takeshi Kimura, David J. Moliterno. (2010) Stent Thrombosis. Journal of the American College of Cardiology 56:17, 1357-1365
CrossRef395
Lars Wallentin, Stefan James, Robert F Storey, Martin Armstrong, Bryan J Barratt, Jay Horrow, Steen Husted, Hugo Katus, P Gabriel Steg, Svati H Shah, Richard C Becker. (2010) Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. The Lancet 376:9749, 1320-1328
CrossRef396
Emmanouil S Brilakis, Subhash Banerjee. (2010) Management of patients with coronary stents in the ICU. Current Opinion in Critical Care 16:5, 426-431
CrossRef397
Leo Bossaert, Robert E. O’Connor, Hans-Richard Arntz, Steven C. Brooks, Deborah Diercks, Gilson Feitosa-Filho, Jerry P. Nolan, Terry L. Vanden Hoek, Darren L. Walters, Aaron Wong, Michelle Welsford, Karen Woolfrey. (2010) Part 9: Acute coronary syndromes. Resuscitation 81:1, e175-e212
CrossRef398
Daniela J. Conrado, Daniel Gonzalez, Hartmut Derendorf. (2010) Role of drug absorption in the pharmacokinetics of therapeutic interventions for stroke. Annals of the New York Academy of Sciences 1207:1, 134-142
CrossRef399
Daniel A. Hussar. (2010) New Drug Update: 2010. The Consultant Pharmacist 25:10, 608-635
CrossRef400
Robert S. Epstein, J. Russell Teagarden. (2010) Comparative Effectiveness Research and Personalized Medicine. PharmacoEconomics 28:10, 905-913
CrossRef401
Sergio Leonardi, Pierluigi Tricoci, Richard C. Becker. (2010) Thrombin Receptor Antagonists for the Treatment of Atherothrombosis. Drugs 70:14, 1771-1783
CrossRef402
Matthew A. Cavender, Sunil V. Rao. (2010) Bleeding associated with current therapies for acute coronary syndrome: What are the mechanisms?. Journal of Thrombosis and Thrombolysis 30:3, 332-339
CrossRef403
Jessica L Mega, Sandra L Close, Stephen D Wiviott, Lei Shen, Joseph R Walker, Tabassome Simon, Elliott M Antman, Eugene Braunwald, Marc S Sabatine. (2010) Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis. The Lancet 376:9749, 1312-1319
CrossRef404
Michael A. Gaglia, Steven V. Manoukian, Ron Waksman. (2010) Novel antiplatelet therapy. American Heart Journal 160:4, 595-604
CrossRef405
Ralph Weber, Hans-Christoph Diener. (2010) Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention. Journal of Cellular and Molecular Medicine 14:10, 2371-2380
CrossRef406
Wei Feng Lu, Wei Mo, Zhenjie Liu, Wei Guo Fu, Da Qiao Guo, Yu Qi Wang, Hou Yan Song. (2010) The antithrombotic effect of a novel hirudin derivative after reconstruction of carotid artery in rabbits. Thrombosis Research 126:4, e339-e343
CrossRef407
Samuel Chackalamannil. 2010. Antiplatelet Agents. .
CrossRef408
Xavier Bosch, Jaume Marrugat, Juan Sanchis, Xavier Bosch. 2010. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. .
CrossRef409
Fuster, Valentin, . (2010) Fine-Tuning Therapy for Acute Coronary Syndromes. New England Journal of Medicine 363:10, 976-977
Full Text410
The CURRENT–OASIS 7 Investigators. (2010) Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes. New England Journal of Medicine 363:10, 930-942
Full Text411
Daniel Duerschmied, Christoph Bode, Martin Moser. (2010) Clopidogrel in acute coronary syndrome: implications of recent study findings. Expert Review of Cardiovascular Therapy 8:9, 1215-1229
CrossRef412
Laurent Bonello, Udaya S. Tantry, Rossella Marcucci, Ruediger Blindt, Dominick J. Angiolillo, Richard Becker, Deepak L. Bhatt, Marco Cattaneo, Jean Philippe Collet, Thomas Cuisset, Christian Gachet, Gilles Montalescot, Lisa K. Jennings, Dean Kereiakes, Dirk Sibbing, Dietmar Trenk, Jochem W. Van Werkum, Franck Paganelli, Matthew J. Price, Ron Waksman, Paul A. Gurbel. (2010) Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate. Journal of the American College of Cardiology 56:12, 919-933
CrossRef413
N. Uren. (2010) Acute coronary syndromes: assessing risk and choosing optimal pharmacological regimens for a superior outcome. European Heart Journal Supplements 12:Suppl D, D4-D13
CrossRef414
John Jason Sutton, Colin M. Barker. (2010) Is There a Role for Platelet Function Testing for Patients on Chronic Dual Antiplatelet Therapy?. Current Cardiovascular Risk Reports 4:5, 327-331
CrossRef415
Nathan D Lambert, Robert J Applegate. (2010) The comparative safety of bare-metal and drug-eluting intracoronary stents. Expert Review of Medical Devices 7:5, 611-624
CrossRef416
M. Valgimigli. (2010) Balancing safety and efficacy: recent clinical evidence optimizing outcomes in patients with intermediate to high-risk non-ST-segment elevated acute coronary syndrome. European Heart Journal Supplements 12:Suppl D, D14-D23
CrossRef417
Elisabeth Mahla, Helfried Metzler, Udaya S. Tantry, Paul A. Gurbel. (2010) Controversies in Oral Antiplatelet Therapy in Patients Undergoing Aortocoronary Bypass Surgery. The Annals of Thoracic Surgery 90:3, 1040-1051
CrossRef418
Sadik Acikel, Ramazan Akdemir, Goksel Cagirci, Asuman Bicer Yesilay, Mehmet Dogan, Harun Kilic. (2010) The treatment of clopidogrel resistance: Triple antiplatelet therapy and future directions. International Journal of Cardiology 144:1, 79-82
CrossRef419
Deepak Thomas, Robert P. Giugliano. (2010) Perspectives on the 2009 Focused Updates on the Management of ST-Segment Elevation Myocardial Infarction and Percutaneous Intervention. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 9:3, 126-133
CrossRef420
Fabio Mangiacapra, Emanuele Barbato. (2010) Individual Variability of Response to Antiplatelet Therapy is an Important Determinant of Adverse Clinical Outcome. High Blood Pressure & Cardiovascular Prevention 17:3, 121-130
CrossRef421
Gregory D. Trachiotis. (2010) Early Antiplatelet Therapy in Coronary Artery Bypass Grafting. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery 5:5, 317-325
CrossRef422
Bertram Pitt, Faiez Zannad, Mihai Gheorghiade, Felipe Martínez, Thomas E. Love, Casey Daniel, Ali Ahmed. (2010) Transatlantic similarities and differences in major natural history endpoints of heart failure after acute myocardial infarction: A propensity-matched study of the EPHESUS trial. International Journal of Cardiology 143:3, 309-316
CrossRef423
Kensaku Nishihira, Atsushi Yamashita, Tetsunori Ishikawa, Kinta Hatakeyama, Yoshisato Shibata, Yujiro Asada. (2010) Composition of thrombi in late drug-eluting stent thrombosis versus de novo acute myocardial infarction. Thrombosis Research 126:3, 254-257
CrossRef424
Jeremy S. Paikin, John W. Eikelboom, John A. Cairns, Jack Hirsh. (2010) New antithrombotic agents—insights from clinical trials. Nature Reviews Cardiology 7:9, 498-509
CrossRef425
Junbo Ge, Junren Zhu, Bum-Kee Hong, Sarana Boonbaichaiyapruck, Yew Seong Goh, Charles Jia-Yin Hou, Philippe Pinton. (2010) Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial. Current Medical Research and Opinion 26:9, 2077-2085
CrossRef426
M. VALGIMIGLI, G. CAMPO, M. TEBALDI, M. MONTI, S. GAMBETTI, A. SCALONE, G. PARRINELLO, R. FERRARI, . (2010) Randomized, double-blind comparison of effects of abiciximab bolus only vs. on-label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting. Journal of Thrombosis and Haemostasis 8:9, 1903-1911
CrossRef427
A. W. J. van 't Hof. (2010) Early and aggressive treatment of patients with ST-segment elevation myocardial infarction: deciphering recent clinical trials and the timing of optimal platelet inhibition. European Heart Journal Supplements 12:Suppl D, D24-D35
CrossRef428
Deepak L. Bhatt. (2010) Acute coronary syndrome update for hospitalists. Journal of Hospital Medicine 5:S4, S15-S21
CrossRef429
Manivannan Srinivasan, Charanjit S. Rihal, Mandeep Singh, Ryan J. Lennon, David R. Holmes, Abhiram Prasad. (2010) Percutaneous Coronary Intervention in Native Vessels With Angiographically Visible Thrombus. JACC: Cardiovascular Interventions 3:9, 937-946
CrossRef430
Dominick J. Angiolillo, Jorge F. Saucedo, Roger DeRaad, Andrew L. Frelinger, Paul A. Gurbel, Timothy M. Costigan, Joseph A. Jakubowski, Clement K. Ojeh, Mark B. Effron. (2010) Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology 56:13, 1017-1023
CrossRef431
Moutaz El-Kadri, Hala Sharaf-Dabbagh, David Ramsdale. (2010) REVIEW: Role of Antiischemic Agents in the Management of Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS). Cardiovascular Therapeuticsno-no
CrossRef432
Prakash A. Patel, John G.T. Augoustides. (2010) Progress in Platelet Medicine: Focus on Stent Thrombosis and Drug Resistance. Journal of Cardiothoracic and Vascular Anesthesia 24:4, 722-727
CrossRef433
Yuri B. Pride, Patricia Tung, Satishkumar Mohanavelu, Cafer Zorkun, Stephen D. Wiviott, Elliott M. Antman, Robert Giugliano, Eugene Braunwald, C. Michael Gibson. (2010) Angiographic and Clinical Outcomes Among Patients With Acute Coronary Syndromes Presenting With Isolated Anterior ST-Segment Depression. JACC: Cardiovascular Interventions 3:8, 806-811
CrossRef434
Kathryn Momary, Larisa H Cavallari. (2010) Clopidogrel and Proton Pump Inhibitors: Between a Rock and a Hard Place. Pharmacotherapy 30:8, 762-765
CrossRef435
Martin Moser, Christoph Bode. (2010) Antiplatelet therapy for atherothrombotic disease: How can we improve the outcomes?. Journal of Thrombosis and Thrombolysis 30:2, 240-249
CrossRef436
Dimitris Tousoulis, Ioannis Ph. Paroutoglou, Nikolaos Papageorgiou, Marietta Charakida, Christodoulos Stefanadis. (2010) Recent therapeutic approaches to platelet activation in coronary artery disease. Pharmacology & Therapeutics 127:2, 108-120
CrossRef437
Masafumi Ueno, José Luis Ferreiro, Dominick J Angiolillo. (2010) Mechanism of action and clinical development of platelet thrombin receptor antagonists. Expert Review of Cardiovascular Therapy 8:8, 1191-1200
CrossRef438
Masafumi Ueno, José Luis Ferreiro, Dominick J Angiolillo. (2010) Update on the clinical development of cangrelor. Expert Review of Cardiovascular Therapy 8:8, 1069-1077
CrossRef439
Michele Schiariti, Angela Saladini, Domenico Cuturello, Bindo Missiroli, Paolo Emilio Puddu. (2010) Long-term efficacy of high-dose tirofiban versus double-bolus eptifibatide in patients undergoing percutaneous coronary intervention. Journal of Cardiovascular Medicine1
CrossRef440
S.H. Meves, U. Overbeck, A. Kaiser, C. Krogias, H. Neubauer. (2010) Umstellung von Clopidogrel-Hydrogensulfat auf Clopidogrel-Besilat. Der Nervenarzt 81:8, 992-997
CrossRef441
Scot Garg, Patrick W. Serruys. (2010) Coronary Stents. Journal of the American College of Cardiology 56:10, S1-S42
CrossRef442
Peter B. Berger. (2010) The Glycoprotein IIb/IIIa Inhibitor Wars. Journal of the American College of Cardiology 56:6, 476-478
CrossRef443
H.- S. Kang, B. J. Kwon, J. E. Kim, M. H. Han. (2010) Preinterventional Clopidogrel Response Variability for Coil Embolization of Intracranial Aneurysms: Clinical Implications. American Journal of Neuroradiology 31:7, 1206-1210
CrossRef444
Kumaran Kolandaivelu, Deepak L. Bhatt. (2010) Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence. Nature Reviews Cardiology 7:8, 461-467
CrossRef445
Omar Ait Mokhtar, Gilles Lemesle, Sébastien Armero, Julien Mancini, Caroline Bonello, Iliassou Tahirou, Paul Barragan, Françoise Dignat-George, Laurence Camoin-Jau, Franck Paganelli, Laurent Bonello. (2010) Relationship between platelet reactivity inhibition and non-CABG related major bleeding in patients undergoing percutaneous coronary intervention. Thrombosis Research 126:2, e147-e149
CrossRef446
David Vivas, Dominick J. Angiolillo. (2010) Platelet P2Y12 Receptor Inhibition. American Journal Cardiovascular Drugs 10:4, 217-226
CrossRef447
M. J. SORICH, A. VITRY, M. B. WARD, J. D. HOROWITZ, R. A. MCKINNON. (2010) Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. Journal of Thrombosis and Haemostasis 8:8, 1678-1684
CrossRef448
Nicolas Danchin, Nadia Aïssaoui. (2010) Pharmacologic Therapy for Non ST-segment Elevation Acute Coronary Syndromes: Focus on Antithrombotic Therapy. Cardiovascular Drugs and Therapy 24:4, 325-330
CrossRef449
Jon-David R. Schwalm, Mayraj Ahmad, Omid Salehian, John W. Eikelboom, Madhu K. Natarajan. (2010) Warfarin after anterior myocardial infarction in current era of dual antiplatelet therapy: a randomized feasibility trial. Journal of Thrombosis and Thrombolysis 30:2, 127-132
CrossRef450
Axel Åkerblom, Stefan K. James, Michail Koutouzis, Bo Lagerqvist, Ulf Stenestrand, Bodil Svennblad, Jonas Oldgren. (2010) Eptifibatide Is Noninferior to Abciximab in Primary Percutaneous Coronary Intervention. Journal of the American College of Cardiology 56:6, 470-475
CrossRef451
Tobias Geisler, Meinrad Gawaz, Steven R. Steinhubl, Deepak L. Bhatt, Robert F. Storey, Marcus Flather. (2010) Current strategies in antiplatelet therapy — Does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?. Pharmacology & Therapeutics 127:2, 95-107
CrossRef452
Jorge F. Saucedo. (2010) Balancing the benefits and risks of antiplatelet agents in patients with non-ST-segment elevated acute coronary syndromes and undergoing percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis 30:2, 200-209
CrossRef453
M. Stramba-Badiale. (2010) Women and research on cardiovascular diseases in Europe: a report from the European Heart Health Strategy (EuroHeart) project. European Heart Journal 31:14, 1677-1681
CrossRef454
Chee Tang Chin, Matthew T. Roe, Keith A.A. Fox, Dorairaj Prabhakaran, Debra A. Marshall, Helene Petitjean, Yuliya Lokhnygina, Eileen Brown, Paul W. Armstrong, Harvey D. White, E. Magnus Ohman. (2010) Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non–ST-segment elevation myocardial infarction: The TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. American Heart Journal 160:1, 16-22.e1
CrossRef455
Yee W Wong, Roshan Prakash, Derek P Chew. (2010) Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents. Current Opinion in Cardiology 25:4, 305-311
CrossRef456
Miles W Behan, Derek P Chew, Philip E Aylward. (2010) The role of antiplatelet therapy in the secondary prevention of coronary artery disease. Current Opinion in Cardiology 25:4, 321-328
CrossRef457
Kimberly L Campbell, John R Cohn, Michael P Savage. (2010) Clopidogrel hypersensitivity: clinical challenges and options for management. Expert Review of Clinical Pharmacology 3:4, 553-561
CrossRef458
Sergio Leonardi, Sunil V. Rao, Robert A. Harrington, Deepak L. Bhatt, C. Michael Gibson, Matthew T. Roe, Janusz Kochman, Kurt Huber, Uwe Zeymer, Mina Madan, Daniel D. Gretler, Matthew W. McClure, Gayle E. Paynter, Vivian Thompson, Robert C. Welsh. (2010) Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). American Heart Journal 160:1, 65-72
CrossRef459
Kathleen Butler, Renli Teng. (2010) Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. British Journal of Clinical Pharmacology 70:1, 65-77
CrossRef460
David R. Holmes, Gregory J. Dehmer, Sanjay Kaul, Dana Leifer, Patrick T. O'Gara, C. Michael Stein. (2010) ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”. Journal of the American College of Cardiology 56:4, 321-341
CrossRef461
C. Richard Conti. (2010) Antiplatelets and Anticoagulants. Clinical Cardiology 33:7, 388-389
CrossRef462
Stephen D. Wiviott, Elliott M. Antman, Eugene Braunwald. (2010) Mortality in the TRITON Trial: Update from the FDA Prasugrel Action Package. The American Journal of Cardiology 106:2, 293-294
CrossRef463
Young-Hoon Jeong, In-Suk Kim, Yongwhi Park, Min-Kyung Kang, Jin-Sin Koh, Seok-Jae Hwang, Choong Hwan Kwak, Jin-Yong Hwang. (2010) Carriage of Cytochrome 2C19 Polymorphism Is Associated With Risk of High Post-Treatment Platelet Reactivity on High Maintenance-Dose Clopidogrel of 150 mg/day. JACC: Cardiovascular Interventions 3:7, 731-741
CrossRef464
Masafumi Ueno, Sunil V Rao, Dominick J Angiolillo. (2010) Elinogrel: pharmacological principles, preclinical and early phase clinical testing. Future Cardiology 6:4, 445-453
CrossRef465
(2010) Meeting the Unmet Needs in Anticoagulant Therapy. European Journal of Haematology 85, 1-28
CrossRef466
Samir B. Damani, Eric J. Topol. (2010) The Case for Routine Genotyping in Dual-Antiplatelet Therapy. Journal of the American College of Cardiology 56:2, 109-111
CrossRef467
Neal S. Kleiman. (2010) PLATO Study of Ticagrelor Versus Clopidogrel in Patients With High-Risk Acute Coronary Syndromes. Current Cardiology Reports 12:4, 283-285
CrossRef468
Guliz Erdem, Tobias Geisler, Marcus D. Flather. (2010) What Goes Into a Major Acute Coronary Syndrome Trial and What Will Future Trials Look Like?. Current Cardiology Reports 12:4, 348-355
CrossRef469
Wiebke Kurre, René Chapot, Richard du Mesnil de Rochemont, Joachim Berkefeld. (2010) Intracranial stenting in atherosclerotic disease—recent results and challenges to face. Neuroradiology 52:7, 633-644
CrossRef470
E. I. Tucker, U. M. Marzec, M. A. Berny, S. Hurst, S. Bunting, O. J. T. McCarty, A. Gruber, S. R. Hanson. (2010) Safety and Antithrombotic Efficacy of Moderate Platelet Count Reduction by Thrombopoietin Inhibition in Primates. Science Translational Medicine 2:37, 37ra45-37ra45
CrossRef471
G. Y. H. Lip, K. Huber, F. Andreotti, H. Arnesen, J. K. Airaksinen, T. Cuisset, P. Kirchhof, F. Marin. (2010) Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal 31:11, 1311-1318
CrossRef472
J. Hankowitz, P. Bramlage. (2010) Pharmaka zur Thrombozyten- und Gerinnungshemmung in der Behandlung des akuten Koronarsyndroms. Der Kardiologe 4:3, 239-248
CrossRef473
Jerrold H Levy, Marc Azran. (2010) Anesthetic concerns for patients with coagulopathy. Current Opinion in Anaesthesiology 23:3, 400-405
CrossRef474
Timm Bauer, Uwe Zeymer. (2010) Impact of age on outcomes of percutaneous coronary intervention in acute coronary syndromes patients. Interventional Cardiology 2:3, 319-325
CrossRef475
Nihar R. Desai, Deepak L. Bhatt. (2010) The State of Periprocedural Antiplatelet Therapy After Recent Trials. JACC: Cardiovascular Interventions 3:6, 571-583
CrossRef476
E. Magnus Ohman, Matthew T. Roe, Paul W. Armstrong, Keith A. Fox, Dorairaj Prabhakaran, Harvey D. White. (2010) Public Sensationalism and Clinical Trials: How to Address the Challenges of Science?. The American Journal of Medicine 123:6, 481-483
CrossRef477
G. Davì, F. Santilli. (2010) Aspirin as antiplatelet agent in diabetes. PROS-. European Journal of Internal Medicine 21:3, 149-153
CrossRef478
Soraya El Ghannudi, Patrick Ohlmann, Nicolas Meyer, Marie-Louise Wiesel, Bogdan Radulescu, Michel Chauvin, Pierre Bareiss, Christian Gachet, Olivier Morel. (2010) Impact of P2Y12 Inhibition by Clopidogrel on Cardiovascular Mortality in Unselected Patients Treated by Percutaneous Coronary Angioplasty. JACC: Cardiovascular Interventions 3:6, 648-656
CrossRef479
Michael A. Gaglia Jr., Ron Waksman. (2010) Proton Pump Inhibitors and Clopidogrel. Cardiovascular Therapeutics 28:3, 169-176
CrossRef480
J.M. Cotton, A.M. Worrall, A.R. Hobson, A. Smallwood, V. Amoah, S. Dunmore, A.M. Nevill, R. Rajendra, J. Vickers, N. Curzen. (2010) Individualised Assessment of Response to Clopidogrel in Patients Presenting with Acute Coronary Syndromes: A Role for Short Thrombelastography?. Cardiovascular Therapeutics 28:3, 139-146
CrossRef481
Keith A.A. Fox, Tim C. Clayton, Peter Damman, Stuart J. Pocock, Robbert J. de Winter, Jan G.P. Tijssen, Bo Lagerqvist, Lars Wallentin. (2010) Long-Term Outcome of a Routine Versus Selective Invasive Strategy in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology 55:22, 2435-2445
CrossRef482
L. Testa, R. Bhindi, W. J. Van Gaal, R. A. Latini, S. Pizzocri, S. Lanotte, G. G. L. Biondi Zoccai, M. Valgimigli, M. L. Laudisa, N. Brambilla, A. P. Banning, F. Bedogni. (2010) What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel. QJM 103:6, 367-377
CrossRef483
G. Di Sciascio, G. Patti, V. Pasceri, G. Colonna, F. Mangiacapra, A. Montinaro, . (2010) Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. European Heart Journal 31:11, 1337-1343
CrossRef484
Li Liu, Fandian Zeng, Xiaohua Zeng, Qingmei Xue, Shaoping Nie, Cailian Kang, Jianhong Wu, Qingyun Kang, Xingao Wang, Xiaoqing Liu, Tao Li, Jun Chen, Qing Li, Rong Xu, Xiaoyan Yang, Hui Kang, Fagang Jiang, Zongtao Li, Xuwu Wang, Li Zhang, Yu Long. (2010) Revaluation of clopidogrel: let the data speak for themselves. Journal of Huazhong University of Science and Technology [Medical Sciences] 30:3, 299-306
CrossRef485
Daniel Eberli, Pierre-Guy Chassot, Tullio Sulser, Charles Marc Samama, Jean Mantz, Alain Delabays, Donat R. Spahn. (2010) Urological Surgery and Antiplatelet Drugs After Cardiac and Cerebrovascular Accidents. The Journal of Urology 183:6, 2128-2136
CrossRef486
Federico M. Goodsaid, Shashi Amur, Jiri Aubrecht, Michael E. Burczynski, Kevin Carl, Jennifer Catalano, Rosane Charlab, Sandra Close, Catherine Cornu-Artis, Laurent Essioux, Albert J. Fornace, Lois Hinman, Huixiao Hong, Ian Hunt, David Jacobson-Kram, Ansar Jawaid, David Laurie, Lawrence Lesko, Heng-Hong Li, Klaus Lindpaintner, James Mayne, Peter Morrow, Marisa Papaluca-Amati, Timothy W. Robison, John Roth, Ina Schuppe-Koistinen, Leming Shi, Olivia Spleiss, Weida Tong, Sharada L. Truter, Jacky Vonderscher, Agnes Westelinck, Li Zhang, Issam Zineh. (2010) Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact. Nature Reviews Drug Discovery 9:6, 435-445
CrossRef487
Fabio Mangiacapra, Emanuele Barbato. (2010) Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization. Biomarkers in Medicine 4:3, 421-434
CrossRef488
Ashequl M Islam, Pranav M Patel. (2010) Preventing Serious Sequelae After an Acute Coronary Syndrome: The Consequences of Thrombosis Versus Bleeding With Antiplatelet Therapy. Journal of Cardiovascular Pharmacology 55:6, 585-594
CrossRef489
Roxana Mehran, Stuart J. Pocock, Eugenia Nikolsky, Tim Clayton, George D. Dangas, Ajay J. Kirtane, Helen Parise, Martin Fahy, Steven V. Manoukian, Frederick Feit, Magnus E. Ohman, Bernard Witzenbichler, Giulio Guagliumi, Alexandra J. Lansky, Gregg W. Stone. (2010) A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology 55:23, 2556-2566
CrossRef490
Jeffrey S. Berger, Richard C. Becker. 2010. Cardiology. , 185-193.
CrossRef491
Andrew J. Jackson, Paul Coats, Douglas J. Orr, R. Paul Teenan, Roger M. Wadsworth. (2010) Pharmacotherapy to Improve Outcomes in Infrainguinal Bypass Graft Surgery: A Review of Current Treatment Strategies. Annals of Vascular Surgery 24:4, 562-572
CrossRef492
Debbie Yee, Joanne Meyer, Gina Caliendo, Veronica Oviedo. (2010) Prasugrel, a New Platelet Inhibitor. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77:3, 315-323
CrossRef493
Victor L. Serebruany. (2010) Mortality in the TRITON Trial: Update from the FDA Prasugrel Action Package. The American Journal of Cardiology 105:9, 1356-1357
CrossRef494
Richard L Seip, Jorge Duconge, Gualberto Ruaño. (2010) Implementing genotype-guided antithrombotic therapy. Future Cardiology 6:3, 409-424
CrossRef495
Thomas Cuisset, Marco Valgimigli, Harald Mudra, Olivier Muller, William Wijns, Kurt Huber. (2010) Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update. EuroIntervention 6:1, 39-45
CrossRef496
Parham Eshtehardi, Stephan Windecker, Stéphane Cook, Michael Billinger, Mario Togni, Ali Garachemani, Bernhard Meier, Otto M. Hess, Peter Wenaweser. (2010) Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation. American Heart Journal 159:5, 891-898.e1
CrossRef497
Itsik Ben-Dor, Rebecca Torguson, Mickey Scheinowitz, Yanlin Li, Cedric Delhaye, Kohei Wakabayashi, Gabriel Maluenda, Asmir I. Syed, Sara D. Collins, Manuel A. Gonzalez, Michael A. Gaglia, Zhenyi Xue, Kimberly Kaneshige, Lowell F. Satler, William O. Suddath, Kenneth M. Kent, Augusto D. Pichard, Ron Waksman. (2010) Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents. American Heart Journal 159:5, 871-875
CrossRef498
Renli Teng, Kathleen Butler. (2010) Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects. European Journal of Clinical Pharmacology 66:5, 487-496
CrossRef499
Somjot S Brar, Gregg W Stone. (2010) Decision-making: stenting in acute myocardial infarction. Future Cardiology 6:3, 301-314
CrossRef500
S. Michael Gharacholou, Renato D. Lopes, Jeffrey B. Washam, L. Kristin Newby, Stefan K. James, John H. Alexander. (2010) Antithrombotic therapy in acute coronary syndromes: guidelines translated for the clinician. Journal of Thrombosis and Thrombolysis 29:4, 516-528
CrossRef501
Till F. Althoff, Matthias Fischer, Elisabeth Langer, Sabine Ziemer, Gert Baumann. (2010) Sustained enhancement of residual platelet reactivity after coronary stenting in patients with myocardial infarction compared to elective patients. Thrombosis Research 125:5, e190-e196
CrossRef502
Maisha Kelly Freeman. (2010) Thienopyridine Antiplatelet Agents: Focus on Prasugrel. The Consultant Pharmacist 25:4, 241-257
CrossRef503
Wiktor Kuliczkowski, James Floyd, Alex Malinin, Victor Serebruany. (2010) Aptamers: the emerging class of future anticoagulation for vascular disease. Expert Review of Cardiovascular Therapy 8:4, 503-507
CrossRef504
, T. Lickfeld, C. Hamm, M. Möckel, J. Vollert, M. Haude. (2010) Antithrombotische Therapie beim ST-Streckenhebungsinfarkt. Der Kardiologe 4:2, 107-123
CrossRef505
S. Silber, M. Borggrefe, G. Hasenfuß, V. Falk, A. Kastrati, M. Weis, C.W. Hamm. (2010) Kommentare zu den Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zur Diagnostik und Therapie von Patienten mit ST-Streckenhebungsinfarkt (STEMI). Der Kardiologe 4:2, 84-92
CrossRef506
Michele Schiariti, Angela Saladini, Bindo Missiroli, Francesco Papalia, Domenico Cuturello, Paolo Emilio Puddu, Carlo Gaudio. (2010) Safety of downstream high-dose tirofiban bolus among 1578 patients undergoing percutaneous coronary intervention: the SantʼANna TIrofiban Safety study. Journal of Cardiovascular Medicine 11:4, 250-259
CrossRef507
V. L. Serebruany, D. Atar. (2010) The PLATO trial: do you believe in magic?. European Heart Journal 31:7, 764-767
CrossRef508
NEIL GUPTA, RAHUL NAYAK, SCOTT W. GRISOLANO, DANIEL C. BUCKLES, PETER N. TADROS. (2010) Defining Patients at High Risk for Gastrointestinal Hemorrhage after Drug-Eluting Stent Placement: A Cost Utility Analysis. Journal of Interventional Cardiology 23:2, 179-187
CrossRef509
Atholl Johnston. (2010) Challenges of therapeutic substitution of drugs for economic reasons: focus on CVD prevention. Current Medical Research and Opinion 26:4, 871-878
CrossRef510
H. Darius. (2010) Update: orale Thrombozyteninhibitoren in der Kardiologie. Der Internist 51:4, 533-538
CrossRef511
Harold L. Dauerman, Deepak L. Bhatt, Daniel D. Gretler, Patricia A. French, Susan S. Smyth, Richard C. Becker. (2010) Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients. American Heart Journal 159:4, 508-517.e1
CrossRef512
S. SCHULMAN, F. A. SPENCER. (2010) Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding. Journal of Thrombosis and Haemostasis 8:4, 641-650
CrossRef513
James M. Gebel. (2010) Heterogeneity of Efficacy and Safety of Antiplatelet Therapy in Cardiovascular and Cerebrovascular Disease. American Journal Cardiovascular Drugs 10:2, 115-124
CrossRef514
Michel R Hoenig, Constantine N Aroney, Ian A Scott, Michel R Hoenig. 2010. Early invasive versus conservative strategies for unstable angina and non-ST elevation myocardial infarction in the stent era. .
CrossRef515
K. A.A. Fox, K. Carruthers, Ph. G. Steg, A. Avezum, C. B. Granger, G. Montalescot, S. G. Goodman, J. M. Gore, A. L. Quill, K. A. Eagle, . (2010) Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The Global Registry of Acute Coronary Events. European Heart Journal 31:6, 667-675
CrossRef516
David P. Faxon. (2010) Antiplatelet therapy: Cangrelor for ACS—lessons from the CHAMPION trials. Nature Reviews Cardiology 7:3, 124-125
CrossRef517
M. L. Simoons, S. Windecker. (2010) Chronic stable coronary artery disease: drugs vs. revascularization. European Heart Journal 31:5, 530-541
CrossRef518
Graeme J Hankey, John W Eikelboom. (2010) Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. The Lancet Neurology 9:3, 273-284
CrossRef519
Jaya Prakash Sugunaraj, Chandrasekar Palaniswamy, Dhana Rekha Selvaraj, Sri Krishna Chaitanya Arudra, Rishi Sukhija. (2010) Clopidogrel Resistance. American Journal of Therapeutics 17:2, 210-215
CrossRef520
Scot Garg, Patrick Serruys. (2010) Benefits of and safety concerns associated with drug-eluting coronary stents. Expert Review of Cardiovascular Therapy 8:3, 449-470
CrossRef521
Erik Vandermeulen. (2010) Regional anaesthesia and anticoagulation. Best Practice & Research Clinical Anaesthesiology 24:1, 121-131
CrossRef522
Pierre Albaladejo, Charles Marc Samama. (2010) Patients under anti-platelet therapy. Best Practice & Research Clinical Anaesthesiology 24:1, 41-50
CrossRef523
Dominick J. Angiolillo, Esther Bernardo, Davide Capodanno, David Vivas, Manel Sabaté, José Luis Ferreiro, Masafumi Ueno, Pilar Jimenez-Quevedo, Fernando Alfonso, Theodore A. Bass, Carlos Macaya, Antonio Fernandez-Ortiz. (2010) Impact of Chronic Kidney Disease on Platelet Function Profiles in Diabetes Mellitus Patients With Coronary Artery Disease Taking Dual Antiplatelet Therapy. Journal of the American College of Cardiology 55:11, 1139-1146
CrossRef524
Samin K. Sharma. (2010) Oral antiplatelet therapy in PCI patients. Catheterization and Cardiovascular Interventions 75:S1, S7-S14
CrossRef525
Kathryn M Momary, Michael P Dorsch. (2010) Factors associated with clopidogrel nonresponsiveness. Future Cardiology 6:2, 195-210
CrossRef526
Harald Arnesen. (2010) Thrombocardiology: an update. Expert Review of Cardiovascular Therapy 8:3, 331-333
CrossRef527
Rahul Sakhuja, Robert W. Yeh, Deepak L. Bhatt. (2010) Antiplatelet Agents in Acute Coronary Syndromes. Current Problems in Cardiology 35:3, 123-170
CrossRef528
Kathryn M Momary, Michael P Dorsch, Eric R Bates. (2010) Genetic Causes of Clopidogrel Nonresponsiveness: Which Ones Really Count?. Pharmacotherapy 30:3, 265-274
CrossRef529
Rahul Sakhuja, Laura Mauri. (2010) Controversies in the Use of Drug-Eluting Stents for Acute Myocardial Infarction: A Critical Appraisal of the Data. Annual Review of Medicine 61:1, 215-231
CrossRef530
Graeme J Hankey. (2010) Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?. Current Opinion in Neurology 23:1, 65-72
CrossRef531
Seung-Whan Lee, Seong-Wook Park, Sung-Cheol Yun, Young-Hak Kim, Duk-Woo Park, Won-Jang Kim, Jong-Young Lee, Cheol Whan Lee, Myeong-Ki Hong, Jae-Joong Kim, Seung-Jung Park. (2010) Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). American Heart Journal 159:2, 284-291.e1
CrossRef532
Jolanta M Siller-Matula, Julia Krumphuber, Bernd Jilma. (2010) Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. British Journal of Pharmacology 159:3, 502-517
CrossRef533
Roberta Rossini, Giuseppe Musumeci, Alessandro Aprile, Orazio Valsecchi. (2010) Long-term outcomes in patients undergoing percutaneous coronary intervention with drug-eluting stents. Expert Review of Pharmacoeconomics & Outcomes Research 10:1, 49-61
CrossRef534
Carlo Patrono, Bianca Rocca. (2010) The Future of Antiplatelet Therapy in Cardiovascular Disease. Annual Review of Medicine 61:1, 49-61
CrossRef535
Alan D. Michelson. (2010) Antiplatelet therapies for the treatment of cardiovascular disease. Nature Reviews Drug Discovery 9:2, 154-169
CrossRef536
D. SIBBING, S. SCHULZ, S. BRAUN, T. MORATH, J. STEGHERR, J. MEHILLI, A. SCHÖMIG, N. VON BECKERATH, A. KASTRATI. (2010) Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. Journal of Thrombosis and Haemostasis 8:2, 250-256
CrossRef537
Elias B. Hanna, David Luke Glancy, Jorge F. Saucedo. (2010) Antiplatelet and Anticoagulant Therapies in Acute Coronary Syndromes. Cardiovascular Drugs and Therapy 24:1, 61-70
CrossRef538
Ali O. Abualsaud, Mark J. Eisenberg. (2010) Perioperative Management of Patients With Drug-Eluting Stents. JACC: Cardiovascular Interventions 3:2, 131-142
CrossRef539
Sanjay Kaul, George A. Diamond. (2010) Trial and Error. Journal of the American College of Cardiology 55:5, 415-427
CrossRef540
Harish Ramakrishna, Jens Fassl, Ashish Sinha, Prakash Patel, Hynek Riha, Michael Andritsos, Insung Chung, John G.T. Augoustides. (2010) The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights From 2009. Journal of Cardiothoracic and Vascular Anesthesia 24:1, 7-17
CrossRef541
David S. Small, Christopher D. Payne, Prajakti Kothare, Eunice Yuen, Fanni Natanegara, Mei Teng Loh, Joseph A. Jakubowski, D. Richard Lachno, Ying G. Li, Kenneth J. Winters, Nagy A. Farid, Lan Ni, Daniel E. Salazar, Molly Tomlin, Ronan Kelly. (2010) Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy chinese and white volunteers: An open-label trial. Clinical Therapeutics 32:2, 365-379
CrossRef542
Jon C. George, George D. Dangas. (2010) 2009 Focused Updates to Guidelines in ST-Elevation Myocardial Infarction and Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions 3:2, 256-258
CrossRef543
Chetan Varma. (2010) Clopidogrel and proton pump inhibitors: Are the goal posts shifting?. Thrombosis Research 125:2, 110-111
CrossRef544
David S. Small, Prajakti Kothare, Eunice Yuen, D. Richard Lachno, Ying G. Li, Kenneth J. Winters, Nagy A. Farid, Lan Ni, Joseph A. Jakubowski, Daniel E. Salazar, Vivian T. Thieu, Christopher D. Payne. (2010) The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects. European Journal of Clinical Pharmacology 66:2, 127-135
CrossRef545
Terry K.W. Ma, Yat-Yin Lam, Victoria P. Tan, Thomas J. Kiernan, Bryan P. Yan. (2010) Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel. Pharmacology & Therapeutics 125:2, 249-259
CrossRef546
Luke Tapp, Eduard Shantsila, Gregory Y.H. Lip. (2010) Aspirin—A Drug Whose Time Has Gone?. The American Journal of Cardiology 105:4, 577-578
CrossRef547
Pierre-Frédéric Keller, Marco Roffi. 2010. Acute Coronary Syndromes. , 1-22.
CrossRef548
2010. General Preoperative Considerations and Preparation of the Patient for Surgery. , 129-171.
CrossRef549
V. Serebruany, S. V. Rao, M. A. Silva, J. L. Donovan, A. O. Kannan, L. Makarov, S. Goto, D. Atar. (2010) Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. European Heart Journal 31:2, 227-235
CrossRef550
Inmaculada Roldán Rabadán. (2010) Nuevos antiagregantes en el síndrome coronario agudo. El futuro es hoy. Revista Española de Cardiología Suplementos 10:4, 12D-22D
CrossRef551
Álvaro Merino, Andrés Grau, Ignacio Segura. (2010) Novedades en el tratamiento antitrombótico en intervencionismo coronario. Revista Española de Cardiología Suplementos 10:4, 34D-41D
CrossRef552
Marc Bonaca, Robert P. Giugliano. (2010) Antithrombotics in Acute Coronary Syndromes: Updates from the Past Year. Current Treatment Options in Cardiovascular Medicine 12:1, 84-99
CrossRef553
Dániel Aradi, András Vorobcsuk, Zsófia Lenkey, Iván Gábor Horváth, András Komócsi. (2010) Low platelet disaggregation predicts poor response to 150 mg clopidogrel in patients with elevated platelet reactivity. Platelets 21:1, 1-10
CrossRef554
Antonio Salvador Sanz. (2010) ¿Qué dicen las guías?. Revista Española de Cardiología Suplementos 10:4, 29D-33D
CrossRef555
T. GREMMEL, S. STEINER, D. SEIDINGER, R. KOPPENSTEINER, S. PANZER, C. W. KOPP. (2010) Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel. Journal of Thrombosis and Haemostasis 8:1, 37-42
CrossRef556
Sunil V. Rao. (2010) Hemorragia en pacientes con síndromes coronarios agudos: de un hallazgo molesto a un reto importante. Revista Española de Cardiología 63:1, 1-4
CrossRef557
Christopher P Cannon, Robert A Harrington, Stefan James, Diego Ardissino, Richard C Becker, Håkan Emanuelsson, Steen Husted, Hugo Katus, Matyas Keltai, Nardev S Khurmi, Frederic Kontny, Basil S Lewis, Philippe Gabriel Steg, Robert F Storey, Daniel Wojdyla, Lars Wallentin. (2010) Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. The Lancet 375:9711, 283-293
CrossRef558
Antonio Fernández-Ortiz, David Vivas, Juan C. García-Rubira. (2010) Tratamiento antitrombótico en diabéticos con síndrome coronario agudo. Revista Española de Cardiología Suplementos 10:4, 42D-48D
CrossRef559
P. A. GURBEL, K. P. BLIDEN, M. J. ANTONINO, G. STEPHENS, D. D. GRETLER, M. M. JUREK, R. E. PAKYZ, A. R. SHULDINER, P. B. CONLEY, U. S. TANTRY. (2010) The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to cyp 2c19*2 genotype: first experience in patients. Journal of Thrombosis and Haemostasis 8:1, 43-53
CrossRef560
Dominick J. Angiolillo, José Luis Ferreiro. (2010) Inhibición del receptor plaquetario P2Y12 de adenosina difosfato plaquetario: efectos beneficiosos y limitaciones de las estrategias terapéuticas actuales y perspectivas futuras. Revista Española de Cardiología 63:1, 60-76
CrossRef561
Tullio Palmerini, Diego Sangiorgi, Antonio Marzocchi, Corrado Tamburino, Imad Sheiban, Massimo Margheri, Giuseppe Vecchi, Giuseppe Sangiorgi, Nicoletta Franco, Antonio Bartorelli, Carlo Briguori, Luigi Vignali, Francesco Di Pede, Angelo Ramondo, Massimo Medda, Marco De Carlo, Leonardo Bolognese, Alberto Benassi, Cataldo Palmieri, Vincenzo Filippone, Giulia Lauria, Stefano De Servi. (2010) Impact of Acute Coronary Syndromes on Two-Year Clinical Outcomes in Patients With Unprotected Left Main Coronary Artery Stenosis Treated With Drug-Eluting Stents. The American Journal of Cardiology 105:2, 174-178
CrossRef562
Dennis J. Cada, Terri L. Levien, Danial E. Baker. (2010) Formulary Drug Reviews - Prasugrel. Hospital Pharmacy 45:1, 54-66
CrossRef563
William M. Stone, Sailendra G. Naidu, Alyssa Chapital, Samuel R. Money. (2010) Antiplatelet Medications: Old and Emerging Therapies. Annals of Vascular Surgery 24:1, 140-148
CrossRef564
Nicolas von Beckerath, Dirk Sibbing, Stefan Jawansky, Siegmund Braun, Tanja Morath, Wolfgang Vogt, Albert Schömig, Adnan Kastrati. (2010) Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet vasodilator-stimulated phosphoprotein flow cytometry. Blood Coagulation & Fibrinolysis 21:1, 46-52
CrossRef565
Jean-Etienne Fabre, Mark E. Gurney. (2010) Limitations of current therapies to prevent thrombosis: a need for novel strategies. Molecular BioSystems 6:2, 305
CrossRef566
Dominick J. Angiolillo, Masafumi Ueno, Shinya Goto. (2010) Basic Principles of Platelet Biology and Clinical Implications. Circulation Journal 74:4, 597-607
CrossRef567
Kengo Tsukahara, Kazuo Kimura, Satoshi Morita, Toshiaki Ebina, Masami Kosuge, Kiyoshi Hibi, Jun Okuda, Noriaki Iwahashi, Nobuhiko Maejima, Tatsuya Nakachi, Fumiyuki Ohtsuka, Katsutaka Hashiba, Yoshio Tahara, Teruyasu Sugano, Satoshi Umemura. (2010) Impact of High-Responsiveness to Dual Antiplatelet Therapy on Bleeding Complications in Patients Receiving Drug-Eluting Stents. Circulation Journal 74:4, 679-685
CrossRef568
Min-Kyung Kang, Young-Hoon Jeong, Seong-Eun Yoon, Jin-Sin Koh, In-Suk Kim, Yongwhi Park, Seok-Jae Hwang, Choong Hwan Kwak, Jin-Yong Hwang. (2010) Pre-Procedural Platelet Reactivity After Clopidogrel Loading in Korean Patients Undergoing Scheduled Percutaneous Coronary Intervention. Journal of Atherosclerosis and Thrombosis 17:11, 1122-1131
CrossRef569
Dal-Sung Ryu, Chang-Ki Hong, Yoo-Sik Sim, Chang-Hyun Kim, Jin-Young Jung, Jin-Yang Joo. (2010) Anti-Platelet Drug Resistance in the Prediction of Thromboembolic Complications after Neurointervention. Journal of Korean Neurosurgical Society 48:4, 319
CrossRef570
Serdar Farhan, Thomas Höchtl, Alexandra Kautzky-Willer, Johann Wojta, Kurt Huber. (2010) Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus. Wiener Medizinische Wochenschrift 160:1-2, 30-38
CrossRef571
D. J. Angiolillo, D. Capodanno, S. Goto. (2010) Platelet thrombin receptor antagonism and atherothrombosis. European Heart Journal 31:1, 17-28
CrossRef572
Haifeng M Wu, LiHui Xu, Daniel D Sedmak, Clay B Marsh, Mark W Wurster. (2010) Personalized healthcare in clotting disorders. Personalized Medicine 7:1, 65-73
CrossRef573
Gregg W Stone. (2010) Ticagrelor in ACS: redefining a new standard of care?. The Lancet 375:9711, 263-265
CrossRef574
Shepard D. Weiner, LeRoy E. Rabbani. (2010) Secondary prevention strategies for coronary heart disease. Journal of Thrombosis and Thrombolysis 29:1, 8-24
CrossRef575
Shinya Goto, Tetsu Yamaguchi, Yasuo Ikeda, Kenichi Kato, Hiroya Yamaguchi, Peder Jensen. (2010) Safety and Exploratory Efficacy of the Novel Thrombin Receptor (PAR-1) Antagonist SCH530348 for Non-ST-Segment Elevation Acute Coronary Syndrome. Journal of Atherosclerosis and Thrombosis 17:2, 156-164
CrossRef576
L. Testa, G. G. L. Biondi Zoccai, M. Valgimigli, R. A. Latini, S. Pizzocri, S. Lanotte, M. L. Laudisa, N. Brambilla, M. R. Ward, G. A. Figtree, F. Bedogni, R. Bhindi. (2010) Current Concepts on Antiplatelet Therapy: Focus on the Novel Thienopyridine and Non-Thienopyridine Agents. Advances in Hematology 2010, 1-7
CrossRef577
Thomas Cuisset, Corinne Frere, Jacques Quilici, Sabrina Uhry, Marie Christine Alessi, Jean Louis Bonnet. (2010) Post-PCI fatal bleeding in aspirin and clopidogrel hyper responder. International Journal of Cardiology 138:2, 212-213
CrossRef578
Samip Vasaiwala, Daniel E. Forman, Laura Mauri. (2010) Drug-Eluting Stents in the Elderly. Current Treatment Options in Cardiovascular Medicine 12:1, 76-83
CrossRef579
Loren Laine, Charles Hennekens. (2010) Proton Pump Inhibitor and Clopidogrel Interaction: Fact or Fiction?. The American Journal of Gastroenterology 105:1, 34-41
CrossRef580
Harrington, Robert A., Stone, Gregg W., McNulty, Steven, White, Harvey D., Lincoff, A. Michael, Gibson, C. Michael, Pollack, Charles V. Jr., Montalescot, Gilles, Mahaffey, Kenneth W., Kleiman, Neal S., Goodman, Shaun G., Amine, Maged, Angiolillo, Dominick J., Becker, Richard C., Chew, Derek P., French, William J., Leisch, Franz, Parikh, Keyur H., Skerjanec, Simona, Bhatt, Deepak L., . (2009) Platelet Inhibition with Cangrelor in Patients Undergoing PCI. New England Journal of Medicine 361:24, 2318-2329
Full Text581
Bhatt, Deepak L., Lincoff, A. Michael, Gibson, C. Michael, Stone, Gregg W., McNulty, Steven, Montalescot, Gilles, Kleiman, Neal S., Goodman, Shaun G., White, Harvey D., Mahaffey, Kenneth W., Pollack, Charles V. Jr., Manoukian, Steven V., Widimsky, Petr, Chew, Derek P., Cura, Fernando, Manukov, Ivan, Tousek, Frantisek, Jafar, M. Zubair, Arneja, Jaspal, Skerjanec, Simona, Harrington, Robert A., . (2009) Intravenous Platelet Blockade with Cangrelor during PCI. New England Journal of Medicine 361:24, 2330-2341
Full Text582
(2009) Ticagrelor versus Clopidogrel in Acute Coronary Syndromes. New England Journal of Medicine 361:24, 2385-2388
Full Text583
Kastrati, Adnan, Ndrepepa, Gjin, . (2009) Cangrelor — A Champion Lost in Translation?. New England Journal of Medicine 361:24, 2382-2384
Full Text584
G. Montalescot. (2009) Benefits for specific subpopulations in TRITON-TIMI 38. European Heart Journal Supplements 11:Suppl G, G18-G24
CrossRef585
Avelyn Kwok, Douglas O Faigel. (2009) Management of Anticoagulation Before and After Gastrointestinal Endoscopy. The American Journal of Gastroenterology 104:12, 3085-3097
CrossRef586
Salman M. Azam, Joseph Jozic. (2009) Variable platelet responsiveness to aspirin and clopidogrel: role of platelet function and genetic polymorphism testing. Translational Research 154:6, 309-313
CrossRef587
Laurent Bonello, Gilles Lemesle, Axel De Labriolle, Paul Barragan, Laurence Camoin-Jau, Franck Paganelli. (2009) Personalized antiplatelet therapy for coronary artery disease patients: is this the future?. Expert Review of Cardiovascular Therapy 7:12, 1525-1532
CrossRef588
F.-J. Neumann. (2009) Balancing efficacy and safety in the TRITON-TIMI 38 trial. European Heart Journal Supplements 11:Suppl G, G14-G17
CrossRef589
J. L. Lopez-Sendon, R. F. Storey. (2009) Introduction. European Heart Journal Supplements 11:Suppl G, G2-G3
CrossRef590
Magdalena Heras, Alfonso del Río. (2009) Update on Antiplatelet Therapy in Acute Coronary Syndromes. American Journal Cardiovascular Drugs 9:Supplement 1, 13-17
CrossRef591
M. Cattaneo. (2009) Fast, potent, and reliable inhibition of platelet aggregation. European Heart Journal Supplements 11:Suppl G, G9-G13
CrossRef592
Kurt M Reinhart, C. Michael White, William L Baker. (2009) Prasugrel: A Critical Comparison with Clopidogrel. Pharmacotherapy 29:12, 1441-1451
CrossRef593
J. L. Lopez-Sendon, R. F. Storey. (2009) Conclusions. European Heart Journal Supplements 11:Suppl G, G25-G26
CrossRef594
Marc Cohen. (2009) Oral Antiplatelet Therapy for Acute and Chronic Management of NSTE ACS: Residual Ischemic Risk and Opportunities for Improvement. Cardiovascular Drugs and Therapy 23:6, 489-499
CrossRef595
Armando Perez de Prado, Carlos Cuellas, Alejandro Diego, Antonio de Miguel, Beatriz Samaniego, Norberto Alonso-Orcajo, Raul Carbonell, Cristina Pascual, Felipe Fernandez-Vazquez, Ramon G. Calabozo. (2009) Influence of platelet reactivity and response to clopidogrel on myocardial damage following percutaneous coronary intervention in patients with non-st-segment elevation acute coronary syndrome. Thrombosis Research 124:6, 678-682
CrossRef596
Frederick G. Kushner, Mary Hand, Sidney C. Smith, Spencer B. King, Jeffrey L. Anderson, Elliott M. Antman, Steven R. Bailey, Eric R. Bates, James C. Blankenship, Donald E. Casey, Lee A. Green, Alice K. Jacobs, Judith S. Hochman, Harlan M. Krumholz, Douglass A. Morrison, Joseph P. Ornato, David L. Pearle, Eric D. Peterson, Michael A. Sloan, Patrick L. Whitlow, David O. Williams. (2009) 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). Catheterization and Cardiovascular Interventions 74:7, E25-E68
CrossRef597
Frederick G. Kushner, Mary Hand, Sidney C. Smith, Spencer B. King, Jeffrey L. Anderson, Elliott M. Antman, Steven R. Bailey, Eric R. Bates, James C. Blankenship, Donald E. Casey, Lee A. Green, Judith S. Hochman, Alice K. Jacobs, Harlan M. Krumholz, Douglass A. Morrison, Joseph P. Ornato, David L. Pearle, Eric D. Peterson, Michael A. Sloan, Patrick L. Whitlow, David O. Williams. (2009) 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). Journal of the American College of Cardiology 54:23, 2205-2241
CrossRef598
Leslie Cole Manace, Tapan N. Godiwala, Mark W. Babyatsky. (2009) Genomics of Cardiovascular Disease. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 76:6, 613-623
CrossRef599
Massimo Franchini, Pier Mannuccio Mannucci. (2009) New antiplatelet agents: Why they are needed. European Journal of Internal Medicine 20:8, 733-738
CrossRef600
Victor Serebruany, Ganesh Cherala, Craig Williams, Serge Surigin, Christopher Booze, Wiktor Kuliczkowski, Dan Atar. (2009) Association of platelet responsiveness with clopidogrel metabolism: Role of compliance in the assessment of “resistance”. American Heart Journal 158:6, 925-932
CrossRef601
David E. Kandzari, Dominick J. Angiolillo, Matthew J. Price, Paul S. Teirstein. (2009) Identifying the “Optimal” Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Revascularization. JACC: Cardiovascular Interventions 2:12, 1279-1285
CrossRef602
Deepak L. Bhatt. (2009) Antiplatelet therapy: Ticagrelor in ACS—what does PLATO teach us?. Nature Reviews Cardiology 6:12, 737-738
CrossRef603
Steen Husted, J.J.J. van Giezen. (2009) Ticagrelor: The First Reversibly Binding Oral P2Y 12 Receptor Antagonist. Cardiovascular Therapeutics 27:4, 259-274
CrossRef604
Paul P Dobesh. (2009) Clopidogrel versus Prasugrel: Times Are Changing, but Not for Everyone. Pharmacotherapy 29:12, 1393-1396
CrossRef605
David Fitchett, John Eikelboom, Stephen Fremes, David Mazer, Steve Singh, Bindu Bittira, Stephanie Brister, John J. Graham, Milan Gupta, Keyvan Karkouti, Agnes Lee, Michael Love, Rod McArthur, Mark Peterson, Subodh Verma, Terrence M. Yau. (2009) Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: A position statement of the Canadian Cardiovascular Society. Canadian Journal of Cardiology 25:12, 683-689
CrossRef606
Lloyd W. Klein. (2009) Cardiac enzyme elevations after apparently successful percutaneous interventions are a marker of extensive coronary artery disease and complex stenoses. Catheterization and Cardiovascular Interventions 74:6, 823-825
CrossRef607
S. Schulz, T. Schuster, J. Mehilli, R. A. Byrne, J. Ellert, S. Massberg, J. Goedel, O. Bruskina, K. Ulm, A. Schomig, A. Kastrati. (2009) Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. European Heart Journal 30:22, 2714-2721
CrossRef608
Paul A. Gurbel, Udaya S. Tantry, Alan R. Shuldiner. (2009) The Worry About Clopidogrel “Nonresponsiveness”. JACC: Cardiovascular Interventions 2:11, 1102-1104
CrossRef609
Victor L Serebruany. (2009) Late Prasugrel Benefit in STEMI Patients?. American Journal of Therapeutics 16:6, 469-470
CrossRef610
H. D. White. (2009) Is there an acceptable ceiling for bleeding for an antithrombotic drug dose to be tested in a phase 3 trial?. European Heart Journal 30:21, 2556-2557
CrossRef611
Aamir Badruddin, Philip B. Gorelick. (2009) Antiplatelet therapy for prevention of recurrent stroke. Current Treatment Options in Neurology 11:6, 452-459
CrossRef612
J.J.J. van Giezen, Pia Berntsson, Helen Zachrisson, Jan-Arne Björkman. (2009) Comparison of ticagrelor and thienopyridine P2Y12 binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. Thrombosis Research 124:5, 565-571
CrossRef613
Daniel R. Guerra, James E. Tcheng. (2009) Prasugrel: Clinical development and therapeutic application. Advances in Therapy 26:11, 999-1011
CrossRef614
David P. Faxon. (2009) Women Are Like Men … Sometimes
CrossRef615
Patrick Gladding, Harvey White, Jamie Voss, John Ormiston, Jim Stewart, Peter Ruygrok, Badi Bvaldivia, Ruth Baak, Catherine White, Mark Webster. (2009) Pharmacogenetic Testing for Clopidogrel Using the Rapid INFINITI Analyzer. JACC: Cardiovascular Interventions 2:11, 1095-1101
CrossRef616
Kyle J Ellis, George A Stouffer, Howard L McLeod, Craig R Lee. (2009) Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics 10:11, 1799-1817
CrossRef617
Richard C. Becker. (2009) Pharmacogenetics and safety parameters for platelet P2Y12 receptor antagonists. Journal of Thrombosis and Thrombolysis 28:4, 513-514
CrossRef618
K. Schrör. (2009) Prasugrel oder Clopidogrel bei Koronarinterventionen. Der Internist 50:11, 1293-1296
CrossRef619
Jason B. Lindsey, Steven P. Marso, Michael Pencina, Joshua M. Stolker, Kevin F. Kennedy, Charanjit Rihal, Greg Barsness, Robert N. Piana, Steven L. Goldberg, Donald E. Cutlip, Neal S. Kleiman, David J. Cohen. (2009) Prognostic Impact of Periprocedural Bleeding and Myocardial Infarction After Percutaneous Coronary Intervention in Unselected Patients. JACC: Cardiovascular Interventions 2:11, 1074-1082
CrossRef620
Cathie LM Sudlow, Gillian Mason, James B Maurice, Catherine J Wedderburn, Graeme J Hankey, Cathie LM Sudlow. 2009. Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. .
CrossRef621
B. ALEIL, C. LÃON, J.-P. CAZENAVE, C. GACHET. (2009) CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring. Journal of Thrombosis and Haemostasis 7:10, 1747-1749
CrossRef622
Luke Tapp, Ben Wrigley, Gregory Y. H. Lip. (2009) Acute coronary syndromes: Oral factor Xa inhibitors in acute coronary syndromes. Nature Reviews Cardiology 6:10, 619-620
CrossRef623
J. Röther, U. Laufs, M. Böhm, S. Willems, B. Scheller, M. Borggrefe, H. Darius, M. Endres, U. Zeymer, H.-C. Diener, M. Grond, W. Hacke, M. Forsting, M. Schumacher, M. Hennerici. (2009) Konsensuspapier „Peri- und postinterventioneller Schlaganfall bei Herzkatheterprozeduren“. Der Kardiologe 3:5, 375-387
CrossRef624
Jeremiah P Depta, Deepak L Bhatt, Kandice Kottke-Marchant, Rishi Gupta, Gurunathan Murugesan, Anil Jain, A Michael Lincoff, Stephen G Ellis. (2009) Management of patients with aspirin and clopidogrel impaired response. Interventional Cardiology 1:1, 31-40
CrossRef625
Aravinda Nanjundappa, Sangeeta Mandapaka, Robert S Dieter. (2009) Impaired response to aspirin and clopidogrel: how do we treat?. Interventional Cardiology 1:1, 29-30
CrossRef626
D. S. Small, R. E. Wrishko, C. S. Ernest II, L. Ni, K. J. Winters, N. A. Farid, Y. G. Li, J. T. Brandt, D. E. Salazar, A. G. Borel, K. A. Kles, C. D. Payne. (2009) Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease. Journal of Clinical Pharmacy and Therapeutics 34:5, 585-594
CrossRef627
A. A. C. M. HEESTERMANS, J. W. VAN WERKUM, C. HAMM, T. DILL, A. T. M. GOSSELINK, M. J. DE BOER, G. VAN HOUWELINGEN, J. C. A. HOORNTJE, P. C. KOOPMANS, J. M. TEN BERG, A. W. J. VAN âT HOF. (2009) Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. Journal of Thrombosis and Haemostasis 7:10, 1612-1618
CrossRef628
Thomas Cuisset, Corinne Frere, Jacques Quilici, Bénédicte Gaborit, Christel Castelli, Raphael Poyet, Laurent Bali, Pierre-Emmanuel Morange, Marie-Christine Alessi, Jean-Louis Bonnet. (2009) Predictive Values of Post-Treatment Adenosine Diphosphate–Induced Aggregation and Vasodilator-Stimulated Phosphoprotein Index for Stent Thrombosis After Acute Coronary Syndrome in Clopidogrel-Treated Patients. The American Journal of Cardiology 104:8, 1078-1082
CrossRef629
Ralph A Stewart. (2009) Underestimation of the effect of bleeding in clinical trials. The Lancet 374:9696, 1145
CrossRef630
Marc Cohen. (2009) Antiplatelet therapy in percutaneous coronary intervention: A critical review of the 2007 AHA/ACC/SCAI guidelines and beyond. Catheterization and Cardiovascular Interventions 74:4, 579-597
CrossRef631
Daniel I. Simon, Sahil A. Parikh. (2009) Hunting for the “Sweet Spot” in P2Y12 Receptor Blockade
CrossRef632
Patrick Goldstein, Frederic Lapostolle, Gabriel Steg, Nicolas Danchin, Nathalie Assez, Gilles Montalescot, Sandrine Charpentier, Eric Wiel, Jean Michel Juliard. (2009) Lowering mortality in ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: key prehospital and emergency room treatment strategies. European Journal of Emergency Medicine 16:5, 244-255
CrossRef633
C. Jámbor, M. Spannagl, B. Zwissler. (2009) Perioperatives Management von Patienten mit Koronarstents bei nichtherzchirurgischen Eingriffen. Der Anaesthesist 58:10, 971-985
CrossRef634
A. Kumar, C. P. Cannon. (2009) Acute Coronary Syndromes: Diagnosis and Management, Part I. Mayo Clinic Proceedings 84:10, 917-938
CrossRef635
Schömig, Albert, . (2009) Ticagrelor — Is There Need for a New Player in the Antiplatelet-Therapy Field?. New England Journal of Medicine 361:11, 1108-1111
Full Text636
Wallentin, Lars, Becker, Richard C., Budaj, Andrzej, Cannon, Christopher P., Emanuelsson, Håkan, Held, Claes, Horrow, Jay, Husted, Steen, James, Stefan, Katus, Hugo, Mahaffey, Kenneth W., Scirica, Benjamin M., Skene, Allan, Steg, Philippe Gabriel, Storey, Robert F., Harrington, Robert A., . (2009) Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine 361:11, 1045-1057
Full Text637
Bhatt, Deepak L., . (2009) Prasugrel in Clinical Practice. New England Journal of Medicine 361:10, 940-942
Full Text638
Unger, Ellis F., . (2009) Weighing Benefits and Risks — The FDA's Review of Prasugrel. New England Journal of Medicine 361:10, 942-945
Full Text639
Paul P Dobesh. (2009) Pharmacokinetics and Pharmacodynamics of Prasugrel, a Thienopyridine P2Y12 Inhibitor. Pharmacotherapy 29:9, 1089-1102
CrossRef640
Peter P. Toth, Annemarie Armani. (2009) Thienopyridine therapy and risk for cardiovascular events in secondary prevention. Current Atherosclerosis Reports 11:5, 364-370
CrossRef641
William Wilson, Ronen Gurvitch, Andrew E. Ajani. (2009) Prasugrel: A Novel Platelet ADP P2Y 12 Receptor Antagonist. Cardiovascular Therapeutics 27:3, 194-198
CrossRef642
Dirk Sibbing, Adnan Kastrati. (2009) Risk of combining PPIs with thienopyridines: fact or fiction?. The Lancet 374:9694, 952-954
CrossRef643
David S. Small, Rebecca E. Wrishko, C. Steven Ernest, Lan Ni, Kenneth J. Winters, Nagy A. Farid, Ying G. Li, Daniel E. Salazar, Christopher D. Payne. (2009) Effect of Age on the Pharmacokinetics and Pharmacodynamics of Prasugrel during Multiple Dosing. Drugs & Aging 26:9, 781-790
CrossRef644
John W Eikelboom, Jeffrey I Weitz. (2009) Otamixaban in acute coronary syndromes. The Lancet 374:9692, 762-764
CrossRef645
Marc S Sabatine, Elliott M Antman, Petr Widimsky, Iftikhar O Ebrahim, Robert G Kiss, André Saaiman, Rostislav Polasek, Charles F Contant, Carolyn H McCabe, Eugene Braunwald. (2009) Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. The Lancet 374:9692, 787-795
CrossRef646
Ahmed Abdel-Latif, David J. Moliterno. (2009) Prasugrel versus clopidogrel in primary PCI: Considerations of the TRITON-TIMI 38 substudy. Current Cardiology Reports 11:5, 323-324
CrossRef647
Inna Shalito, Olga Kopyleva, Victor Serebruany. (2009) Novel Antiplatelet Agents in Development: Prasugrel, Ticagrelor, and Cangrelor and Beyond. American Journal of Therapeutics 16:5, 451-458
CrossRef648
Leonardo De Luca, Gianni Casella, Maddalena Lettino, Giuseppe Fradella, Vincenzo Toschi, Maria Rosa Conte, Filippo Ottani, Giovanna Geraci, Luigi O Visconti, Marco Tubaro, Aldo P Maggioni. (2009) Clinical implications and management of bleeding events in patients with acute coronary syndromes. Journal of Cardiovascular Medicine 10:9, 677-686
CrossRef649
Alan D Michelson. (2009) New P2Y12 antagonists. Current Opinion in Hematology 16:5, 371-377
CrossRef650
Marc P Bonaca, David A Morrow. (2009) SCH 530348: a novel oral thrombin receptor antagonist. Future Cardiology 5:5, 435-442
CrossRef651
Marc P. Bonaca, Philippe Gabriel Steg, Laurent J. Feldman, John F. Canales, James J. Ferguson, Lars Wallentin, Robert M. Califf, Robert A. Harrington, Robert P. Giugliano. (2009) Antithrombotics in Acute Coronary Syndromes. Journal of the American College of Cardiology 54:11, 969-984
CrossRef652
Michelle L O'Donoghue, Eugene Braunwald, Elliott M Antman, Sabina A Murphy, Eric R Bates, Yoseph Rozenman, Alan D Michelson, Raymond W Hautvast, Peter N Ver Lee, Sandra L Close, Lei Shen, Jessica L Mega, Marc S Sabatine, Stephen D Wiviott. (2009) Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. The Lancet 374:9694, 989-997
CrossRef653
Joanna J. Wykrzykowska, Patrick W. Serruys, Yoshinobu Onuma, Ton de Vries, Gerrit-Anne van Es, Pawel Buszman, Axel Linke, Thomas Ischinger, Volker Klauss, Roberto Corti, Franz Eberli, William Wijns, Marie-Claude Morice, Carlo di Mario, Robert Jan van Geuns, Peter Juni, Stephan Windecker. (2009) Impact of Vessel Size on Angiographic and Clinical Outcomes of Revascularization With Biolimus-Eluting Stent With Biodegradable Polymer and Sirolimus-Eluting Stent With Durable Polymer. JACC: Cardiovascular Interventions 2:9, 861-870
CrossRef654
Francisco Marín, Rocío González-Conejero, Piera Capranzano, Theodore A. Bass, Vanessa Roldán, Dominick J. Angiolillo. (2009) Pharmacogenetics in Cardiovascular Antithrombotic Therapy. Journal of the American College of Cardiology 54:12, 1041-1057
CrossRef655
L. Wallentin. (2009) P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. European Heart Journal 30:16, 1964-1977
CrossRef656
Mark Crowther, Mark Crowther. (2009) Management of bleeding in patients on antithrombotics: maintaining the balance between thrombosis and hemorrhage. Expert Review of Hematology 2:4, 357-360
CrossRef657
, Roberta Joppi, Luca Demattè, Anna Michela Menti, Daniela Pase, Chiara Poggiani, Luigi Mezzalira. (2009) The Italian Horizon Scanning Project. European Journal of Clinical Pharmacology 65:8, 775-781
CrossRef658
Thomas Cuisset, Guillaume Cayla, Corinne Frere, Jacques Quilici, Raphael Poyet, Bénédicte Gaborit, Laurent Bali, Pierre Morange, Marie-Christine Alessi, Jean-Louis Bonnet. (2009) Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome.. EuroIntervention 5:3, 325-329
CrossRef659
N. A. Farid, J. A. Jakubowski, C. D. Payne, Y. G. Li, Y. Jin, C. S. Ernest, K. J. Winters, J. T. Brandt, D. E. Salazar, D. S. Small. (2009) Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects. Current Medical Research and Opinion 25:8, 1821-1829
CrossRef660
P L Gross, J I Weitz. (2009) New Antithrombotic Drugs. Clinical Pharmacology & Therapeutics 86:2, 139-146
CrossRef661
Victor L. Serebruany. (2009) Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens?. Fundamental & Clinical Pharmacology 23:4, 411-417
CrossRef662
Sean T. Duggan, Gillian M. Keating. (2009) Prasugrel. Drugs 69:12, 1707-1726
CrossRef663
Paolo Gresele. (2009) Perioperative handling of antiplatelet therapy: watching the two sides of the coin. Internal and Emergency Medicine 4:4, 275-276
CrossRef664
Michelle O'Donoghue, Elliott M. Antman, Eugene Braunwald, Sabina A. Murphy, P. Gabriel Steg, Ariel Finkelstein, William F. Penny, Viliam Fridrich, Carolyn H. McCabe, Marc S. Sabatine, Stephen D. Wiviott. (2009) The Efficacy and Safety of Prasugrel With and Without a Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Undergoing Percutaneous Intervention. Journal of the American College of Cardiology 54:8, 678-685
CrossRef665
Fredrik Karlsson, Angelo Modica, Thomas Mooe. (2009) Association of Level of Kidney Function and Platelet Aggregation in Acute Myocardial Infarction. American Journal of Kidney Diseases 54:2, 262-269
CrossRef666
William L. Baker, C. Michael White. (2009) Role of Prasugrel, a Novel P2Y12 Receptor Antagonist, in the Management of Acute Coronary Syndromes. American Journal Cardiovascular Drugs 9:4, 213-229
CrossRef667
LEROY E. RABBANI, SRINIVAS IYENGAR, GEORGE D. DANGAS, CINDY L. GRINES, DAVID A. COX, EULOGIO GARCIA, JAMES E. TCHENG, JOHN J. GRIFFIN, GIULIO GUAGLIUMI, THOMAS STUCKEY, MARK TURCO, JENNIFER STANT, MARTIN FAHY, ALEXANDRA J. LANSKY, ROXANA MEHRAN, GREGG W. STONE. (2009) Impact of Thienopyridine Administration Prior to Primary Stenting in Acute Myocardial Infarction. Journal of Interventional Cardiology 22:4, 378-384
CrossRef668
G. Helft, P. Leger. (2009) Que retenir de la littérature récente concernant les antithrombotiques ?. Annales de Cardiologie et d'Angéiologie 58:4, 230-235
CrossRef669
F. Van de Werf. (2009) New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome?. European Heart Journal 30:14, 1695-1702
CrossRef670
A. D. Michelson, A. L. Frelinger, E. Braunwald, W. E. Downey, D. J. Angiolillo, N. P. Xenopoulos, J. A. Jakubowski, Y. Li, S. A. Murphy, J. Qin, C. H. McCabe, E. M. Antman, S. D. Wiviott, . (2009) Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. European Heart Journal 30:14, 1753-1763
CrossRef671
Sarah A Spinler. (2009) Safety and Tolerability of Antiplatelet Therapies for the Secondary Prevention of Atherothrombotic Disease. Pharmacotherapy 29:7, 812-821
CrossRef672
Dmitriy Kireyev, Edward C. Yun, Brian J. Page, William E. Boden. (2009) Medical therapy in acute coronary syndromes: Which medicines and at what doses?. Current Cardiology Reports 11:4, 267-275
CrossRef673
Somjot S. Brar, Gregg W. Stone. (2009) Advances in percutaneous coronary intervention. Current Cardiology Reports 11:4, 245-251
CrossRef674
Susanne Alban. (2009) Prasugrel - ein neuer ADP-Rezeptor-Antagonist. Prodrug -Aktivierung als entscheidender Unterschied. Pharmazie in unserer Zeit 38:4, 320-328
CrossRef675
Joost DE Haeck, Niels JW Verouden, José PS Henriques, Karel T Koch. (2009) Current status of distal embolization in percutaneous coronary intervention: mechanical and pharmacological strategies. Future Cardiology 5:4, 385-402
CrossRef676
Matthew B Sellers, Pierluigi Tricoci, Robert A Harrington. (2009) A new generation of antiplatelet agents. Current Opinion in Cardiology 24:4, 307-312
CrossRef677
M.-M. Samama, I. Elalamy. (2009) Étude de la variabilité de réponse à l’aspirine et au clopidogrel : résistance clinique et/ou biologique ?. Annales Pharmaceutiques Françaises 67:4, 265-271
CrossRef678
Renato Valenti, Guido Parodi, Angela Migliorini. 2009. Platelet Glycoprotein IIb-IIIa Inhibitors. , 67-76.
CrossRef679
Dominick J. Angiolillo, Piera Capranzano, Bhaloo Desai, Steven B. Shoemaker, Ronald Charlton, Martin M. Zenni, Luis A. Guzman, Theodore A. Bass. (2009) Impact of P2Y12 Inhibitory Effects Induced by Clopidogrel on Platelet Procoagulant Activity in Type 2 Diabetes Mellitus Patients. Thrombosis Research 124:3, 318-322
CrossRef680
M. CATTANEO. (2009) New P2Y 12 blockers. Journal of Thrombosis and Haemostasis 7, 262-265
CrossRef681
David R. Holmes, Dean J. Kereiakes, Neal S. Kleiman, David J. Moliterno, Giuseppe Patti, Cindy L. Grines. (2009) Combining Antiplatelet and Anticoagulant Therapies. Journal of the American College of Cardiology 54:2, 95-109
CrossRef682
Bernd Stratmann, Diethelm Tschoepe. (2009) Atherogenesis and atherothrombosis – focus on diabetes mellitus. Best Practice & Research Clinical Endocrinology & Metabolism 23:3, 291-303
CrossRef683
Neville Kukreja, Yoshinobu Onuma, Hector M. Garcia-Garcia, Joost Daemen, Ron van Domburg, Patrick W. Serruys. (2009) The Risk of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Bare-Metal and Drug-Eluting Stents. JACC: Cardiovascular Interventions 2:6, 534-541
CrossRef684
Shaker A. Mousa, James T. Willerson, Robert P. Giugliano. 2009. Overview of Antiplatelet Therapy. , 399-408.
CrossRef685
Dominick J. Angiolillo, Siva Suryadevara. (2009) Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. Best Practice & Research Clinical Endocrinology & Metabolism 23:3, 375-388
CrossRef686
C.W. Hamm, U. Zeymer. (2009) IQWiG gegen den Rest der Welt. Der Kardiologe 3:3, 207-210
CrossRef687
Alan D. Michelson. 2009. The Role of Platelet Function Testing in the Development of Platelet Inhibitors. , 99-116.
CrossRef688
Byron Cryer. (2009) Management of Patients with High Gastrointestinal Risk on Antiplatelet Therapy. Gastroenterology Clinics of North America 38:2, 289-303
CrossRef689
Kurt Huber, Uma Yasothan, Bashar Hamad, Peter Kirkpatrick. (2009) Prasugrel. Nature Reviews Drug Discovery 8:6, 449-450
CrossRef690
Udaya S. Tantry, Paul A. Gurbel. 2009. Markers of Platelet Function. , 409-428.
CrossRef691
Taketoshi Ogawa, Masami Hashimoto, Yoichi Niitsu, Joseph A. Jakubowski, Yoshiro Tani, Ken-ichi Otsuguro, Fumitoshi Asai, Atsuhiro Sugidachi. (2009) Effects of prasugrel, a novel P2Y12 inhibitor, in rat models of cerebral and peripheral artery occlusive diseases. European Journal of Pharmacology 612:1-3, 29-34
CrossRef692
Marco Cattaneo. 2009. Direct P2Y 12 Antagonists. , 485-498.
CrossRef693
Michael J. Cowley, Louis Kuritzky. (2009) Developments in antiplatelet therapy for acute coronary syndromes and considerations for long-term management. Current Medical Research and Opinion 25:6, 1477-1490
CrossRef694
Ezra A. Amsterdam. (2009) Clopidogrel in the Management of Acute Coronary Syndromes. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 8:2, 49-54
CrossRef695
Stephen D. Wiviott, Elliott M. Antman. 2009. Three Generations of Thienopyridines: Ticlopidine, Clopidogrel, and Prasugrel. , 471-484.
CrossRef696
Allison G. Dupont, Don A. Gabriel, Mauricio G. Cohen. (2009) Antiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome. Thrombosis Research 124:1, 6-13
CrossRef697
Victor L. Serebruany. (2009) Platelet Inhibition with Prasugrel and Increased Cancer Risks: Potential Causes and Implications. The American Journal of Medicine 122:5, 407-408
CrossRef698
A. Siddique, M. Butt, E. Shantsila, G. Y. H. Lip. (2009) New antiplatelet drugs: beyond aspirin and clopidogrel. International Journal of Clinical Practice 63:5, 776-789
CrossRef699
Matthew J. Price, Peter B. Berger, Dominick J. Angiolillo, Paul S. Teirstein, Jean-François Tanguay, David E. Kandzari, Christopher P. Cannon, Eric J. Topol. (2009) Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial. American Heart Journal 157:5, 818-824.e1
CrossRef700
Julie H. Oestreich, John Holt, Steven P. Dunn, Susan S. Smyth, Charles L. Campbell, Richard Charnigo, Wendell S. Akers, Steven R. Steinhubl. (2009) Considerable variability in platelet activity among patients with coronary artery disease in response to an increased maintenance dose of clopidogrel. Coronary Artery Disease 20:3, 207-213
CrossRef701
Erik L Grove, Steen D Kristensen. (2009) Update on oral antiplatelet therapy: principles, problems and promises. Future Cardiology 5:3, 247-258
CrossRef702
Antwon Robinson, Kanak Das, Santosh KG Koshy, Pranab Das. (2009) Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention. Future Cardiology 5:3, 237-246
CrossRef703
James Floyd, Sidney Wolfe. (2009) Prasugrel STEMI subgroup analysis. The Lancet 373:9678, 1845-1846
CrossRef704
Gilles Montalescot, Stephen D Wiviott, Eugene Braunwald, Sabina A Murphy, Elliott M Antman. (2009) Prasugrel STEMI subgroup analysis – Authors' reply. The Lancet 373:9678, 1846-1848
CrossRef705
Jan Smid, Ruediger Braun-Dullaeus, Meinrad Gawaz, Harald F Langer. (2009) Platelet interactions as therapeutic targets for prevention of atherothrombosis. Future Cardiology 5:3, 285-296
CrossRef706
H. Thiele. (2009) Optimales prähospitales Management des ST-Strecken-Hebungsinfarktes. Clinical Research in Cardiology Supplements 4:S2, 142-149
CrossRef707
S. Husted, R. A. Harrington, C. P. Cannon, R. F. Storey, P. Mitchell, H. Emanuelsson. (2009) Bleeding risk with AZD6140, a reversible P2Y 12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial. International Journal of Clinical Practice 63:4, 667-670
CrossRef708
C.W. Hamm. (2009) Kommentar zu den Leitlinien der European Society of Cardiology (ESC) zur Diagnose und Therapie des akuten Koronarsyndroms ohne ST-Strecken-Hebung (NSTE-ACS). Der Kardiologe 3:2, 81-100
CrossRef709
Joseph M. Sweeny, Diana A. Gorog, Valentin Fuster. (2009) Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements. Nature Reviews Cardiology 6:4, 273-282
CrossRef710
Tullio Palmerini, Antonio Marzocchi, Corrado Tamburino, Imad Sheiban, Massimo Margheri, Giuseppe Vecchi, Giuseppe Sangiorgi, Andrea Santarelli, Antonio L. Bartorelli, Carlo Briguori, Luigi Vignali, Francesco Di Pede, Angelo Ramondo, Luigi Inglese, Marco De Carlo, Leonardo Bolognese, Alberto Benassi, Cataldo Palmieri, Vincenzo Filippone, Diego Sangiorgi, Fabio Barlocco, Giulia Lauria, Stefano De Servi. (2009) Temporal Pattern of Ischemic Events in Relation to Dual Antiplatelet Therapy in Patients With Unprotected Left Main Coronary Artery Stenosis Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology 53:14, 1176-1181
CrossRef711
Carlo Patrono. (2009) Antiplatelet therapy: The P2Y12 receptor: no active metabolite, no party. Nature Reviews Cardiology 6:4, 271-272
CrossRef712
Stefan James, Axel Åkerblom, Christopher P. Cannon, Håkan Emanuelsson, Steen Husted, Hugo Katus, Allan Skene, Philippe Gabriel Steg, Robert F. Storey, Robert Harrington, Richard Becker, Lars Wallentin. (2009) Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal 157:4, 599-605
CrossRef713
Piera Capranzano, Jose Luis Ferreiro, Dominick J Angiolillo. (2009) Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. Expert Review of Cardiovascular Therapy 7:4, 361-369
CrossRef714
A. Siddique, E. Shantsila, G. Y. H. Lip. (2009) AZD6140 and bleeding: towards safer antiplatelet therapy?. International Journal of Clinical Practice 63:4, 537-539
CrossRef715
Robert A. Byrne, Stefanie Schulz, Julinda Mehilli, Raisuke Iijima, Steffen Massberg, Franz-Josef Neumann, Jurriёn M. ten Berg, Albert Schömig, Adnan Kastrati. (2009) Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. American Heart Journal 157:4, 620-624.e2
CrossRef716
Srinivas Iyengar, LeRoy E. Rabbani. (2009) Beyond platelet inhibition: potential pleiotropic effects of ADP-receptor antagonists. Journal of Thrombosis and Thrombolysis 27:3, 300-306
CrossRef717
David P. Faxon, Jane E. Freedman. (2009) Facts and controversies of aspirin and clopidogrel therapy. American Heart Journal 157:3, 412-422
CrossRef718
Julie H Oestreich, Steven R Steinhubl. (2009) Cangrelor in percutaneous coronary intervention. Expert Review of Clinical Pharmacology 2:2, 137-145
CrossRef719
Yoshinobu Onuma, Neville Kukreja, Steve Ramcharitar, Matthias Hochadel, Anselm Gitt, Patrick Serruys. (2009) Interventional treatment in diabetics in the era of drug-eluting stents and compliance to the ESC guidelines: lessons learned from the Euro Heart Survey Programme. EuroIntervention 4:5, 578-587
CrossRef720
Jean-Philippe Collet, Gilles Montalescot. (2009) Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: When does the risk outweigh the benefit?. International Journal of Cardiology 133:1, 8-17
CrossRef721
Christoph Varenhorst, Stefan James, David Erlinge, Oscar Ö. Braun, John T. Brandt, Kenneth J. Winters, Joseph A. Jakubowski, Sylvia Olofsson, Lars Wallentin, Agneta Siegbahn. (2009) Assessment of P2Y12 inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. American Heart Journal 157:3, 562.e1-562.e9
CrossRef722
Young-Hoon Jeong, Seung-Whan Lee, Bong-Ryong Choi, In-Suk Kim, Myung-Ki Seo, Choong Hwan Kwak, Jin-Yong Hwang, Seong-Wook Park. (2009) Randomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet Reactivity. Journal of the American College of Cardiology 53:13, 1101-1109
CrossRef723
(2009) In Brief. Nature Reviews Drug Discovery 8:3, 182-183
CrossRef724
Deepak Thomas, Robert P. Giugliano. (2009) Antiplatelet Therapy in Percutaneous Coronary Intervention. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 8:1, 12-19
CrossRef725
Richard C Becker, David J Moliterno, Lisa K Jennings, Karen S Pieper, Jinglan Pei, Alan Niederman, Khaled M Ziada, Gail Berman, John Strony, Diane Joseph, Kenneth W Mahaffey, Frans Van de Werf, Enrico Veltri, Robert A Harrington. (2009) Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. The Lancet 373:9667, 919-928
CrossRef726
Martin A. Malý, Ivana Hadačová, Petr Hájek, David Zemánek, Josef Veselka. (2009) High-residual platelet activity despite dual antiplatelet treatment associated with subacute stent thrombosis. Central European Journal of Medicine 4:1, 119-124
CrossRef727
Christopher Hansi, Amina Arab, Alexander Rzany, Ingo Ahrens, Christoph Bode, Christoph Hehrlein. (2009) Differences of platelet adhesion and thrombus activation on amorphous silicon carbide, magnesium alloy, stainless steel, and cobalt chromium stent surfaces. Catheterization and Cardiovascular Interventions 73:4, 488-496
CrossRef728
Steen Husted. (2009) Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents. Fundamental & Clinical Pharmacology 23:1, 1-9
CrossRef729
Paul A. Gurbel, Udaya S. Tantry. (2009) Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease. Current Treatment Options in Cardiovascular Medicine 11:1, 22-32
CrossRef730
Herbert D. Aronow, Steven R. Steinhubl, Danielle M. Brennan, Peter B. Berger, Eric J. Topol. (2009) Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. American Heart Journal 157:2, 369-374
CrossRef731
J. Horowitz, W. J. Remme, C. Torp-Pedersen. (2009) Clinical Trials Update from the European Society of Cardiology Congress in Munich, 2008: TIME-CHF, CARESS-in-AMI, TRITON-TIMI 38, EUROPA, AF-CHF, and ADVANCE. Cardiovascular Drugs and Therapy 23:1, 25-29
CrossRef732
Dominick J. Angiolillo. (2009) Pruebas de función plaquetaria en la práctica clínica: ¿estamos preparados para que pasen a la primera línea?. Revista Española de Cardiología 62:2, 113-116
CrossRef733
Gilles Montalescot, Stephen D Wiviott, Eugene Braunwald, Sabina A Murphy, C Michael Gibson, Carolyn H McCabe, Elliott M Antman. (2009) Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. The Lancet 373:9665, 723-731
CrossRef734
Gregg W Stone. (2009) Ischaemia versus bleeding: the art of clinical decision-making. The Lancet 373:9665, 695-696
CrossRef735
Thomas Cuisset, Corinne Frere, Jacques Quilici, Pierre-Emmanuel Morange, Laurence Camoin, Laurent Bali, Marc Lambert, Irène Juhan-Vague, Marie-Christine Alessi, Jean-Louis Bonnet. (2009) Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. Thrombosis Research 123:4, 597-603
CrossRef736
Eduard Shantsila, Gregory Y.H. Lip. (2009) Variability of response to antiplatelet therapy: what should we do next?. Fundamental & Clinical Pharmacology 23:1, 19-22
CrossRef737
Harvey D White. (2009) HORIZONS trial: a step forward for primary percutaneous coronary intervention. Expert Review of Cardiovascular Therapy 7:2, 125-129
CrossRef738
M. Cohen. (2009) Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care. Mayo Clinic Proceedings 84:2, 149-160
CrossRef739
Mega, Jessica L., Close, Sandra L., Wiviott, Stephen D., Shen, Lei, Hockett, Richard D., Brandt, John T., Walker, Joseph R., Antman, Elliott M., Macias, William, Braunwald, Eugene, Sabatine, Marc S., . (2009) Cytochrome P-450 Polymorphisms and Response to Clopidogrel. New England Journal of Medicine 360:4, 354-362
Full Text740
Jean-Philippe Collet, Jean-Sébastien Hulot, Anna Pena, Eric Villard, Jean-Baptiste Esteve, Johanne Silvain, Laurent Payot, Delphine Brugier, Guillaume Cayla, Farzin Beygui, Gilbert Bensimon, Christian Funck-Brentano, Gilles Montalescot. (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. The Lancet 373:9660, 309-317
CrossRef741
Hiroshi Yasuda, Masaya Yamada, Susumu Sawada, Yutaka Endo, Kazuaki Inoue, Fuyuki Asano, Youichi Takeyama, Makoto Yoshiba. (2009) Upper Gastrointestinal Bleeding in Patients Receiving Dual Antiplatelet Therapy after Coronary Stenting. Internal Medicine 48:19, 1725-1730
CrossRef742
Yasuhiro NISHIKAWA. (2009) 4. Clinical Perspectives of New Antiplatelet Drugs. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 40:6, 273-278
CrossRef743
Marc Cohen, James J Ferguson. (2009) Re-evaluating risk factors for periprocedural complications during percutaneous coronary intervention in patients with unstable angina/non-ST-elevation myocardial infarction: who may benefit from more intensive antiplatelet therapy?. Current Opinion in Cardiology 24:1, 88-94
CrossRef744
Yuichiro YANO. (2009) Determinants of thrombin generation, fibrinolytic activity and endothelial dysfunction in dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad. Japanese Journal of Thrombosis and Hemostasis 20:1, 48-55
CrossRef745
Giuseppe Patti, Germano Di Sciascio. (2009) Antithrombotic strategies in patients on oral anticoagulant therapy undergoing percutaneous coronary intervention: A proposed algorithm based on individual risk stratification. Catheterization and Cardiovascular InterventionsNA-NA
CrossRef746
D. Varon, G. Spectre. (2009) Antiplatelet agents. Hematology 2009:1, 267-272
CrossRef747
Jang-Young Kim. (2009) Strategy for the Treatment of Clopidogrel Low Responsiveness in Diabetes Mellitus and Stent Implantation. Korean Circulation Journal 39:11, 459
CrossRef748
Stefano Savonitto, Nuccia Morici, Alice Sacco, Silvio Klugmann. (2009) Target populations and relevant therapeutic end points to further improve outcomes in NSTEACS patients. Future Cardiology 5:1, 27-41
CrossRef749
Victoria P. Tan, Bryan P. Yan, Thomas J. Kiernan, Andrew E. Ajani. (2009) Risk and management of upper gastrointestinal bleeding associated with prolonged dual-antiplatelet therapy after percutaneous coronary intervention. Cardiovascular Revascularization Medicine 10:1, 36-44
CrossRef750
José A. Barrabés, Juan Sanchís, Pedro L. Sánchez, Alfredo Bardají. (2009) Actualización en cardiopatía isquémica. Revista Española de Cardiología 62, 80-91
CrossRef751
Dominick J. Angiolillo, Siva Suryadevara, Piera Capranzano, Martin Z. Zenni, Luis A. Guzman, Theodore A. Bass. (2009) Antiplatelet drug response variability and the role of platelet function testing: A practical guide for interventional cardiologists. Catheterization and Cardiovascular Interventions 73:1, 1-14
CrossRef752
Laurent Bonello, Laurence Camoin-Jau, Sébastien Armero, Olivier Com, Stéphane Arques, Caroline Burignat-Bonello, Marie-Paule Giacomoni, Roland Bonello, Frédéric Collet, Philippe Rossi, Paul Barragan, Françoise Dignat-George, Franck Paganelli. (2009) Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Acute and Subacute Stent Thrombosis. The American Journal of Cardiology 103:1, 5-10
CrossRef753
Richard C. Becker. (2009) Biological and pharmacological aspects of perioperative hemorrhagic complications associated with oral platelet-directed antithrombotic agents. Thrombosis Research 123:3, 419-428
CrossRef754
C. G. Schuhmann, H. Y. Sohn, J. Nagel, M. Spannagl, V. Klauss, F. Krötz. (2009) Clinical management of clopidogrel inefficiency by point of care platelet function testing and individual adjustment of anti-platelet therapy – initial experiences. Platelets 20:7, 498-504
CrossRef755
Matteo Mariani, Giuseppe Mariani, Stefano De Servi. (2009) Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. Expert Review of Cardiovascular Therapy 7:1, 17-23
CrossRef756
Peter M. Vila, M. Urooj Zafar, Juan J. Badimon. (2009) Platelet reactivity and nonresponse to dual antiplatelet therapy: A review. Platelets 20:8, 531-538
CrossRef757
Gerald Yong, Jamie Rankin, Louise Ferguson, Jim Thom, John French, David Brieger, Derek P. Chew, Ron Dick, David Eccleston, Bernard Hockings, Darren Walters, Alan Whelan, John W. Eikelboom. (2009) Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non–ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: Results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial. American Heart Journal 157:1, 60.e1-60.e9
CrossRef758
Yasuhiro NISHIKAWA. (2009) Current status and limitation of thienopyridine antiplatelets. Japanese Journal of Thrombosis and Hemostasis 20:3, 329-335
CrossRef759
F. Andreotti, T. Rio, A. Lavorgna. (2008) Body fat and cardiovascular risk: understanding the obesity paradox. European Heart Journal 30:7, 752-754
CrossRef760
Pieter J. Vlaar, Gilles F. Diercks, Tone Svilaas, Mathijs Vogelzang, Bart J. de Smet, Ad F. van den Heuvel, Rutger L. Anthonio, Gillian A. Jessurun, Eng-Shiong Tan, Albert J. Suurmeijer, Felix Zijlstra. (2008) The feasibility and safety of routine thrombus aspiration in patients with non-ST-elevation myocardial infarction. Catheterization and Cardiovascular Interventions 72:7, 937-942
CrossRef761
Boris Aleil, Laurent Jacquemin, Fabien De Poli, Michel Zaehringer, Jean-Philippe Collet, Gilles Montalescot, Jean-Pierre Cazenave, Marie-Claude Dickele, Jean-Pierre Monassier, Christian Gachet. (2008) Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions 1:6, 631-638
CrossRef762
Deepak L. Bhatt. (2008) Resisting the Temptation to Oversimplify Antiplatelet Resistance. JACC: Cardiovascular Interventions 1:6, 660-662
CrossRef763
David Erlinge, Christoph Varenhorst, Oscar Ö. Braun, Stefan James, Kenneth J. Winters, Joseph A. Jakubowski, John T. Brandt, Atsuhiro Sugidachi, Agneta Siegbahn, Lars Wallentin. (2008) Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo. Journal of the American College of Cardiology 52:24, 1968-1977
CrossRef764
DAVID J. MOLITERNO. (2008) Advances in Antiplatelet Therapy for ACS and PCI. Journal of Interventional Cardiology 21, S18-S24
CrossRef765
C. Steven Ernest, David S. Small, Shashank Rohatagi, Daniel E. Salazar, Lars Wallentin, Kenneth J. Winters, Rebecca E. Wrishko. (2008) Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease. Journal of Pharmacokinetics and Pharmacodynamics 35:6, 593-618
CrossRef766
Lowell F. Satler. (2008) Clopidogrel under scrutiny. Catheterization and Cardiovascular Interventions 72:7, 925-926
CrossRef767
A. NATARAJAN, S. M. MARSHALL, S. G. WORTHLEY, J. J. BADIMON, A. G. ZAMAN. (2008) The presence of coronary artery disease increases platelet-dependent thrombosis in patients with type 2 diabetes mellitus. Journal of Thrombosis and Haemostasis 6:12, 2210-2213
CrossRef768
Thomas Cuisset, Corinne Frere, Jacques Quilici, Pierre-Emmanuel Morange, Jean-Philippe Mouret, Laurent Bali, Pierre-Julien Moro, Marc Lambert, Marie-Christine Alessi, Jean Louis Bonnet. (2008) Glycoprotein IIb/IIIa Inhibitors Improve Outcome After Coronary Stenting in Clopidogrel Nonresponders. JACC: Cardiovascular Interventions 1:6, 649-653
CrossRef769
Nina C Raju, John W Eikelboom, Jack Hirsh. (2008) Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nature Clinical Practice Cardiovascular Medicine 5:12, 766-780
CrossRef770
G. De Luca. (2008) Adjunctive antithrombotic therapy during primary percutaneous coronary intervention. European Heart Journal Supplements 10:Suppl J, J2-J14
CrossRef771
PAUL A. GURBEL, UDAYA S. TANTRY. (2008) The Rationale for and Comparisons of Different Antiplatelet Treatments in Acute Coronary Syndrome. Journal of Interventional Cardiology 21, S10-S17
CrossRef772
Patrick Gladding, Mark Webster, Irene Zeng, Helen Farrell, Jim Stewart, Peter Ruygrok, John Ormiston, Seif El-Jack, Guy Armstrong, Patrick Kay, Douglas Scott, Arzu Gunes, Marja-Liisa Dahl. (2008) The Antiplatelet Effect of Higher Loading and Maintenance Dose Regimens of Clopidogrel. JACC: Cardiovascular Interventions 1:6, 612-619
CrossRef773
A. Betriu. (2008) Clinical implications of the results of recent atherothrombotic trials on patient management. European Heart Journal Supplements 10:Suppl I, I30-I32
CrossRef774
R. A. Byrne, A. Kastrati. (2008) Duration of antiplatelet therapy following intracoronary stenting: are changes needed?. European Heart Journal Supplements 10:Suppl I, I25-I29
CrossRef775
M. Zimarino, R. De Caterina. (2008) Long-term treatment strategies for atherothrombotic disease: do platelets define the course?. European Heart Journal Supplements 10:Suppl I, I8-I13
CrossRef776
Jeffrey S. Berger, Carla B. Frye, Qing Harshaw, Fred H. Edwards, Steven R. Steinhubl, Richard C. Becker. (2008) Impact of Clopidogrel in Patients With Acute Coronary Syndromes Requiring Coronary Artery Bypass Surgery. Journal of the American College of Cardiology 52:21, 1693-1701
CrossRef777
Michael H. Koo, James J. Nawarskas, William H. Frishman. (2008) Prasugrel. Cardiology in Review 16:6, 314-318
CrossRef778
R. Charles Callison, Harold P. Adams. (2008) Use of Antiplatelet Agents for Prevention of Ischemic Stroke. Neurologic Clinics 26:4, 1047-1077
CrossRef779
M. Cattaneo. (2008) Advances in antiplatelet therapy: overview of new P2Y12 receptor antagonists in development. European Heart Journal Supplements 10:Suppl I, I33-I37
CrossRef780
Dominick J Angiolillo, Siva Suryadevara, Piera Capranzano, Theodore A Bass. (2008) Prasugrel: a novel platelet ADP P2Y 12 receptor antagonist. A review on its mechanism of action and clinical development. Expert Opinion on Pharmacotherapy 9:16, 2893-2900
CrossRef781
V. L. Serebruany, S. Goto. (2008) The challenge of monitoring platelet response after clopidogrel. European Heart Journal 29:23, 2833-2834
CrossRef782
Deepak L. Bhatt. (2008) Prasugrel versus clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. Current Atherosclerosis Reports 10:5, 367-368
CrossRef783
Gregg W. Stone, Stephen G. Ellis, Antonio Colombo, Eberhard Grube, Keith D. Dawkins, Mark Friedman, Donald S. Baim. (2008) Effect of Prolonged Thienopyridine Use After Drug-Eluting Stent Implantation (from the TAXUS Landmark Trials Data). The American Journal of Cardiology 102:8, 1017-1022
CrossRef784
Marc Cohen. (2008) High-risk Acute Coronary Syndrome Patients with Non-ST-Elevation Myocardial Infarction: Definition and Treatment. Cardiovascular Drugs and Therapy 22:5, 407-418
CrossRef785
G. CAMPO, M. VALGIMIGLI, A. FRANGIONE, M. TEBALDI, R. FERRARI. (2008) Prognostic value of serial platelet reactivity measurements on long-term clinical outcome in patients with ST-elevation myocardial infarction undergoing primary PCI. Journal of Thrombosis and Haemostasis 6:10, 1824-1826
CrossRef786
A. S. Wierzbicki. (2008) Muddy waters: more stormy SEAS for ezetimibe. International Journal of Clinical Practice 62:10, 1470-1473
CrossRef787
W. Kuliczkowski, A. Witkowski, L. Polonski, C. Watala, K. Filipiak, A. Budaj, J. Golanski, D. Sitkiewicz, J. Pregowski, J. Gorski, M. Zembala, G. Opolski, K. Huber, H. Arnesen, S. D. Kristensen, R. De Caterina. (2008) Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. European Heart Journal 30:4, 426-435
CrossRef788
S. S. Jolly, J. Pogue, K. Haladyn, R. J.G. Peters, K. A.A. Fox, A. Avezum, B. J. Gersh, H. J. Rupprecht, S. Yusuf, S. R. Mehta. (2008) Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. European Heart Journal 30:8, 900-907
CrossRef789
M. L. Fokkema, P. J. Vlaar, T. Svilaas, M. Vogelzang, D. Amo, G. F.H. Diercks, A. J.H. Suurmeijer, F. Zijlstra. (2008) Incidence and clinical consequences of distal embolization on the coronary angiogram after percutaneous coronary intervention for ST-elevation myocardial infarction. European Heart Journal 30:8, 908-915
CrossRef790
Joshua F. Zeidner, William H. Frishman, Robert G. Lerner. (2008) Investigational Antiplatelet Drugs for the Treatment and Prevention of Coronary Artery Disease. Cardiology in Review 16:5, 250-259
CrossRef791
Stephan Windecker, Patrick W Serruys, Simon Wandel, Pawel Buszman, Stanislaw Trznadel, Axel Linke, Karsten Lenk, Thomas Ischinger, Volker Klauss, Franz Eberli, Roberto Corti, William Wijns, Marie-Claude Morice, Carlo di Mario, Simon Davies, Robert-Jan van Geuns, Pedro Eerdmans, Gerrit-Anne van Es, Bernhard Meier, Peter Jüni. (2008) Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. The Lancet 372:9644, 1163-1173
CrossRef792
Robert P. Giugliano, Eugene Braunwald. (2008) The Year in Non–ST-Segment Elevation Acute Coronary Syndrome. Journal of the American College of Cardiology 52:13, 1095-1103
CrossRef793
M. Moser, C. Bode. (2008) Antithrombotische Therapie bei akutem Myokardinfarkt. Der Internist 49:9, 1031-1037
CrossRef794
Keith AA Fox, Frederick A Anderson Jr, Shaun G Goodman, P Gabriel Steg, Karen Pieper, Ann Quill, Joel M Gore. (2008) Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. Nature Clinical Practice Cardiovascular Medicine 5:9, 580-589
CrossRef795
B. Stratmann. (2008) Thrombozytenfunktion bei Diabetes mellitus. Der Diabetologe 4:6, 429-434
CrossRef796
Deepak L. Bhatt. (2008) What Makes Platelets Angry. Journal of the American College of Cardiology 52:13, 1060-1061
CrossRef797
Laurent Bonello, Laurence Camoin-Jau, Stéphane Arques, Paul Barragan, Francoise Dignat-George, Franck Paganelli. (2008) Reply. Journal of the American College of Cardiology 52:9, 791-792
CrossRef798
Thomas Cuisset, Corinne Frere, Jacques Quilici, Marie Christine Alessi, Jean Louis Bonnet. (2008) Adjusting Clopidogrel Loading Doses According to Vasodilator-Stimulated Phosphoprotein Index: On Time, Too Early, or Too Late?. Journal of the American College of Cardiology 52:9, 790-791
CrossRef799
Girish R. Mood, Anthony A. Bavry, Deepak L. Bhatt. (2008) Clopidogrel and coronary stents: Risks and benefits. Current Atherosclerosis Reports 10:4, 303-308
CrossRef800
R. Bhindi, O. Ormerod, J. Newton, A.P. Banning, L. Testa. (2008) Interaction between statins and clopidogrel: is there anything clinically relevant?. QJM 101:12, 915-925
CrossRef801
MARC COHEN, JAMES HOEKSTRA, ROBERT GIUGLIANO, CHRISTOPHER B. GRANGER, PAUL A. GURBEL, JUDD E. HOLLANDER, STEVEN V. MANOUKIAN, CHARLES V. POLLACK, JR, JORGE F. SAUCEDO. (2008) Treatment Strategies in Non-ST-Elevation Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention: An Evidence-Based Review of Clinical Trial Results and Treatment Guidelines: Report on a Roundtable Discussion. Journal of Interventional Cardiology 21:4, 283-299
CrossRef802
Harvey D White, Derek P Chew. (2008) Acute myocardial infarction. The Lancet 372:9638, 570-584
CrossRef803
Rossella Marcucci, Anna Maria Gori, Gian Franco Gensini, Rosanna Abbate. (2008) Intensive antiplatelet therapy for reduction of ischaemic events. The Lancet 372:9638, 531
CrossRef804
Matthew A Cavender, Sunil V Rao, E Magnus Ohman. (2008) Major bleeding: management and risk reduction in acute coronary syndromes. Expert Opinion on Pharmacotherapy 9:11, 1869-1883
CrossRef805
N. L. DOVLATOVA, J. A. JAKUBOWSKI, A. SUGIDACHI, S. HEPTINSTALL. (2008) The reversible P2Y 12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. Journal of Thrombosis and Haemostasis 6:7, 1153-1159
CrossRef806
Rik Hermanides, Jan Paul Ottervanger. (2008) Treatment of ST-elevation myocardial infarction. Future Cardiology 4:4, 391-397
CrossRef807
Colin M. Barker, Matthew J. Price. (2008) Antiplatelet therapy in acute coronary syndromes. Current Cardiology Reports 10:4, 327-333
CrossRef808
Lisa K Jennings, Jorge F Saucedo. (2008) Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes. Current Opinion in Cardiology 23:4, 302-308
CrossRef809
Sameer Bansilal, Michael E. Farkouh, Valentin Fuster. (2008) Optimal treatment of the diabetic patient with multivessel disease. Current Cardiology Reports 10:4, 272-284
CrossRef810
David P. Faxon. (2008) New data on early management of patients with ST-elevation myocardial infarction. Current Cardiology Reports 10:4, 291-298
CrossRef811
P. W. Kamphuisen. (2008) Thrombogenicity in patients with percutaneous coronary artery intervention and dual antiplatelet treatment. European Heart Journal 29:14, 1699-1700
CrossRef812
Simon R. Dixon, Cindy L. Grines, William W. O'Neill. (2008) The Year in Interventional Cardiology. Journal of the American College of Cardiology 51:24, 2355-2369
CrossRef813
H.-R. Arntz. (2008) Reperfusion strategies in ST-elevation myocardial infarction—Current status and perspectives for early and pre-hospital treatment. Resuscitation 77:3, 296-305
CrossRef814
Stephan Windecker, Peter Jüni. (2008) Safety of drug-eluting stents. Nature Clinical Practice Cardiovascular Medicine 5:6, 316-328
CrossRef815
Stone, Gregg W., Witzenbichler, Bernhard, Guagliumi, Giulio, Peruga, Jan Z., Brodie, Bruce R., Dudek, Dariusz, Kornowski, Ran, Hartmann, Franz, Gersh, Bernard J., Pocock, Stuart J., Dangas, George, Wong, S. Chiu, Kirtane, Ajay J., Parise, Helen, Mehran, Roxana, . (2008) Bivalirudin during Primary PCI in Acute Myocardial Infarction. New England Journal of Medicine 358:21, 2218-2230
Full Text816
Morrow, David A., . (2008) Antithrombotic Therapy to Support Primary PCI. New England Journal of Medicine 358:21, 2280-2282
Full Text817
, J. Daemen, M. L. Simoons, W. Wijns, A. Bagust, G. Bos, J. M. Bowen, E. Braunwald, E. Camenzind, B. Chevalier, C. DiMario, J. Fajadet, A. Gitt, G. Guagliumi, H. L. Hillege, S. James, P. Juni, A. Kastrati, S. Kloth, S. D. Kristensen, M. Krucoff, V. Legrand, M. Pfisterer, M. Rothman, P. W. Serruys, S. Silber, P. G. Steg, I. Tariah, L. Wallentin, S. W. Windecker, , A. Aimonetti, D. Allocco, A. Baczynska, A. Bagust, M. Berenger, G. Bos, A. Boam, J.M. Bowen, E. Braunwald, J.P. Calle, E. Camenzind, G. Campo, S. Carlier, B. Chevalier, J. Daemen, J. de Schepper, G. Di Bisceglie, C. DiMario, H. Dobbels, J. Fajadet, A. Farb, J.C. Ghislain, A. Gitt, G. Guagliumi, S. Hellbardt, H.L. Hillege, R. ten Hoedt, C. Isaia, S. James, P. de Jong, P. Juni, A. Kastrati, E. Klasen, S. Kloth, S.D. Kristensen, M. Krucoff, V. Legrand, M. Lekehal, L. LeNarz, F. Ni Mhullain, H. Nagai, A. Patteet, D. Paunovic, M. Pfisterer, A. Potgieter, I. Purdy, C. Raveau-Landon, M. Rothman, P.W. Serruys, S. Silber, M.L. Simoons, P.G. Steg, I. Tariah, S. Ternstrom, J. Van Wuytswinkel, M. Waliszewski, L. Wallentin, W. Wijns, S.W. Windecker. (2008) Meeting Report: ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007. European Heart Journal 30:2, 152-161
CrossRef818
S. A. Murphy, E. M. Antman, S. D. Wiviott, G. Weerakkody, G. Morocutti, K. Huber, J. Lopez-Sendon, C. H. McCabe, E. Braunwald, . (2008) Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. European Heart Journal 29:20, 2473-2479
CrossRef819
(2008) More on Subgroup Analyses in Clinical Trials. New England Journal of Medicine 358:19, 2076-2077
Full Text820
Victor L. Serebruany. (2008) Excess Rates of Nonfatal Myocardial Infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel (Preventing Clinical Events or Chasing Enzymatic Ghosts?†)†Conflict of interest: Dr. Serebruany is listed as an inventor and received compensation for U.S. Patent Application P-17232, “Method for Treating Vascular Diseases With Prasugrel,” assigned to Eli Lilly and Company, Indianapolis, Indiana. He has received funding for research studies with clopidogrel and prasugrel.. The American Journal of Cardiology 101:9, 1364-1366
CrossRef821
Ioannis Iakovou. (2008) Thrombosis after stent implantation: how much of a problem is there?. Future Cardiology 4:3, 261-267
CrossRef822
Elliott M. Antman, Stephen D. Wiviott, Sabina A. Murphy, Juri Voitk, Yonathan Hasin, Petr Widimsky, Harish Chandna, William Macias, Carolyn H. McCabe, Eugene Braunwald. (2008) Early and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology 51:21, 2028-2033
CrossRef823
John A. Cairns, John Eikelboom. (2008) Clopidogrel Resistance. Journal of the American College of Cardiology 51:20, 1935-1937
CrossRef824
Stephen D. Wiviott, Eugene Braunwald, Sabina A. Murphy, Elliott M. Antman. (2008) A Perspective on the Efficacy and Safety of Intensive Antiplatelet Therapy in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38. The American Journal of Cardiology 101:9, 1367-1370
CrossRef825
Deepak L Bhatt. (2008) Is prasugrel superior to clopidogrel for patients with acute coronary syndromes undergoing PCI?. Nature Clinical Practice Cardiovascular Medicine 5:5, 252-253
CrossRef826
M. T. NIEMAN, F. BURKE, M. WARNOCK, Y. ZHOU, J. SWEIGART, A. CHEN, D. RICKETTS, B. R. LUCCHESI, Z. CHEN, E. DI CERA, J. HILFINGER, J. S. KIM, H. I. MOSBERG, A. H. SCHMAIER. (2008) Thrombostatin FM compounds: direct thrombin inhibitors – mechanism of action in vitro and in vivo. Journal of Thrombosis and Haemostasis 6:5, 837-845
CrossRef827
Lina Badimon, Gemma Vilahur. (2008) Enfermedad aterotrombótica coronaria: avances en el tratamiento antiplaquetario. Revista Española de Cardiología 61:5, 501-513
CrossRef828
Xacobe Flores-Ríos, Raquel Marzoa-Rivas, Juan Pablo Abugattás-de Torres, Pablo Piñón-Esteban, Guillermo Aldama-López, Jorge Salgado-Fernández, Ramón Calviño-Santos, José Manuel Vázquez-Rodríguez, Nicolás Vázquez-González, Alfonso Castro-Beiras. (2008) Late thrombosis of paclitaxel-eluting stents: Long-term incidence, clinical consequences, and risk factors in a cohort of 604 patients. American Heart Journal 155:4, 648-653
CrossRef829
Jose G. Romano, Ralph L. Sacco. (2008) Progress in secondary stroke prevention. Annals of Neurology 63:4, 418-427
CrossRef830
Dean J. Kereiakes, Paul A. Gurbel. (2008) Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions 1:2, 111-121
CrossRef831
Neal S. Kleiman. (2008) Will Measuring Vasodilator-Stimulated Phosphoprotein Phosphorylation Help Us Optimize the Loading Dose of Clopidogrel?
CrossRef832
Patrick Gladding, Mark Webster, John Ormiston, Sarah Olsen, Harvey White. (2008) Antiplatelet drug nonresponsiveness. American Heart Journal 155:4, 591-599
CrossRef833
Subrata Chakrabarti, Jane E. Freedman. (2008) Dipyridamole, cerebrovascular disease, and the vasculature. Vascular Pharmacology 48:4-6, 143-149
CrossRef834
Stephen D Wiviott, Eugene Braunwald, Carolyn H McCabe, Ivan Horvath, Matyas Keltai, Jean-Paul R Herrman, Frans Van de Werf, William E Downey, Benjamin M Scirica, Sabina A Murphy, Elliott M Antman. (2008) Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. The Lancet 371:9621, 1353-1363
CrossRef835
Andrew E Ajani, Jeffrey Lefkovits. (2008) Approaching an age of reason with antiplatelet therapy. The Lancet 371:9621, 1315-1316
CrossRef836
(2008) Prasugrel versus Clopidogrel. New England Journal of Medicine 358:12, 1298-1301
Full Text837
D. J. Angiolillo, P. Capranzano, S. Goto, M. Aslam, B. Desai, R. K. Charlton, Y. Suzuki, L. C. Box, S. B. Shoemaker, M. M. Zenni, L. A. Guzman, T. A. Bass. (2008) A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. European Heart Journal 29:18, 2202-2211
CrossRef838
Javier Sanz, Pedro R. Moreno, Valentin Fuster. (2008) The Year in Atherothrombosis. Journal of the American College of Cardiology 51:9, 944-955
CrossRef839
Dietmar Trenk, Franz-Josef Neumann. (2008) Drug-eluting coronary stents: as safe as bare-metal stents, but optimized antiplatelet therapy may further improve clinical outcome. European Journal of Clinical Pharmacology 64:3, 227-232
CrossRef840
Eugene Braunwald, Dominick Angiolillo, Eric Bates, Peter B. Berger, Deepak Bhatt, Christopher P. Cannon, Mark I. Furman, Paul Gurbel, Alan D. Michelson, Eric Peterson, Stephen Wiviott. (2008) Antiplatelet Therapy and Platelet Function Testing. Clinical Cardiology 31:S1, I36-I36
CrossRef841
Mátyás Keltai. (2008) Thrombocytaaggregáció-gátló kezelés akut ischaemiás szindrómában. Tények és várakozások. Orvosi Hetilap 149:11, 483-491
CrossRef842
Nigel Mackman. (2008) Triggers, targets and treatments for thrombosis. Nature 451:7181, 914-918
CrossRef843
Javier Bermejo, Javier Segovia, Fernando Alfonso. (2008) Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association 2007 (Orlando, EE.UU., 4-7 de noviembre de 2007). Revista Española de Cardiología 61:2, 185-193
CrossRef844
Ramez R Fares, Lawrence S Lansing, Christine A Gallati, Shaker A Mousa. (2008) Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: clinical evidence for and against the combination. Expert Opinion on Pharmacotherapy 9:3, 377-386
CrossRef845
D.H. Lee, A. Arat, H. Morsi, H. Shaltoni, J.R. Harris, M.E. Mawad. (2008) Dual Antiplatelet Therapy Monitoring for Neurointerventional Procedures Using a Point-of-Care Platelet Function Test: A Single-Center Experience. American Journal of Neuroradiology 29:7, 1389-1394
CrossRef846
Lukasz A. Malek, Bartlomiej Kisiel, Mateusz Spiewak, Marcin Grabowski, Krzysztof J. Filipiak, Grazyna Kostrzewa, Zenon Huczek, Rafal Ploski, Grzegorz Opolski. (2008) Coexisting Polymorphisms of P2Y12 and CYP2C19 Genes as a Risk Factor for Persistent Platelet Activation With Clopidogrel. Circulation Journal 72:7, 1165-1169
CrossRef847
Madhu Chintala, Kenji Shimizu, Masami Ogawa, Hiroya Yamaguchi, Masaki Doi, Peder Jensen. (2008) Basic and Translational Research on Proteinase-Activated Receptors: Antagonism of the Proteinase-Activated Receptor 1 for Thrombin, a Novel Approach to Antiplatelet Therapy for Atherothrombotic Disease. Journal of Pharmacological Sciences 108:4, 433-438
CrossRef848
Judi Bryant, Joseph M. Post, Serene Alexander, Yi-Xin Wang, Lorraine Kent, Sabine Schirm, Jih-Lie Tseng, Babu Subramanyam, Brad Buckman, Imadul Islam, Shendong Yuan, Mark E. Sullivan, Mike Snider, John Morser. (2008) Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): In vitro effects on platelets. Thrombosis Research 122:4, 523-532
CrossRef849
Ulrich Laufs, Holger Nef, Helge Möllmann, Florian Custodis, Michael Böhm. (2008) Clinical Trial Updates and Hotline Sessions presented at the Scientific Session 2007 of the American heart association. Clinical Research in Cardiology 97:1, 1-11
CrossRef850
Giuseppe De Luca, Paolo Marino. (2008) Antithrombotic Therapies in Primary Angioplasty. Drugs 68:16, 2325-2344
CrossRef851
Tsukasa OHMORI. (2008) Anti-platelet treatment for acute coronary syndrome in Japan. Japanese Journal of Thrombosis and Hemostasis 19:4, 504-509
CrossRef852
Norio Tanahashi. (2008) Antiplatelet agents for ischemic stroke: current status and future directions. Nosotchu 30:6, 834-840
CrossRef853
Joseph A. Jakubowski, Kenneth J. Winters, Hideo Naganuma, Lars Wallentin. (2007) Prasugrel: A Novel Thienopyridine Antiplatelet Agent. A Review of Preclinical and Clinical Studies and the Mechanistic Basis for Its Distinct Antiplatelet Profile. Cardiovascular Drug Reviews 25:4, 357-374
CrossRef854
Bhatt, Deepak L., . (2007) Intensifying Platelet Inhibition — Navigating between Scylla and Charybdis. New England Journal of Medicine 357:20, 2078-2081
Full Text855
Dominick J Angiolillo. (2007) ADP Receptor Antagonism. American Journal of Cardiovascular Drugs 7:6, 423-432
CrossRef
- Letters
